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1. Introduction 
 
1.1. Neurodegenerative disorders 
 
Neurodegenerative disorders (NDDs) encompass a wide range of pathologies which are 
characterized by progressive loss of neurons in central and peripheral nervous systems. Alongside 
with cardiovascular diseases and cancer, NDDs belong to the most common causes of death and 
disability in the industrialized world, and their role constantly increases with the aging of the 
world population. Alzheimer’s (AD) and Parkinson’s (PD) diseases are the most prevalent NDDs 
affecting, respectively, more than 35 and 6.3 million people worldwide (Bourdenx et al., 2015). 
Besides, NDDs include dementia with Lewy bodies (DLB), fronto-temporal dementia (FTD), 
amyotrophic lateral sclerosis (ALS) etc., as well as rare rapidly progressive prion disorders such 
as Creutzfeldt-Jakob disease (CJD). Most of the NDD cases are sporadic or idiopathic, meaning 
that the etiology of the disease is not known, and only in a small subset of the familial NDD cases 
genetic causes were found (de Pedro-Cuesta et al., 2015). NDDs do not only have debilitating 
effects on patients’ health and quality of life but also create an immense socio-economic burden. 
NDDs differ in clinical presentations, pathophysiology and the underlying molecular agents, but 
there is also a striking similarity – most of NDDs are characterized by protein misfolding and 
aggregation (Bourdenx et al., 2015). Further elucidation of the molecular mechanisms of protein 
aggregation, as well as the understanding of physiological and pathological functions of the 
proteins involved in NDDs, are needed for developing new therapeutic approaches. 
 
1.2. Synucleinopathies: Parkinson’s disease (PD), Parkinson’s disease 
dementia (PDD), and dementia with Lewy bodies (DLB) 
 
1.2.1. General overview 
The NDDs which are characterized by abnormal accumulation of alpha-synuclein (αS) are 
commonly referred as synucleinopathies. They include PD, DLB, multiple systems atrophy 
(MSA), neurodegeneration with brain iron accumulation (NBIA) and some other less prevalent 
disorders. In case of PD and DLB, αS forms so-called Lewy bodies and Lewy neurites in the cell 
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bodies or processes of neurons, respectively. Glial cytoplasmic inclusions of αS can be found in 
MSA (Spillantini et al., 1998; Galvin et al., 2001). 
The first clinical description of PD appeared nearly 200 years ago when Dr. James Parkinson in 
“An essay on the shaking palsy”, 1817, described 6 individuals with the distinctive motor 
symptoms: tremor, lessened muscular power, a characteristic leaned posture, as well as decrease 
in intelligence (Parkinson J, 2002 reprint). All these symptoms, with exception of cognitive 
impairment, remain valid for PD diagnosis nowadays, although many nuances were added to our 
understanding of the disease manifestation and progression and a variety of neurologic disorders 
with Parkinsonism were distinguished as individual disease entities (Goedert et al., 2017).  
PD, PDD, and DLB are disorders of the parkinsonian spectrum which share many pathological 
features. Some clinicians and scientists even recognize these related conditions as “diagnostic 
categories” which represent a biological continuum of Lewy body disease rather than single 
pathologies (Donaghy and McKeith, 2014; Jellinger and Korczyn, 2018). However, the 
differences in the clinical manifestation of PD, PDD and DLB indicate that neurons of different 
regions may be specifically vulnerable to these disorders (Surmeier and Sulzer, 2013). 
 
1.2.2. Prevalence of PD, PDD, and DLB 
PD is the second most common neurodegenerative disorder, outnumbered only by AD. In the 
general population, the prevalence of PD amounts to 0.3%, and it increases up to 1% for over 60-
year-old (y/o) individuals, and to 3% for people above 80 y/o. The incidence of the disease is 8–
18 cases per 100 000 person per year. Males receive PD diagnosis 1.5 – 2 times more often than 
females. The mean age of disease onset is 60 y/o, and life expectancy after the diagnosis is ~15 
years. Nearly 30% of PD patients develop PDD, and the incidence of this dementia increases with 
the duration of the PD (Erkkinen et al., 2018). 
DLB is the second most common disorder among neurodegenerative dementias. Its prevalence is 
estimated to be between 4.2% (Vann Jones and O’Brien, 2014) to 30% (Zaccai et al., 2005) of all 
dementia cases depending on the diagnostic inclusion criteria (Hogan et al., 2016). The overall 
incidence of DLB is 3.5 – 5.9 cases per 100 000 person per year with higher numbers for men 
than for women (Savica et al., 2013). The mean age of onset also varies greatly in different 
populations: from 59 to 78 years. The disease lasts on average approx. 7 years but its duration can 
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vary from 2 to 20 years in individual patients (Erkkinen et al., 2018). 
 
1.2.3. Clinical manifestation of PD, PDD, and DLB 
Typical symptoms of PD include motor symptoms (resting tremor, bradykinesia, rigidity, and 
postural instability) and a variety of non-motor symptoms such as anosmia, REM sleep 
behavioural disorder, orthostatic hypotension, constipation, mood and sensory disturbances etc. 
(Barker and Williams-Gray, 2016). 
PDD and DLB share many common symptoms. Besides parkinsonian motor and non-motor 
symptoms, they are characterized by the progressive cognitive decline (dementia), recurring 
visual hallucinations, fluctuations in alertness and attention, depression, delusions etc. These 
patients also show severe sensitivity to neuroleptics, and cannot be treated against psychosis with 
pharmaceutical methods. They are usually responsive to the “golden standard” PD medication L-
DOPA, but due to the side effects, such as hallucinations and other psychotic manifestations, 
levodopa is often omitted. Subsequently, even the symptomatic treatment of PDD and DLB is 
limited which has drastic effects on the quality of life of patients and caregivers (Donaghy and 
McKeith, 2014; Snyder, 2015).   
According to the international consensus, the diagnosis PDD is given if movement symptoms 
precede dementia at least for 1 year. In DLB, dementia is present before parkinsonism, or 
cognitive impairment and motor symptoms appear at the same time (McKeith et al., 2005). 
 
1.2.4. Histopathology and molecular basis of PD, PDD, and DLB 
Two major histopathological hallmarks of PD have been known since the beginning of the 20th 
century. First, the distinctive protein aggregates in neuronal cell bodies were discovered by the 
German neurologist Frederic Lewy in 1912. These pathological structures were named after him 
Lewy bodies (LB), and, by analogy, Lewy neurites (LN).  Second, in the year 1919, Konstantin 
Tretiakoff postulated a hypothesis that the loss of dopaminergic neurons in the Substantia nigra 
(SN) is related to PD pathology. Only decades later this idea was accepted and until now remains 
to be one of the cardinal hallmarks of PD (Drew, 2016). How Lewy pathology relates to the loss 
of dopaminergic neurons is still not clearly understood. 
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In 2003 Braak and colleagues proposed that Lewy pathology in PD develops in 6 consequent 
stages, ascending from the enteric part of PNS to neocortex (as described in Figure 1.1. E) and 
correlates with the progression of the disease and the severity of the symptoms (Braak et al., 
2003). In DLB brains, αS-positive LBs and LNs can be found in various regions, including SN 
and hippocampus (Figure 1.1. A-D; Spillantini et al., 1998), but also in the olfactory pathways, 
brainstem, limbic and cerebral cortex which probably can explain heterogeneity of the DLB 
symptoms (Harding et al., 2002; Snyder, 2015). Postmortem analysis of the DLB brains usually 
shows an advanced form of the disease with massive cortical involvement corresponding to the 
Braak’s stages 5 or 6 and does not provide any information about the initial phases of the disease. 
At the Braak’s stages 5 and 6 there are no histopathological differences in Lewy body pathology 
between PD and DLB, despite the differences in symptomatology (Donaghy and McKeith, 2014). 
Histopathological analysis of 88 PD brains showed that widespread cortical LBs do not 
necessarily lead to dementia or cognitive decline (Braak et al., 2005). 
 
 
Figure 1.1. Lewy body pathology. 
Lewy bodies and Lewy neurites in the Substantia nigra (A, B; scale bar: 100 µm) and in the hippocampus 
(C, D; scale bar: 80 µm) of the DLB brain (reproduced from Spillantini et al., 1998). (E) Braak’s stages of 
Lewy body pathology (modified from Donaghy et al., 2014). 
 
The discrepancies between symptoms and LB pathology in PD and DLB might be explained by 
involvement of different molecular agents in the pathophysiology of the disorders. Although the 
main component of LB and LN, αS, probably plays the central role in the pathophysiology of PD 
and DLB, other proteins may modulate αS properties and aggravate its toxicity or act as the 
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independent pathological factors.  
In addition to its major component αS, the LBs and LNs are composed of neurofilaments 
(Trojanowski and Lee, 1988), proteolytic marker ubiquitin (Lowe et al., 1988), autophagy marker 
p62 (Kuusisto et al., 2003), heat-shock proteins (Uryu et al., 2006), synphilin 1 (Wakabayashi et 
al., 2000), chaperon-like protein 14-3-3 (Kawamoto et al., 2002) etc. These proteins may interact 
with αS and influence LB formation. A close homologue of αS – beta-synuclein (βS) was not 
found in LB, but it is present in the axonal spheroid-like structures in PD and DLB (Galvin et al., 
1999). So far, no apparent differences in the immunostainings were revealed between LBs of PD 
and DLB (Galvin et al., 1999; Kawamoto et al., 2002; Trojanowski and Lee, 1988; Uryu et al., 
2006).  
Markers of AD pathology (β-amyloid Aβ and tau) are also often present in DLB brains, though 
there are DLB cases without any signs of Aβ or tau aggregations as revealed by amyloid PET 
imaging (Donaghy et al., 2015). Aβ-plaques are present also in PD and healthy aged brains, but 
the load of Aβ is statistically higher in DLB (Halliday et al., 2011).  
Compared with PD, DLB brains have more abundant αS depositions in the hippocampal CA2/3 
area (Jellinger et al., 2012), a higher density of the serotonin 1A receptor in the frontal cortex 
(Francis et al., 2007), and virtually no upregulation of D2-dopamine receptor in the striatum 
(Piggott, 1999). A close homologue of αS, βS might be also involved in PD and DLB pathology, 
since a genetic link between DLB and βS was identified (Ohtake et al., 2004; see section 1.2.6.). 
Also, it was suggested that different strains of αS can produce a number of αS macromolecular 
assemblies (oligomers, ribbons, fibrils) with different pathological potential and seeding 
capabilities. E.g., fibrils were more toxic to the dopaminergic neurons, while ribbons were more 
prone to aggregation and formation of LB-like structures when different structural strains of αS 
were injected into the rat’s brain. Such variability might explain the heterogeneity in the 
symptomatology of different synucleinopathies (Peelaerts et al., 2015). 
 
1.2.5. Genetics of PD, PDD, and DLB 
Most cases of synucleinopathies are sporadic, where some environmental factors and aging 
probably trigger the conversion of αS into a toxic species. Genetic predispositions play an 
important role in approx. 5 – 10% of PD cases. The genome-wide association studies (GWAS) 
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identified the association between PD and over 20 human genes and this number will probably 
increase in the future (Peeraully et al., 2012; Nussbaum RL, 2017). Familial PD forms with 
autosomal dominant and autosomal recessive inheritance were described. Besides, some alleles 
are characteristic for the age of the PD onset: juvenile (under 20 y/o), early (20-40 y/o) or late 
(above 40 y/o) (Sekiyama et al., 2014). Mutations in the LRRK2 (PARK8) gene are the most 
common causes of familial PD. LRRK2 (leucine-reach repeat kinase 2) is a GTPase/kinase 
protein which is involved in cell proliferation, differentiation and survival (Funayama et al., 
2002; Funayama et al., 2005). Several monogenic conditions with autosomal recessive 
inheritance were described. These genes include but are not limited to: parkin (PARK2) coding 
for E3 ubiquitin protein ligase (Kitada et al., 1998); PINK1 (PARK6) coding for PTEN-induced 
putative kinase 1 which is important for sustaining mitochondria (Rogaeva et al., 2004; Valente 
et al., 2004; Exner et al., 2007), DJ1 (PARK7) coding for protein and nucleotide deglycase 
involved in the protection against oxidative stress (Bonifati et al., 2003), ATP13A2 (PARK9) 
coding for a lysosomal ATPase (Ramirez et al., 2006).  
Several missense mutations were also identified in the SNCA gene (PARK1/4) coding for αS.  
Single amino acid substitutions A53T, A30P, H50Q, and G51D were identified in rare familial 
PD cases (Polymeropoulos et al., 1996; Polymeropoulos et al., 1997; Kruger et al., 1998; 
Proukakis et al., 2013; Kiely et al., 2013). The E46K mutation was reported causal in PD and 
DLB cases (Zarranz et al., 2004). The A53E mutation was described in a MSA case (Pasanen et 
al., 2014). A18T and A29S mutations were associated with sporadic PD (Hoffman-Zacharska et 
al., 2013). Duplication and triplication of the SNCA gene were also identified in PD patients 
(Ibanez et al., 2004; Singleton et al., 2003). 
Although no specific mutations of SNCA gene were identified in DLB so far, several mutations 
mentioned above are associated with poor prognosis and progression to dementia: E46K, 
duplication, and triplication of the SNCA gene (Obi et al., 2008; Farrer et al., 2004). In two 
familial cases with A53T mutation of αS cognitive impairment was also described, although the 
patients did not meet the consensus criteria for DLB diagnosis (Tsuang et al., 2004). Besides, the 
MAPT gene coding for tau, the GBA gene coding for a lysosomal enzyme glucocerebrosidase 
and the Apoε4 gene for apolipoprotein are associated with DLB (Nussbaum RL, 2017). 
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1.2.6. Genetic link between βS and DLB 
Ohtake et al., 2004 suggested that genetic alterations in the βS gene may contribute to the 
pathophysiology of DLB. The authors sequenced the SNCB gene from 33 human subjects with 
sporadic DLB, 10 patients from DLB families and over 330 control individuals. As a result, 2 
single-amino-acid mutations were identified: P123H in familial and V70M in sporadic cases of 
DLB. These mutations were absent in all 660 SNCB alleles of the control individuals of 
Caucasian and Japanese origin.  
The 64-year old patient with P123H mutation initially demonstrated an atypical clinical picture 
for DLB: dementia, language and cognitive dysfunctions and was diagnosed with fronto-temporal 
lobar degeneration (FTLD). Only 3 years after the first diagnosis, he developed characteristic for 
DLB audio and visual hallucinations and, later, parkinsonian symptoms. Besides, 7 members of 
his family had dementia, 4 of these cases were consistent with DLB (Figure 1.1). Autopsy 
confirmed both Lewy bodies and AD pathology (Bonner et al., 2003). Further neuropathological 
examination revealed a high amount of Lewy bodies in hippocampus, amygdala, and Substantia 
nigra with immunoreactivity to αS. Positive diffuse staining for βS was also present in these brain 
regions, but no aggregates of βS were detected (Ohtake et al., 2004).  
 
Figure 1.2. Pedigree of the patient with P123H SNCB allele (Ohtake et al., 2004). 
The P123H mutation is an autosomal dominant trait with incomplete penetrance. Four generations of the 
family with P123H SNCB allele are shown. The proband is marked with an arrow. Individuals marked 
with (+) are heterozygous for P123H SNCB allele, those who have a (-) mark do not carry the mutation. 
Ages of family members at the time of ascertainment are provided in the figure. Black symbols indicate 
diseased individuals, gray symbols stand for probable DLB case, and white symbols are assigned to 
healthy family members. 
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The 83-year old patient with V70M SNCB allele was a sporadic case of DLB. His disease 
manifested at the age of 78 with visual hallucinations, cognitive impairment, and parkinsonian 
gait. Bradykinesia, rigidity, and tremor, as well as dysarthria and dysphasia, developed later. 
Unfortunately, the autopsy was not permitted in this case (Ohtake et al., 2004). 
 
1.3. Synuclein family of proteins 
 
1.3.1. The proteins of the synuclein family: αS, βS, and γS 
The synuclein family of proteins includes 3 members: alpha-, beta- and gamma-synuclein (αS, 
βS, and γS), which were so far described only in vertebrates. The genes coding for the synuclein 
proteins are highly conserved between species, so that, for example, human and rodent αS are 
95.3 % identical, and human and rodent βS share 97.8 % of the amino acid sequence (Surguchov, 
2008). 
αS was discovered nearly 30 years ago in neurons of the electric lobe of the Pacific electric ray 
Torpedo californica. Due to its subcellular localization in presynaptic terminals and adjacent to 
the nuclear envelop the protein was called synuclein (Maroteaux et al., 1988). Later, two other 
highly homologous to αS proteins were discovered: first, neuronal phosphoprotein PNP14 from 
bovine brain (Nakajo et al., 1990; Nakajo et al., 1993) and, second, BCSG1 from the advanced 
breast carcinoma or presyn from PNS (Ji et al., 1997; Ninkina et al., 1998). For the consistency, 
they were later called βS and γS respectively. 
In the human genome, the αS gene SNCA was mapped to chromosome 4q21.3-q22 (Campion et 
al., 1995), the SNCB gene coding for βS was mapped to chromosome 5q35 (Spillantini et al., 
1995), and the SNCG coding for γS was mapped to chromosome 10q23 (Lavedan et al., 1998). 
Human αS is composed of 140 amino acid residues, βS and γS consist of 134 and 127 amino acid 
residues (AA), respectively (Von Bohlen und Halbach O, 2004). 
The synuclein proteins share many structural similarities. They are composed of 3 common 
domains: N-terminal region, central NAC-domain (non-amyloid component of Alzheimer’s 
disease amyloid) and C-terminal region (Figure 1.3.). The N-terminal region is the most 
conserved between the 3 synuclein species and contains five to seven imperfect motif repeats 
KTKEGV. This part of the molecule (AA 1-60) is positively charged due to the high amount of 
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basic amino acid residues. It forms an α-helix which is able to bind to lipids and membranes. The 
central part of the molecule, AA 60 – 95 in αS, comprises the NAC domain (non-amyloid-
component of Alzheimer’s disease β-amyloid). This highly hydrophobic region is thought to be 
involved in fibrillation of αS. In βS, 11 AA of the core NAC domain are naturally deleted which 
leads to a lower aggregation propensity of this protein. The NAC domain of γS is less 
hydrophobic than in αS which results in the decreased ability to form fibrils (Biere et al., 2000; 
Surguchov, 2013). The acidic C-terminal region of synucleins is the least conserved part of the 
molecule. This region in αS is relatively stable to proteolysis and it might regulate aggregation 
(Hoyer et al., 2004; Surguchov, 2008). 
 
 
 
Figure 1.3. Structure of synuclein proteins. 
αS, βS, and γS are composed of 3 structural domains: highly conserved basic N-terminal region, 
hydrophobic NAC domain, and highly flexible C-terminal region. The DLB-associated mutations of βS, 
V70M and P123H, lie in NAC domain and C-terminus respectively. 
 
 
1.3.2. Physiological functions of synuclein proteins 
Synucleins are highly abundant proteins. Thus, αS comprises 0.1% of the protein in the brain 
homogenate (Shibayama-Imazu et al., 1993) or 1% of the soluble protein in cytosolic brain 
fractions (Iwai et al., 1995). Additionally, αS is present in CSF, blood plasma, saliva, as well as 
erythrocytes, lymphocytes, and platelets (Galvin et al., 2001; Surguchov, 2008). Similarly to αS, 
its close homologue βS is also highly abundant in CNS, especially in the presynaptic terminals. 
The highest expression of βS in the rat brain was observed in the olfactory bulb, the CA3 region 
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of the hippocampus, cortical layer IV, as well as in basal and thalamic nuclei (Mori et al., 2002). 
γS was shown to be predominantly expressed in PNS: in primary sensory neurons, motor 
neurons, and sympathetic neurons (Buchman et al., 1998). 
So far, physiological functions of synuclein proteins were not clearly defined but numerous 
studies suggest that these proteins may be involved in several important cellular processes 
(Surguchov, 2013; Lashuel et al., 2013; Gallegos et al., 2015). A great level of homology 
between the synuclein species and their frequent co-localization may indicate functional 
redundancy of these proteins. 
Presynaptic location of αS and βS indicates their involvement in the regulation of the synaptic 
function. Burré et al. showed that the C-terminal region of αS can bind to synaptobrevin-
2/VAMP2 and that αS can catalyze SNARE complex assembly in HEK293 cells and transgenic 
mice (Burré et al., 2010). αS may participate in synaptic vesicle traffic and maintenance of the 
synaptic vesicle pool (Chandra et al., 2004), in regulation of dopamine release (Abeliovich et al., 
2000; Larsen et al., 2006; Hara et al., 2013), and synaptic plasticity (Jin and Clayton, 1997). 
Although single KO of αS, βS or γS genes do not impair animals’ survival or normal activities of 
the brain (Lashuel et al., 2013), triple KO mice are characterized by a progressive age-dependent 
neuronal dysfunction and impairments of synaptic structure and transmission which shows the 
importance of synucleins for the long-term maintenance of the nervous system (Greten-Harrison 
et al., 2010). 
A physical link between αS and mitochondria was found: the N-terminus of αS directly binds to 
the mitochondrial outer membrane which leads to changes in the shape of mitochondria. αS also 
interacts with mitochondria complex I and may regulate mitochondria homeostasis (Hashimoto et 
al., 2004; Li et al., 2007; Mullin and Schapira, 2013). 
Moreover, all three synuclein proteins may be implicated in regulation of the proteasomal 
function (Snyder et al., 2005), chaperon-like activity (Ahn et al., 2006), and phospholipase D 2 
(PLD2) inhibition (Payton et al., 2004). 
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1.3.3. Mechanisms of neurotoxicity of αS and βS 
Pathophysiological mechanisms of αS were extensively studied, numerous cellular processes 
leading to neuronal cell death and to propagation of synuclein pathology were reported but the 
exact molecular mechanisms of pathogenicity and the nature of toxic species are far from being 
completely understood and are often the subject of disputes in the research community 
(Surguchov, 2013; Lashuel et al., 2013; Gallegos et al., 2015). Even less is known about 
neuropathology of βS and γS. Misfolding and aggregation of synuclein proteins and their role in 
pathogenicity will be further discussed in the section 1.3.4. Here, just a few cellular pathways 
involved in synucleinopathies will be mentioned. Major subcellular targets of toxic αS are 
summarized in Figure 1.4. 
 
 
Figure 1.4. Mechanisms of αS aggregation and toxicity (modified from Lashuel et al., 2013). 
Under physiological conditions, αS persists as an intrinsically disordered monomer. Misfolded αS can 
propagate to dimers, oligomers, pre-fibrils, and amyloid fibrils which then make up LB and LN. Although 
the nature of a toxic species is still under debate, several cellular pathways are involved in the αS 
pathology including mitochondrial, ER, Golgi and proteasomal dysfunctions, inhibition of autophagy etc. 
 
 
Mitochondrial dysfunction is considered to be one of the major pathological mechanisms 
underlying both sporadic and familial PD. αS can directly interact with mitochondrial outer 
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membrane and influence fission/fusion homeostasis of mitochondria. A53T-αS transgenic mice 
were characterized by deformed mitochondria and damages of mitochondrial DNA (Martin et al., 
2006). Incorporation of αS into mitochondrial membrane can lead to an intervention in 
mitochondrial fusion and subsequent impairment of mitochondrial motility in neurites, and 
mitophagy, the process through which damaged mitochondria are removed (Mullin and Schapira, 
2013). Besides, αS inhibits mitochondrial complex I (Devi et al., 2008) and may induce apoptosis 
by caspase activation (Parihar et al., 2008). Our lab showed that overexpression of αS, as well as 
βS, in primary cultured cortical neurons can induce morphological abnormalities of 
mitochondria: condensation to swollen rounded structures (Taschenberger et al., 2013), and αS 
can increase thiol oxidation, permeabilization of mitochondrial outer membrane and caspase 
activation (Tolö et al., 2018). 
ER and Golgi stress due to accumulation of misfolded αS can lead to the activation of the 
neuronal death cascade. Abnormal ER morphology and activation of caspase 12 and subsequent 
apoptosis were reported in A53T-αS tg mice (Colla et al., 2012). Oxidative stress and 
proteasomal dysfunction are also typical for PD and DLB pathology and were described in 
several cell culture and animal models in association with αS. Increased intracellular ROS levels 
may be one of the reasons for the selective vulnerability of dopaminergic neurons in PD brains 
(Puspita et al., 2017). Pore formation in the cellular membrane and disruption of ion homeostasis 
was also suggested as one of the synucleins pathological mechanisms (Tsigelny et al., 2007). Not 
only αS but also wild type βS (WT-βS) was shown to form transient channels in artificial 
membranes (Taschenberger et al., 2013). 
Besides recent publication on βS toxicity in primary cortical cells and rats SN with some 
mechanisms mentioned above (Taschenberger et al., 2013), βS axonal pathology was also 
detected in hippocampi of PD and DLB patients (Galvin et al., 1999). βS accumulations in form 
of axonal spheroids but not in LB were found in NBIA type 1, rare synucleinopathy characterized 
by the combination of parkinsonism and cognitive impairment (Galvin et al., 2000). Extensive βS 
accumulations were described in Purkinje cells of MSA patients (Mori et al., 2003). βS was 
found to be toxic and formed cytosolic inclusions in a similar way as αS in the yeast model of PD 
(Tenreiro et al., 2016). βS may also cause inflammation in NDDs (Mor et al., 2003). 
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1.3.4. Aggregation properties of synuclein proteins 
In solutions, αS is usually present as a natively unfolded intrinsically disordered monomer. 
Alternatively, Bartels et al. suggested that endogenous αS may persist in form of a 58 kDa helical 
tetramer, a stable physiological form of αS which resists aggregation (Bartels et al., 2011), 
though this hypothesis remains under debate (Fauvet et al., 2012). Upon binding to lipid 
membranes or SDS-micelles with its N-terminal region, αS can obtain a more stable 
conformation with 2 canonical α-helices (Alderson and Markley, 2013). 
Once αS is misfolded, it can aggregate into dimers, oligomers, and fibrils (Figure 1.4). The 
mechanisms of conversion of αS into a toxic species, the molecular basis of aggregation and 
nucleation, and the nature of such toxic species are not yet clearly understood. Growing evidence 
indicates that soluble αS oligomers or protofibrils of certain confirmation may be the pathogenic 
species which could initiate seed formation or nucleation, while the large filamentous aggregates 
in LBs and LNs are rather cytoprotective side products of the aggregation process (Karpinar et 
al., 2009; Paleologou et al., 2009; Winner et al., 2011).  
Numerous factors can influence αS aggregation. Thus, increase in αS concentration, such as 
observed with familial duplication or triplication of SNCA gene, promotes fibrillation. Besides, 
the missense mutations of αS, associated with rare familial PD and DLB cases may induce the 
pathological cascade of αS aggregation (see section 1.2.5.). Post-translational modifications 
(PTM) also regulate αS aggregation propensities, e.g. phosphorylation of serine 129 promotes 
fibrillation (Fujiwara Het al., 2002) while nitration reduces aggregation of αS (Yamin et al., 
2003). Environmental factors, such as metals (Fe2+, Cu2+) and pesticides (paraquat, rotenone) can 
accelerate fibrillation of αS (Deleersnijder et al., 2013). 
Previous studies have demonstrated that βS and γS may reduce αS aggregation in vitro under 
certain conditions (Uversky et al., 2002; Leitao et al., 2018), thus, a role of βS as a negative 
regulator of αS and as a neuroprotective factor was suggested (Hashimoto et al., 2001). The 
differences in aggregation propensities are connected not only to the 11-AA deletion in the NAC 
domain in βS but also lies in the structure of the C-terminal region and intramolecular 
electrostatic interactions between N- and C-termini. Such interactions are stronger in βS than in 
αS which leads to a more stable monomeric form of βS (Allison et al., 2014). However, certain 
conditions can stimulate βS aggregation. Yamin et al. showed that βS fibrillation can be triggered 
by the presence of macromolecular crowding agents, heavy metals (Zn2+, Pb2+, and Cu2+), and 
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pesticides while organic solvents cause the formation of the amorphous βS aggregates (Yamin et 
al., 2005). βS can also form a high-affinity complex with Cu+-ion which changes the 
conformation of βS to an α-helix (Miotto et al., 2017). Moreover, a switch of pH to the more acid 
one (pH 5.8) which is characteristic for some compartments of the cell, e.g. lysosomes, can 
promote βS aggregation (Moriarty et al., 2017; Landau, 2017). Previously our group showed that 
βS could form PK-resistant aggregates also in vivo which correlated to a dramatic loss of 
dopaminergic neurons in rats SN (Taschenberger et al., 2013). 
Although βS was not found in LB or LN, some histopathological findings showed that it might 
aggregate also in patients’ brains. βS was accumulated in axonal spheroids in PD, DLB and 
NBIA type 1 brains (Galvin et al., 1999; Galvin et al., 2000). WT-βS was found in Triton X 
detergent-insoluble fractions but not in LBs of the DLB brains (Wei et al.,2007). 
 
1.3.5. P123H and V70M mutants of βS 
Although P123H-βS and V70M-βS were discovered in 2004 there are just a few publications 
devoted to these DLB-associated synuclein species.  
Ohtake et al., 2004 suggested that P123H and V70M mutations of βS may have an effect on its 
tertiary structure and aggregation propensities. Amino acid residues at positions 123 and 70 of βS 
are highly conserved between vertebrate species. They are identical in human, rat, mice, pig etc 
(UniProt search). P123H, the proline to histidine substitution at codon 123 results in the reduction 
of negative charge at the C-terminal region of βS since histidine, unlike proline, has a basic side 
chain at physiological pH. Proline, in its turn, is uncharged and sterically constrained due to the 
pyrrolidine ring. The valine to methionine substitution at codon 70 is located to the NAC-domain, 
which was shown to be important for αS fibrillation. Bulky sulfur group of methionine might also 
influence confirmation properties of βS with consequent functional implications (Ohtake et al., 
2004). 
In 2007 Wei et al., showed that stable overexpression of P123H-βS and V70M-βS in the 
neuroblastoma cell line B103 caused an increase in lysosomal activity and formation of 
lysosomal inclusion bodies where mutant βS accumulated. These effects were greatly enhanced 
when αS was co-expressed with the βS mutants (Wei et al., 2007). Addition of gangliosides, 
inhibited such accumulation of P123H-βS and lysosomal pathology in cultured cells (Wei et al., 
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2009). Recombinant P123H-βS and V70M-βS were more prone to aggregation than WT-βS 
under cell-free conditions which suggested a possible connection between toxicity and 
aggregation properties of these proteins (Wei et al., 2007). 
A P123H-βS transgenic mouse line was recently generated. These animals were characterized by 
neuritic pathology (axonal swellings), astrogliosis, and memory deficits. Histopathological 
analysis revealed an age-dependent accumulation of insoluble P123H-βS. The double transgene 
animals obtained by the cross-breeding ofP123H-βS-tg mice and αS-tg mice were characterized 
by enhanced loss of hippocampal neurons and striatal dopaminergic fibers. Altogether these data 
suggested a putative causative role of P123H-βS in familial DLB pathology (Fujita et al., 2010). 
Ultrastructural analysis of axonal swellings in P123H-βS-tg and αS-tg mice revealed the 
accumulation of autophagosome-like membranous structures in both conditions but only 
axonopathies of αS-tg mice were positive for LRRK2 and mitochondrial factors cytochrome c, 
VDAC1, and COX IV (Sekigawa et al., 2012; Sekigawa et al., 2013). However, no mouse line 
with overexpression of WT-βS or double transgene of WT-βS and αS were generated in these 
studies for control. One cannot exclude that the observed neuropathology arisen not due to the 
P123H mutation but due to mere increase in βS concentration due to overexpression. 
Already during this Ph.D. project, some conformational propensities of P123H-βS were 
characterized by Janowska and Baum with biophysical methods on recombinant proteins in vitro. 
ESI-MS experiments revealed more compact conformation of the C-terminal region in P123H-βS 
than in WT βS acetylated recombinant proteins. Thioflavin T (ThT) spectroscopic assay showed 
increased fibril formation of co-incubated P123H-βS and αS in contrast to a “WT-βS + αS” 
condition where fibril formation was delayed. Further biophysical investigation showed that the 
P123H mutation renders the C-terminus of βS more flexible and more similar in its conformation 
properties to αS (Janowska and Baum, 2016). Recently, an attenuation of autophagy associated 
with accumulation of βS was described in the brains of DLB patients. Confirmatory in vitro 
experiments of this study showed that WT-βS can inhibit the autophagy flux, and V70M-βS can 
cause an even more dramatic reduction in autophagy which might potentially lead to the 
impairment of protein degradation pathways and neuronal cell death (Evans et al., 2018). 
Overall, the extent to which WT-βS, P123H-βS, and V70M-βS are causative for DLB is largely 
unknown. This work aimed to elucidate if P123H and V70M mutations increase the neurotoxicity 
of the WT-βS. 
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1.4. Viral vector-mediated models of neurodegenerative disorders 
 
1.4.1. AAV vectors 
Adeno-associated viruses (AAV) are small single-stranded DNA non-enveloped viruses of the 
Parvoviridiae family. AAV is classified as a dependovirus because it cannot autonomously 
replicate without a so-called helper virus, such as adenovirus, herpesvirus or papilloma virus 
(Grieger et al., 2012).  
The AAV genome consists of only ~4.7 Kb which is one of a few limitations for AAV use. The 
AAV genome includes 3 major regions: the rep gene which encodes 4 replication and integration 
proteins, the cap gene which encodes 3 proteins of the viral capsid, and the inverted terminal 
repeats (ITR) which flank the rep and cap genes and serve as the origins of replication. In 
recombinant AAV vectors, both rep and cap genes are removed, so these viruses are not able to 
replicate. A transgene cassette can be then introduced into the AAV genome in place of rep and 
cap genes (Ortolano et al., 2012).   
AAV vectors have numerous advantages for application in research and gene therapy. AAV is 
not pathogenic, it has not been associated with any known disease so far. AAV viruses have very 
low immunogenicity in most experimental animal species. They infect both dividing and 
quiescent cells and can provide stable long-term transgene expression without causing 
inflammatory or toxic side-effects. AAV persist mostly in the episomal state which reduces the 
risk of mutagenic insertions in the DNA. A simple structure of the AAV genome allows 
straightforward vector design whereby transgene expression can be modulated with simple 
approaches. For instance, the strength of a promoter can be regulated by changes in the non-
coding sequences of 3´-untranslated region (UTR), 5´UTR, enhancer or polyadenylation sites. 
Cell type-specific promoters can be employed to restrict a transgene expression to a desired cell 
type, e.g. the human synapsin 1 promoter controls strictly neuron-specific expression (Gray, 
2012). Besides, diverse serotypes of AAV viruses have different cellular tropism and 
transduction properties, which makes them a useful tool for targeting specific cells or tissues, for 
focal or global gene delivery (Weinberg et al., 2013).   
rAAV-mediated gene delivery has demonstrated success in a variety of animal species and 
tissues. The viral vectors can be applied at any age of the animal which allows studying the role 
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of a transgene without developmental interference. AAV vectors allow simultaneous delivery of 
multiple genes and have the potential to expand transgenic research to a variety of model 
organisms (Burger et al., 2004).    
 
1.4.2. Advantages of AAV animal models for synucleinopathies. 
The animal models of NDDs are created in order to recapitulate and study the role of 
pathophysiological aspects of these diseases. Although not all features of PD or DLB can be 
recreated in a single animal model, a combination of various model species and approaches can 
facilitate the completion of the mosaic of synucleinopathies’ etiology and pathogenesis.  
The main hallmarks of PD are the aggregation of αS in form of LBs and LNs and the progressive 
loss of dopaminergic neurons in SNpc. Over 30 transgenic mouse lines were generated for 
overexpression of WT αS (Kahle et al., 2000; van der Putten et al., 2000; Rockenstein et al., 
2002), its missense mutations A53T (Giasson et al., 2002), A30P (Neumann et al., 2002), etc., 
and other PD-related genes such as LRRK2 (Tong et al., 2009), parkin (Lu et al., 2009), DJ1 
(Chen et al., 2005) to name a few. These models showed some neuropathological features of PD 
and DLB such as αS accumulation or aggregation, motor, and cognitive phenotypes, but none of 
the described so far genetically engineered mouse models shows progressive loss of 
dopaminergic neurons (Crabtree and Zhang, 2012). Here, AAV animal models appeared to be 
very useful because time-dependent progressive neurodegeneration in SNpc can be recapitulated 
in them (Decressac et al., 2012a, b; Taschenberger et al., 2012).  
The viral models provide several advantages over genetically engineered mice in addition to the 
described loss of dopaminergic neurons in SNpc: 
- The viral animal models can be produced easier, faster and cheaper than transgenic mouse 
lines, since a complex cross-breeding is not needed here. 
- The expression of a transgene can be – to some extent – restricted to the area of interest 
by the stereotaxic injection of AAV vectors. The virus can be applied unilaterally and the 
injected and contralateral sides can be compared. This is especially important for some 
behavioural tests, which depend on the lesion asymmetry, e.g. the apomorphine test.   
- A variety of the AAV serotypes with different cell tropism could be employed. 
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- The expression level of a PD-related protein can be adjusted simply by changing the viral 
dose, a promoter, or other regulatory elements in the expression cassette. 
- The experiments with viral models can be transferred relatively easy to other species: 
from rat to mouse or to non-human primates. This gives additional flexibility with 
experimental design. 
- The AAV vectors can be delivered at any age so that even developmentally lethal genes 
can be studied. 
Some possible disadvantages of the AAV viral vectors lie in the variability of results between the 
laboratories which can be caused even by slight changes of the experimental design, different 
structure of the expression cassettes, by usage of different AAV serotypes or differences in viral 
production and titration protocols (Löw and Aebischer, 2012; Volpicelli-Daley et al., 2016). 
Besides, AAV viral vectors have to be injected into each experimental animal individually using 
stereotaxic surgery techniques.  
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1.5. The aim of the project 
 
200 years after the first description of PD patient and 20 years after the recognition of αS as the 
major component of Lewy bodies, many aspects of synucleinopathies remain unknown. 
Extensive studies of the disease-associated αS mutations brought many valuable insights into our 
understanding of molecular processes leading to a toxic conversion of αS, despite these mutations 
being present in the very rare familial cases. Research on the DLB-associated mutations of βS 
could shed light on this still elusive and controversial homologue of αS. Although it was claimed 
before that βS may inhibit αS aggregation and possibly act as a neuroprotective factor in some 
experimental models (Hashimoto et al., 2001), our lab described the conditions under which βS 
can induce neurotoxicity in vitro and in vivo (Taschenberger et al., 2013).  
Here, I aimed to study further the abilities of βS to aggregate and induce neurodegeneration in 
vitro in cultured cortical neurons and in vivo in rat’s Substantia nigra and compare the respective 
properties with those of the disease-associated mutants of βS: P123H-βS and V70M-βS. I wanted 
to elucidate if these mutations are indeed causative to neuropathological effects or if they are just 
coincidental with DLB. 
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2. Materials and Methods 
 
2.1. Materials 
 
2.1.1. Chemicals 
 
0.9 % NaCl B.Braun (Melsungen, Germany)  
2-log DNA ladder New England BioLabs (Ipswich, MA, USA) 
αSyn, recombinant protein rPeptide (Bogart, USA) 
βSyn, recombinant protein rPeptide (Bogart, USA) 
Aceton Roth (Karlsruhe, Germany) 
Acetic acid Roth (Karlsruhe, Germany) 
Agarose Sigma Aldrich (Taufkirchen, Germany) 
APS       Sigma Aldrich (Taufkirchen, Germany)  
Acrylamide      Roth (Karlsruhe, Germany) 
B-27 Supplement     Gibco (Karlsruhe, Germany)  
Bepanthene      Bayer (Leverkusen, Germany)  
Boric acid Roth (Karlsruhe, Germany) 
Braunol  B.Braun (Melsungen, Germany) 
Bromphenol Blue Sigma Aldrich (Taufkirchen, Germany)  
BSA        Sigma Aldrich (Taufkirchen, Germany) 
Carprieve Bayer (Leverkusen, Germany) 
Coomassie Brilliant Blue R250 Merck (Darmstadt, Germany) 
CutSmart buffer New England BioLabs (Ipswich, MA, USA) 
DAPI       Sigma Aldrich (Taufkirchen, Germany)  
DMEM Sigma Aldrich (Taufkirchen, Germany) 
DMSO Sigma Aldrich (Taufkirchen, Germany) 
DNAseI Roche (Basel, Switzerland) 
dNTPs New England BioLabs (Ipswich, MA, USA) 
DPX       Fluka (Steinheim, Germany)  
EDTA       Merck (Darmstadt, Germany) 
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Ethanol absolute     Applichem (Darmstadt, Germany)  
FCS       Biochrom (Berlin, Germany) 
Glycerin Roth (Karlsruhe, Germany)  
Glycine      Applichem (Darmstadt, Germany)  
Glucose Roth (Karlsruhe, Germany) 
HBSS 10x Gibco (Karlsruhe, Germany)  
HEPES       Sigma Aldrich (Taufkirchen, Germany) 
H2O2 Merck (Darmstadt, Germany) 
KCl Roth (Karlsruhe, Germany) 
Ketamine      Medistar (Ascheberg, Germany)  
L-Glutamine      Lonza (Cologne, Germany)  
Laminin      Sigma Aldrich (Taufkirchen, Germany)  
Luminol      Calbiochem (Darmstadt, Germany)  
LB-agar Roth (Karlsruhe, Germany) 
LB-medium Roth (Karlsruhe, Germany) 
Metapyrin Serumwerk (Bernburg, Germany) 
Methanol      Roth (Karlsruhe, Germany) 
MgCl2 Sigma Aldrich (Taufkirchen, Germany) 
MgSO4 Roth (Karlsruhe, Germany) 
Mineral oil      Sigma Aldrich (Taufkirchen, Germany)  
Mowiol - 488      Calbiochem (Darmstadt, Germany) 
NaCl Roth (Karlsruhe, Germany) 
NaHCO3 7.5% Gibco (Karlsruhe, Germany) 
NaH2PO4 Roth (Karlsruhe, Germany) 
NaN3 Sigma Aldrich (Taufkirchen, Germany)  
NaOH       Applichem (Darmstadt, Germany)  
Neurobasal medium    Gibco (Karlsruhe, Germany)  
NGS       Biochrom (Berlin, Germany) 
Nonfat dried milk     Applichem (Darmstadt, Germany)  
p - cumaric acid     Applichem (Darmstadt, Germany)  
PageRuler™ Plus, protein ladder Thermo Scientific (Waltham, MA, USA). 
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PBS       Applichem (Darmstadt, Germany)  
PFA       Roth (Karlsruhe, Germany) 
Phusion HF buffer New England BioLabs (Ipswich, MA, USA) 
Phusion HF DNA polymerase New England BioLabs (Ipswich, MA, USA) 
PK Invitrogen/Thermo Scientific (Darmstadt, Germany) 
PLO       Sigma Aldrich (Taufkirchen, Germany) 
PSN Gibco (Karlsruhe, Germany) 
Restriction enzymes New England BioLabs (Ipswich, MA, USA) 
Rymadil Zoetis (Parsippany-Troy Hills, NJ, USA) 
SDS pellets Roth (Karlsruhe, Germany) 
Sodium acetate Sigma Aldrich (Taufkirchen, Germany) 
Sucrose      Roth (Karlsruhe, Germany) 
TEMED       Roth (Karlsruhe, Germany)  
Transferrin Sigma Aldrich (Taufkirchen, Germany) 
Tris base      Applichem (Darmstadt, Germany)  
Tris HCl      Applichem (Darmstadt, Germany)  
TritonX 100      Roth (Karlsruhe, Germany) 
Trypan blue Sigma Aldrich (Taufkirchen, Germany) 
Trypsin      Sigma Aldrich (Taufkirchen, Germany) 
Tween20      Applichem (Darmstadt, Germany)  
Xylariem Ecuphar (Greifswald, Germany)  
Xylene       Sigma Aldrich (Taufkirchen, Germany) 
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2.1.2. Antibodies 
 
Table 2.1 Primary antibodies 
 
Antigen Host species, 
clonality 
Product 
number 
Company Application Concentration 
6xHis mouse mono ab18184 Abcam WB 1:5000 
AU1 mouse mono MMS-130R HiSS WB 1:500 
αSyn (Syn211, 
human) 
mouse mono 32-8100 Invitrogen WB 
IHC-IF 
1:1000 
1:1000 
αSyn (C-20, 
human) 
rabbit poly sc-7011-R Santa Cruz WB 
IHC-IF 
1:1000 
1:500 
Bcl-xL rabbit mono 2764 Cell 
Signalling 
WB 1:1000 
β-Tubulin mouse mono T-4026 Sigma WB 1:5000 
βSyn (C-termi-
nal) 
rabbit poly ab6165 Abcam WB 1:1000 
βSyn (aa 81-95) rabbit poly SAB1100305 Sigma WB 
IHC-IF 
1:1000 
1:1000 
βSyn (N-termi-
nal) 
rabbit mono ab76111 
(EP1537Y) 
Abcam WB 1:3000 
γSyn rabbit poly ab6169 Abcam WB 1:1000 
GFP mouse mono 11814460001 Roche WB 1:5000 
panSyn rabbit poly ab6176 Abcam WB 1:1000 
TH  rabbit poly ab152 Abcam WB 
IHC-DAB 
1:5000 
1:3000 
TH mouse mono T1299 Sigma IHC-IF 1:1000 
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Table 2.2 Secondary antibodies 
 
Conjugate Species  Product 
number 
Company Application Concentration 
DyLight488 goat-anti- rabbit 115-485-072 Dianova IHC-IF 1:250 
Cy3 goat-anti- mouse 115-165-003 Dianova IHC-IF 1:250 
Biotin goat-anti-rabbit BA-1000 Vector 
Laboratories 
IHC-DAB 1:250 
HRP goat-anti- rabbit sc-2004 Santa Cruz WB 1:4000 
HRP goat-anti- mouse sc-2005 Santa Cruz WB 1:3000 
      
2.1.3. Plasmids 
 
pAAV6-s-SEWB (kindly provided by Dr. Sebastian Kügler) 
pAAV6-s-αSyn-SEIS-WB (kindly provided by Dr. Sebastian Kügler) 
pAAV6-s-WT-βSyn-SEIS-WB (kindly provided by Dr. Sebastian Kügler) 
pAAV6-s-P123H βSyn-SEIS-WB (kindly provided by Dr. Sebastian Kügler) 
pAAV6-s-ɣSyn-SEIS-WB (kindly provided by Dr. Sebastian Kügler) 
pT7.7-αSyn–Amp (subcloned by Anupam Raina) 
 
2.1.4. Oligonucleotides 
 
5’-αSyn-AU1-Asc: 
AAAAAAGGCGCGCCAAACCACCATGGATGTATTCATGAAAGGACTTTCAA 
3’- αSyn-AU1-Sbf: 
TTTTTTCCTGCAGGTTTCTATTAACCTATATATCGGTATGTATCTCCGGCTTCAGGTTC
GTAGTCTTGA 
5’-βSyn-AU1-Asc: 
AAAAAAGGCGCGCCAAACCACCATGGACGTGTTCATGAAGGGCCTGTCCA 
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3’- βSyn-AU1-Sbf: 
TTTTTTCCTGCAGGTTTCTATTAACCTATATATCGGTATGTATCTCCCGCCTCTGGCTC
ATACTCCTGATA 
5’-γSyn-AU1-Asc: 
AAAAAAGGCGCGCCCCACCATGGATGTCTTCAAGAAGGGCTTCTCCATCGC 
3’- γSyn-AU1-Sbf: 
TTTTTTCCTGCAGGTTTCTATTAACCTATATATCGGTATGTATCTCCGTCTCCCCCACT
CTGGGCCTCCT 
5’-αSyn-6xHis-NdeI: 
CGGTGTAATCATATGGATGTATTCATGAAAGGACTTTCAAAGGCCAAGGAG 
3’- αSyn-6xHis-HindIII: 
GCGTTGAAGCTTTTAATGATGATGATGATGATGGGCTTCAGGTTCGTAGTCTTGATAC
C 
5’-βSyn-6xHis-NdeI: 
CGGTGTAATCATATGGACGTGTTCATGAAGGGCCTGTCC 
3’- βSyn-6xHis-HindIII: 
GCGTTGAAGCTTTTAATGATGATGATGATGATGCGCCTCTGGCTCATACTCC 
T7 (for sequencing):  
TAATACGACTCACTATAGGG 
 
2.1.5. Buffers and Solutions 
 
aCSF(1x): 128 mM NaCl, 30 mM HEPES, 3 mM KCl, 1 mM MgSO4, 1 mM NaH2PO4, 10 mM 
Glucose, pH 7.45; filtered and autoclaved. 
Blocking solution for IHC: 5% NGS, 0.1% Triton X-100 in PBS (pH 7.4).  
Blocking solution for WB: 5% non-fat dry milk in TBS-T (pH 7.6).  
Borate buffer: 150 mM boric acid in was diluted in ddH2O, pH was adjusted with NaOH to 8.4, 
then sterile filtered.  
CMF-medium: dilute HBSS 1:9 in ddH2O, add sodium bicarbonat 7.5% until pH 7.2-7.4. The 
color of solution should be red, not orange or pink.  
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Coomassie staining solution: 0.1% Coomassie Brilliant Blue R-250, 7.5% acetic acid, 25% 
methanol, in H2O.  
Coomassie destaining solution: 20% isopropanol, 7.5% acetic acid, in H2O. 
DNA loading buffer (6x): 15% Ficoll 400 DL, 100 mM LiCl, 2% glycerol, 100 mM EDTA (pH 
8.0), 0.6% SDS, 0.03% BPB in H2O. 
DNAseI: 5 mg of DNAse were dissolved in 1 ml of Ca2+/Mg2+ free medium (CMF), aliquoted 
(100 µl) and stored at -20°C. Final concentration was 5 mg/ml.  
ECL 1: 2.5 mM Luminol, 0.4 mM p-Coumaric acid, 0.1 M Tris-HCl; pH 8.5.  
ECL2: 18% H2O2, 0.1 M Tris; pH 8.5.  
Electrophoresis buffer 10x: 1.9M Glycine, 1% SDS, 250 mM Tris-HCl. 1x solution prepared 
fresh before the SDS-PAGE. 
FCS (for cell culture): FCS was thawed, pre-warmed at 37°C and heat inactivated for 30 min at 
56°C.  1ml aliquots were stored at -20°C.  
HCN medium:5 µg/ml Transferrin, PSN (Penicillin 50 μg/ml, Streptomycin 50 μg/ml, 
Neomycin 100 μg/ml), 2 mM L-Glutamin, 2% B-27 supplement in Neurobasal medium (NBM).  
Incubation solution for primary antibody for IF: 2% NGS, 0.02% NaN3 in PBS (pH 7.4) with, 
0.1% Triton X-100.  
Incubation solution for secondary antibody for IF: 2% NGS in PBS (pH 7.4) with 0.1% 
Triton X-100.  
Laminin: Laminin aliquots were stored at -800C. Laminin was diluted 1:1000 (1 µg/ml) in 
DMEM before use.  
LB medium: 25 g of LB powder was dissolved in 1L H2O, autoclaved and stored at 4° C. 10 
mg/ml ampicillin was added right before the use. 
LB agar: 40 g of LB agar was dissolved in 1L H2O. Solution was aliquoted to 100- or 200-ml 
portions, autoclaved and stored at 40C. Upon necessity, an aliquot of LB agar was heated up to 
60°C, 10 mg/ml ampicillin was added, and the solution was poured into sterile Petri dishes in a 
clean bank. Plates were dried o/n, then stored no longer than 2 weeks at 4°C. 
 
2. Materials and Methods 
27 
 
Lysis buffer I: 0.5% SDS, 1 mM DTT, 50 mM Tris-HCl pH 8.0, proteinase and phosphatase 
inhibitors.  
Lysis buffer II (PK digestion): 0.5% SDS in PBS, pH 7.4. 
Mowiol: 4.8 g Mowiol 4-88 was mixed with 12 g glycerol. Then 6 ml of water was added and 
solution was stirred for 3h at RT. After Mowiol dissolved the solution was clarified by 
centrifugation at 5000 x g for 15 min. Then Mowiol was aliquoted and frozen (-20°C) for long-
term storage or kept at 4° C for short-term storage. Mowiol was warmed up at 370C for 30 min 
before each use. 
PFA 4%: 40 g PFA, 9.55 g PBS powder in 1L ddH2O, add 1 ml NaOH for better dissolving of 
PFA, gently heat to 60° C for ~1 h (until PFA is completely dissolved). Adjust pH to 7.4, filter. 
Keep at 40C no longer than 1 week. 
PBS: 9.55 g PBS powder in 1L ddH2O; filtered, autoclaved.  
Poly-D-ornithine (10x): 50 mg of poly-D-ornithine was dissolved in 50 ml of sterile and filtered 
borate buffer. 1x solution (0.1 mg/ml) was prepared before use by dilution in sterile H2O. 
SDS-Sample buffer (6x): 350 mM Tris-HCl, pH 6.8; 10% SDS, 0.6 M DTT, 30% Glycerol, 
0.03% BPB. 
SOC++ medium: 2% bacto-tryptone, 0.5% yeast extract, 2.5 mM KCl, 10 mM MgCl2, 10 mM 
MgSO4, 10 mM NaCl, 20 mM glucose, pH 7.0.  
TE (1x): 10 mM Tris-HCl (pH 7.4) and 1 mM EDTA (pH 8.0).  
TBE (1x):  42 mM boric acid, 10 mM EDTA, 50 mM Tris-HCl, set to pH 8.0.  
TBS (antigen retrieval): 150 mM NaCl, 10 mM Tris-HCl, pH 9.0  
TBS (DAB staining protocol): 0.1MTris-HCl and 150 mM NaCl, pH 7.4. 
TBS-T (10x): 1.5M NaCl, 200 mM Tris, 0.1% Tween 20, pH 7.6. 10x solution was stored at 40C. 
Transfer buffer (1x): 192 mM Glycine, 25 mM Tris-HCl, 20% Methanol. The buffer has to be 
automatically at pH 8.3, pH cannot be adjusted. Addition of Methanol here is exothermic; 
therefore, the buffer has to be prepared 1 day in advance and to be cool down to 40C. 
Trypsin 0.25%: 25 mg Trypsin in 10 ml CMF, sterile filtered  
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Tris pH 6.8(4x): 0.5 M Tris-HCl, 100 ml H2O, pH 6.8.  
Tris pH 8.8 (4x): 1.5 M Tris-HCl, 100 ml H2O, pH 8.8. 
 
2.1.6. Kits 
 
BCA protein assay kit, Pierce Thermo Scientific (Rockford, IL, USA) 
DNA gel extraction kit Quiagen (Hilden, Germany) 
DAB Peroxidase Substrate Kit SK-4100 Vector Laboratories (Burlingame, USA) 
Gel Extraction Kit Quiagen (Hilden, Germany) 
HRP Substrate Pico, Immobilon Western Millipore (Billeria, USA) 
HRP Substrate Femto, SuperSignal West 
Femto 
Thermo Scientific (Rockford, IL, USA) 
Miniprep kit Quiagen (Hilden, Germany) 
Megaprep kit Macherey Nagel (Düren, Germany) 
PCR purification kit Quiagen (Hilden, Germany) 
VECTASTAIN ABC Peroxidase Standard Kit 
PK-4000 
Vector Laboratories (Burlingame, USA) 
VECTASTAIN ABC Peroxidase Elite Kit PK-
6100 
Vector Laboratories (Burlingame, USA) 
 
2.1.7. Animals, cell lines and electrocompetent cells 
 
Wistar rats, Janvier (for in vivo experiments) 
Wistar rats, Central Animal Facility, University of Göttingen (for primary cell culture) 
DH5αE. Coli strain, ElectroMAX 
BL21 (DE3) E. coli strain, Invitrogen 
SURE®E. coli strain, Stratagene 
HEK293 cells, Stratagene 
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2.1.8. Equipment and consumables 
 
24-well sterile cell culture plates Greiner bio-one (Frickenhausen, Germany) 
96-well micro-test plate    Sarstedt (Nümbrecht, Germany) 
Autoclave Systec (Linden, Germany) 
Bacterial incubator, Certomat IS B.Braun (Melsungen, Germany) 
Bead mill homogenizer Precellys 24 Peqlab (Erlangen, Germany) 
Biophotometer Eppendorf (Hamburg, Germany) 
Capillary pipet tips for gel wells Biozym Scientific (Oldendorf, Germany) 
Cell culture incubator, Hera Unity Lab Services, part of Thermo Fisher 
Scientific GmbH (Schwerte, Germany) 
Centrifuge, Heraeus Megafuge 1.0R Unity Lab Services, part of Thermo Fisher 
Scientific GmbH (Schwerte, Germany) 
Clean bank, Hera guard, Heraeus Unity Lab Services, part of Thermo Fisher 
Scientific GmbH (Schwerte, Germany) 
Cover slides, 24 x 60 and 24 x 55 mm Menzel (Braunschweig, Germany) 
Cover slides, diameter 12 mm Menzel (Braunschweig, Germany) 
Cryostat CM 3050S     Leica Microsystems (Mannheim, Germany) 
Cryomatrix Thermo Scientific (Waltham, CA, USA) 
DNA electrophoresis chamber Bio-Rad (Munich, Germany) 
Drill tip 0.8 mm  Dremel (Breda, Netherlands) 
Electrophoresis power supply, E835   Consort (Turnhout, Belgium) 
Freezer -800C, Herafreeze Unity Lab Services, part of Thermo Fisher 
Scientific GmbH (Schwerte, Germany) 
Gel Documentation 2000TM UV 
Transilluminator 
Bio-Rad (Munich, Germany) 
Glass capillaries, 3.5 nanoliter World Precision Instruments (Sarasota, FL, 
USA) 
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High temperature cautery kit Bovie medical corporation (Clearwater, FL, 
USA) 
Ice machine Zigra (Isernhagen, Germany) 
Insulin syringes, U-100, BD Micro-Fine BD Medical (Franklin Lakes, NJ, USA) 
Microcentrifuge 5415R Eppendorf (Hamburg, Germany) 
Micro drill  Proxxon (Wecker, Luxemburg) 
Micro injector Nanoliter 2000 World Precision Instruments (Sarasota; Fl, 
USA) 
Micro pipette puller P97 Satter Instruments Company (Novato, CA, 
USA) 
Micro syringe pump controller, Micro4 World Precision Instruments (Sarasota; Fl, 
USA) 
Micro tube 2 ml, PP Sarstedt (Nümbrecht, Germany) 
Microscope Axio Observer.Z1 Carl Zeiss Microscopy (Jena, Germany) 
Microscope Axioplan 2 Carl Zeiss Microscopy (Jena, Germany) 
Microscope Imager D2 Carl Zeiss Microscopy (Jena, Germany) 
Mini-PROTEAN Tetra Cell system Bio-Rad (Munich, Germany) 
Mini Trans-Blot Cell system Bio-Rad (Munich, Germany) 
Neubauer counting chamber Brand (Wertheim, Germany) 
Nitrile examination gloves, Micro-Touch Ansell (Brussel, Belgium) 
Nitrocellulose membrane, 0.22 µm pore size AppliChem (Darmstadt, Germany) 
Parafilm M Bemis NA (Neenah, WI, USA) 
Pasteur capillary pipettes Sigma Aldrich (Taufkirchen, Germany) 
Peristaltic perfusion pump    Ismatec (Wertheim, Germany) 
Pipette controller, acu-jet pro Integra (Bibertal, Germany) 
Precellys 24 Zirconium oxide beads 1.4 mm Bertin instruments (Hamburg, Germany) 
Protein LoBind tube, 0.5 and 1.5 ml Eppendorf (Hamburg, Germany) 
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Purple nitrile-XTRA exam gloves Halyard (Zaventem, Belgium) 
Sterile bank, LaminAir HB 2448 Unity Lab Services, part of Thermo Fisher 
Scientific GmbH (Schwerte, Germany) 
Sterling nitrile exam gloves Halyard (Zaventem, Belgium) 
Spacer plates and short plates    Bio-Rad (Munich, Germany) 
Spinal needle diameter 1.2 mm Vygon (Ecouen, France) 
Stereotactic frame, rat jaw holder, ear bars   David Kopf Instruments (Tujunga, CA, USA) 
SuperFrost Plus Microscope Slides Menzel (Braunschweig, Germany) 
Surgical instruments Fine Science Tools (Essen, Germany) 
Tecan Spark 10M plate reader Tecan Group Ltd (Männedorf, Switzerland) 
Thermocycler PTC-150 MiniCycler  
MJ Research Inc. (St. Bruno, Canada) 
Transilluminator, Chemi Doc XRS+ 
Bio-Rad (Munich, Germany) 
Ultrasonic homogenizer UW 2070 Bandelin electronics (Berlin, Germany) 
Water bath GFL Schütt Labortechnik (Göttingen, Germany) 
Whatman blotting paper    GE Healthcare (Chalfton St. Gilles, UK) 
  
2.1.9. Software 
 
AxioVision 4.8 (Carl Zeiss Microimaging)  
Clone Manager 6 (Scientific & Educational Software, NC, US) 
Finch TV 1.4.0 (N.I.H.) 
G*Power version 3.0.10. (University of Düsseldorf) 
GraphPad Prism 7.02 (GraphPad Software, Inc.) 
ImageJ 1.50e (N.I.H.)  
Image Lab (Bio-Rad) 
Leica Application Suite Advanced Fluorescence 2.7.3.9723 (Leica Microsystems CMS) 
MS Office (Microsoft) 
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Quantity One 4.6.9 (Bio-Rad) 
Spark Control Magellan 1.2 (Tecan) 
Stereo Investigator 9.14.5 (Micro Bright Field Inc.) 
Zen 2.3 (Zen pro and Image processing) (Carl Zeiss Microimaging) 
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2.2 Methods 
 
2.2.1. Molecular cloning 
In terms of the doctoral research project, the next cloning procedures were performed: 
- cDNA for V70M-βS was cloned into the pAAV6-s-synuclein-SEIS-WB and pAAV2-s-
synuclein-WB plasmisds via MluI and SphI restriction sites. 
- The AU1 tag was introduced at the C-terminal of αS, WT-βS, P123H-βS, and γS, and the 
cDNAs were cloned into pAAV6-s-synuclein-SEIS-WB plasmid via Asc and Sbf 
restriction sites. 
- The 6xHis tag was introduced at the C-terminal of αS, WT-βS, P123H-βS, V70M-βS and 
γS and the cDNAs were cloned into T7.7 plasmid via NdeI and HindIII restriction sites 
All procedures were performed according to the standard molecular cloning protocols as 
described in «Molecular Cloning: A Laboratory Manual» Green MR and Sambrook J, 2012. 
Primers were designed and all cloning procedures were simulated with Clone Manager 6 software 
(Scientific & Educational Software, NC, US). 
 
2.2.1.1. PCR amplification 
PCR amplification of the sequences of interest was carried out in a thermocycler PTC-150 
MiniCycler (MJ Research Inc., Canada). The 100 µl reaction mix contained: 1 µl of Phusion HF 
DNA Polymerase, 20 µl of 5x Phusion HF buffer (New England BioLabs, USA), 2 µl of 10 mM 
dNTPs (dATP, dCTP, dGTP, dTTP), 5 µl of 10 µM forward primer, 5 µl of 10 µM reverse 
primer (Sigma, see section 2.1.4. Oligonucleotides), 5 ng DNA, 3% DMSO and 2 mM MgCl2, 
filled to 100 µl with ddH2O. The PCR reaction was performed following the next steps: 
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Then the reaction mix was placed on ice, PCR purification was performed (PCR purification kit, 
Qiagen), and the products of the PCR amplification were analyzed for their size with 
electrophoresis on 1.7% agarose gels (see section 2.2.1.4). 
 
2.2.1.2. DNA precipitation 
DNA precipitation was performed in order to increase the concentration and purity of DNA 
samples before the next molecular cloning procedures. A DNA eluted from the agarose gel or a 
purified PCR product was mixed with 2.5 volumes of ice-cold 100% ethanol and 1/10 volume of 
3M sodium acetate (pH 5.0). The mixture was briefly vortexed and left for precipitation o/n at      
-200C. Next, the mixture was centrifuged 30´ at 13 000 rpm at 40C, 100% ethanol supernatant 
was removed, and ice-cold 70% ethanol was added. The mix was centrifuged again 30´ at          
13 000 rpm at 40C.  Then the 70% ethanol supernatant was carefully removed, the pellet was 
dried at RT and DNA was resuspended in 1x TE buffer.  
 
2.2.1.3. Quantification of DNA concentration  
DNA concentration was determined by the spectrophotometric method using Eppendorf 
Biophotometer. Optical density (OD) of a sample was measured at 260 nm to determine a DNA 
concentration. Additionally, the ratio OD260/OD280 was used to evaluate protein contamination 
(an expected value for the pure DNA is ~1.8). Absorbance reading at 230 nm was performed in 
order to evaluate possible contamination with ethanol or salts (a value for OD260/OD230 was 
expected to be above 1.5). 
 
2.2.1.4. DNA restriction and agarose gel electrophoresis 
For a restriction digest reaction, 5 to 10 µg of a plasmid DNA and 500-600 ng of a PCR product 
were used. Restriction enzymes and CutSmart buffer (New England BioLabs, USA) were added 
to DNA and incubated for 2h in a 370C water bath. The sizes of the obtained DNA fragments 
were verified on an analytical agarose gel. The gels with 0.8% of agarose were used to verify the 
size of a backbone construct (~3000 bp), and the 1.7% gels were used to determine the exact size 
of an insert (~500 bp). To prepare the gel, agarose was dissolved in 1x TBE buffer by boiling in a 
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microwave oven for 2 min, and 3 µl of EtBr was added to the solution before pouring the gel. For 
an analytical gel, the samples were prepared by mixing ~100 ng of DNA, DNA loading dye (6x) 
and 1x TE buffer to the final volume of 10 µl. DNA samples were loaded onto the polymerized 
gel in parallel with the 2-log DNA ladder. Gels were run at 80 V in 1x TBE buffer long enough to 
obtain good separation of the bands. DNA bands were visualized with UV-light at the Gel 
Documentation 2000TM UV Transilluminator (Bio-Rad) using Quantity One software.  
If DNA fragments had the expected size, the rest of the restricted DNA samples were run on 
preparative 0.8 or 1.7% agarose gels as described above. The desired bands were cut out under 
UV illumination and the gel extraction was performed according to the instructions to the 
QIAGEN gel extraction kit. 
 
2.2.1.5. DNA ligation and E. coli transformation 
To perform a ligation, a vector and an insert DNA were mixed in 1:3 molar ratios. After the DNA 
mixture was incubated 5´at 450C, 1 μl T4 DNA Ligase and T4 ligation buffer were added (final 
volume of the reaction mix = 10 μl). The ligation reaction mix was incubated for 25´at 16°C, then 
for 10´ at 25°C. Afterwards, the reaction mix was placed on ice and used for transformation into 
E. coli cells. 
In case of all pAAV plasmids for viral vector production, SURE® E. coli cells (Stratagene, La 
Jolla, USA) were transformed via electroporation. The name of the strain - SURE®- means Stop 
Unwanted Rearrangement Events. These electrocompetent cells were used in order to prevent the 
corruption of ITR sequences in pAAVs. For the transformation, 80 µl of SURE® cells glycerol 
stock was thawed on ice, mixed with 2 µl of a DNA ligation product, transferred to a pre-cooled 
cuvette and subjected to the 1.8 kV electroporation pulse in Bio-Rad Gene Pulser II. Immediately 
after the electroporation, 800 µl of SOC++ medium (pre-warmed in the water bath to 370C) was 
added to the cuvette, cells were transferred to a sterile tube and then incubated for 45´ at 370C 
incubator with moderate shaking. 
DH5α E. coli strain (ElectroMAX) was used for transformation when several pre-cloning steps 
were necessary. Chemically competent DH5α E. coli cells provide easier transformation and a 
higher number of colonies than SURE® E. coli cells.  
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BL21 DE3 competent E. coli cells (Invitrogen, Karlsruhe, Germany) were used for the 
transformation of pT7.7 plasmids and following production of recombinant proteins. 
Transformation of DH5α and BL21 DE3 E. coli cells was performed with the next steps: 50 µl of 
thawed E. coli cells were mixed with 1 ng of a plasmid DNA from the ligation reaction on ice. 
The mix was kept on ice for 30´ without stirring. Then bacteria were heat-shocked for exactly 30 
sec at 42°C and placed on ice again for 5´. Bacteria were supplied with 950 µl of pre-warmed 
SOC++ medium and incubated at 37°C for 1h under 230 rpm shaking. 
After the transformation, SURE®, DH5α and BL21 DE3 bacteria were plated onto the pre-
warmed in the 37°C incubator LB agar plates. All plasmids, described in this thesis, contained the 
ampicillin-resistance gene, therefore LB agar always contained 100μg/ml ampicillin. LB agar 
plates were incubated at 37°C for 14-15 h and single clones were picked for the follow-up 
procedures. 
 
2.2.1.6. Plasmid Mini- and Megaprep 
Plasmid DNA was extracted and purified from the transformed E. coli cells on a small and large 
scale with Mini- and Megaprep protocols respectively. For a Miniprep plasmid purification, a 
single clone of bacteria was picked from the LB agar plate and inoculated to the 10 ml of 
ampicillin-containing LB medium which was then incubated for 14-15 h at 370C with vigorous 
shaking (190 rpm). For a Megaprep, 2 L of LB medium containing 100 μg/ml ampicillin was 
inoculated with 2 ml of LB bacterial culture. The culture was divided into four 2 L flasks and 
incubated for 15 h at 370C with moderate shaking (110 rpm). The bacterial cells were harvested 
by centrifugation at 8 000 rpm for 5´ at RT. Bacterial pellets were used for DNA plasmid 
extractions with the QIAprep Spin Miniprep kit (Qiagen) and NucleoBond® PC 2000 Megaprep 
kit (Macherey Nagel) according to the protocol of the manufacturer. The main steps of the 
protocol included: RNA degradation with RNAse, alkaline lysis of bacterial cell walls and 
membranes, removing of cellular debris with centrifugation, loading supernatant to an ion 
exchange column, washing out chromosomal DNA and proteins with the high-salt solution, and 
elution of plasmid DNA with low-salt buffer. An eluted DNA was precipitated and resuspended 
in 1x TE buffer as described in the section 2.2.1.2. Control digestion followed every Mini- and 
Megaprep of plasmid DNA. 
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2.2.2. AAV vector production and purification 
All viruses were kindly provided by Dr. Sebastian Kügler. The vectors for the in vitro 
experiments were packaged in the AAV6 capsid. The vectors for the in vivo experiments were 
packaged in the AAV2 capsid. Vector production and purification were performed as previously 
published in Kügler et al., 2007. In short, AAV vectors were propagated in HEK293 cells. HEK 
cells were seeded at 1-1.2 x 108 cells per cell factory in DMEM medium containing 10% FCS 
and 1% PS. After reaching ~50% confluency, HEK293 cells were transfected with AAV plasmid 
and pDG helper plasmid with the calcium-phosphate method. The cells were supplied with 2% 
FCS medium during the transfection and 10% FCS medium afterward. The cells were harvested 
and lysed using citric saline ~2 days after transfection. Viral particles were then puriﬁed by 
iodixanol step gradient ultracentrifugation, followed by fast protein liquid chromatography 
(FPLC) and dialysis against PBS. The purity of the virus was confirmed with SDS-PAGE and 
Coomassie staining. The virus titer (vector genome copies) was determined by qPCR. Since it 
was assumed that every 30th viral particle is infectious, viral concentration in transduction units 
corresponded to 1/30 of the concentration in vector genome copies, e.g. 1x108 tu = 3x109 vg. 
During all procedures dealing with AAV vectors, 0.5% SDS water solution was used for 
disinfection. 
Genetic content of all AAV vectors used in this thesis is schematically described in Figure 2.1: 
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Figure 2.1.Structure of the AAV vector genomes. Bicistronic AAV6 vector which includes a cDNA 
for humansynuclein (either αS, WT-βS, P123H-βS, V70M-βS or γS) and the cDNA for EGFP were 
constructed for expression in primary cortical neuron culture (a-e). cDNAs for αS, WT-βS, P123H-βS or 
γS with the sequence for the C-terminal AU1-tag were cloned into bicistronic AAV6 plasmids (f-i). 
Monocistronic AAV6 vector carrying the cDNA for EGFP was used as a control in primary culture 
experiments (j). Monocistronic AAV6 vector carrying the cDNA for mCherry with nuclear localization 
was used for expression in primary neurons (k). Monocistronic AAV6 vector had the cDNA for 
TdTomato, equipped with 4 copies of mitochondrial localization sequences and was used for 
overexpression in primary neurons (l). Monocistronic AAV2 vectors with sequences for human αS, WT-
βS, P123H-βS or V70M-βS were used for targeted expression in rat’s SN (m-p) and AAV2 vector with 
the cDNA for EGFP was used as a control in in vivo experiments (q). Expression of the transgenes was 
controlled by neuron-specific human synapsin 1 gene promoter (hSyn1) and enhanced by Woodchuck 
hepatitis virus posttranscriptional regulatory element (WPRE). Int - intron; SV40 - SV40 polyadenylation 
site; bGH - bovine growth hormone gene polyadenylation site; TR - inverted terminal repeats; NLS – 
nuclear localization sequence; m - mitochondrial localization sequence. 
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2.2.3. Primary cell culture 
2.2.3.1. Preparation of coverslips and plates coating 
Preparation and maintenance of neuronal culture were performed according to Yavin et al., 1973 
(with modifications). 
Prior to culturing of primary cortical neurons, sterile 24-well plates were coated with Poly-L-
Ornithine (PLO) and laminin to ensure optimal cell growth and adhesion. PLO is a positively 
charged synthetic amino acid, which enhances attachment of the neurons to glass and plastic 
surfaces. Laminin is one of the major extracellular matrix (ECM) glycoproteins which can be 
found in the basement membranes. It improves cell adhesion and supports the growth of neurites.  
For experiments on mitochondria morphology and motility, plates with glass coverslips were 
used. In all other in vitro experiments, neurons were plated without coverslips.  
Coverslips of 12 mm in diameter (Menzel, 4003030) were cleaned in 1M HCl under agitation at 
RT overnight (the acid wash method). Afterward, coverslips were extensively rinsed with ddH2O 
3 times. Before being placed into a 24-well plate, each coverslip was sterilized by high 
temperature (backed in the oven at 2000C for several hours). 
10x PLO stock solution was diluted to 1x (0.1 mg/ml) in the sterile water right before use, and 
500 µl 1x PLO was applied to each well. Plates were sealed with Parafilm and incubated at RT 
for 24 h. Then, plates were placed at 40C for 1 week. Before coating with laminin, PLO was 
aspirated and plates were washed twice with sterile H2O. Laminin was diluted 1:1000 (1 µg/ml) 
in DMEM and 500 µl/well were applied. Plates were incubated with laminin overnight at 370C, 
5% CO2, and 95% humidity. On the day of cell seeding, plates were washed 2x with DMEM, 500 
µl/well of 370C-pre-warmed HCN medium was added. Corner wells and all other empty wells 
were filled with sterile PBS in order to minimize evaporation of the culture medium. 
 
2.2.3.2. Dissection and cell preparation 
Primary cortical neurons were obtained from E17.5 (embryonic day 17.5) Wistar rats. All 
surgical procedures were performed on ice and in CMF medium. Embryos were decapitated, 
cortices were dissected, and hippocampi were removed (as described in Pacifici et al., 2012). 
Pieces of cortical tissue were collected in 15 ml CMF medium, centrifuged at 800 rpm, 4 min, 
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and 40C. CMF medium was aspirated and 1 ml of 0.25% trypsin in CMF was added for cell 
dissociation. After 10 min trypsin incubation in 370C water bath, 50 µl of DNAseI was added for 
1 min in order to dissolve DNA aggregates from the damaged cells. Immediately after, trypsin 
activity was stopped by applying 1 ml ice-cold FCS. The tissue was dissociated by gentle 
trituration with a specially prepared Pasteur pipette (tip of the pipette was cut off and fire-
polished). After centrifugation for 4 min, 800 rpm at 40C cells were resuspended in the HCN 
medium (1 ml per embryo). An aliquot of neurons was stained with trypan blue to assess the 
viability of cells, and living cells were counted in the Neubauer counting chamber. Neurons were 
seeded at a density 250 000 cells/well in 750 μl of the HCN medium in PLO/laminin coated 
plates without coverslips. For plates with coverslips, a drop of the medium, containing 75 000 
cells was applied onto each coverslip; then plates were placed in the 370C incubator for 50 min; 
then the volume of HCN medium was increased to 750 µl/well. 
 
2.2.3.3. Culturing and virus transduction 
Primary cultures were maintained in HCN medium at 37°C in 5% CO2, and 95% humidity. No 
medium replenishment was performed for the duration of the culture (up to 30 days) since our 
initial experiments showed no difference in cell survival between groups with and without 
medium replenishment.  
Neurons were transduced on the day in vitro (div) 3 with AAV vectors of serotype 6. Structure 
and concentrations of AAV6 vectors are described in details in the “Result” section, relevant to 
each experiment. AAV6 vectors were diluted to the appropriate concentration in sterile filtered 
ice-cold PBS so that 10 µl of dilution was applied per well. Plates were gently agitated in an 8-
shape movement to provide even spreading of the viral vector in the well. 
 
2.2.4 Preparation of lysates 
2.2.4.1. Primary cortical cell culture 
After careful aspiration of the medium, plates were washed twice with ice-cold PBS. PBS was 
completely removed, plates were covered with Parafilm and stored in the -800C freezer until 
further procedures. For the cell lysis, plates were thawed on ice for 15 min. 25 µl of lysis buffer 
was applied per well of 24-well plate and cells were scraped while holding the plate in a tilted 
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position. Lysis buffer II, which contained PBS (pH 7.4) and 0.5% SDS, was used for all lysates 
subjected to PK digestion assay. No proteinase inhibitors were added there. For all other 
applications lysis buffer, I was used (0.5% SDS, 1 mM DTT, 50 mM Tris-HCl pH 8.0, and 
proteinase and phosphatase inhibitors). Lysed cortical cells were collected in 1.5 ml Eppendorf 
tubes. Lysates were sonicated with the ultrasonic homogenizer (UW 2070 Bandelin electronics, 
Berlin) for 10 sec with 20% power. Then lysates were cleared by centrifugation for 10 min, at 3 
400 rpm and 40C. Supernatants were collected into the fresh Eppendorf tubes and kept on ice 
until protein concentration measurement. 
 
2.2.4.2. Rat brain 
Brains of the Wistar rats were collected 3 weeks after the unilateral injection of AAV2 vectors 
into the left SN (see section 2.2.7. Animal procedures). Rats were sacrificed by CO2 inhalation. 
Brains were surgically removed and snap-frozen on dry ice (without PBS or PFA perfusion) and 
stored at -800C. The samples of cortex, striatum and Substantia nigra were collected with spinal 
needles with 1.2 mm outer diameter and ~1 mm inner diameter (VYGON, REF 183.92) on the 
Leica Cryostat. The sharp edge of the spinal needle was removed by grinding and polishing, and 
needles were washed with 70% ethanol and ddH2O. Figure 2.2 shows the sites where the pieces 
of tissue were collected.  
 
Figure 2.2. Sites of the collection of the brain tissue samples. Samples of cortex, striatum, and SN were 
collected from the left and right side of the brain starting from the coronal sections with coordinates +1.6 
mm and -4.5 mm from bregma. Red circles represent spinal needle application sites.   
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Two “picks” with the needle were done for each site and sample. With each “pick” a cylinder 
piece of tissue with ~1.5mm length and ~1mm in diameter was collected. Such 2 small pieces of 
tissue from 1 site were placed into a 2 ml micro tube (Sarstedt, REF 72.694.006). The micro 
tubes were prepared beforehand: 100 µl of magnetic beads or ~ 35 beads (Precellys 1.4 mm bulk 
beads) were added to each tube, micro tubes were labeled, weighted and cooled down in the 
cryostat. 
The tissue samples were weighted in the micro tube, and the weight of the tissue was calculated. 
The weight of each probe (2 small pieces of tissue from 2 picks) was approx. 5 to 10 mg (0.005 
to 0.01 g). 250 µl of the lysis buffer (0.5% SDS in PBS) was added to each micro tube. No 
proteinase or phosphatase inhibitors were added to the buffer in order not to interfere with the 
following PK digestion (see section 2.2.5. Proteinase K digestion). Tissue was homogenized with 
a Precellys 24 homogenizer (3 cycles of 45 sec homogenization, 6 800 rpm). Micro tubes with 
lysates were centrifuged 10 min at 40C and 3400 rpm to spin down the beads. Supernatants were 
collected into fresh 1.5 ml Eppies and were cleared by centrifugation (10 min, 40C, 3400 rpm). 
Lysates were collected into 1.5 ml Eppies and stored at -800C until PK digestion and protein 
analysis by immunoblotting. 
 
2.2.5. Proteinase K digestion 
Proteinase K is an alkaline serine protease which shows strong proteolytic activity on a variety of 
native and denaturated proteins in a wide range of pH and temperatures (Ebeling et al., 1974). 
The name of proteinase K comes from its ability to hydrolyze keratin. This enzyme was 
originally purified from the fungus Tritirachium album and is commonly used for cleaning up 
enzymatic reactions from protein contaminants. Although PK can hydrolyze a variety of peptide 
bonds, β-sheets demonstrate resistance to PK. This specificity is commonly used to analyze 
fibrillation state of prions and other misfolded and aggregated proteins, including α-synuclein 
(Neumann et al., 2002; Sajnani et al., 2012). 
After protein concentration was calculated, lysates of primary cortical neurons and brain lysates 
were diluted in PBS/0.5% SDS buffer to the final protein concentration of 2 µg/µl. The same 
volumes of diluted lysates were taken for the PK digestion in each condition. PK solution 
(Invitrogen) of the original concentration of 20 mg/mL was diluted 1:200 (0.1 mg/mL) in ice-cold 
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PBS, and this “stock” solution was then diluted further if lower concentrations of PK were 
needed. PK was applied to lysates in ratio 1:10. The final concentration of PK in most 
experiments was 2-4 µg/mL. PK concentrations from 0.01 to 10 µg/mL were used to establish the 
assay. Lysates were divided into 2 equal parts: 0´ (minutes) and 5´ groups. An equal volume of 
PK was added to both parts. Lysates were well mixed with PK, and Eppendorf tubes were very 
rapidly spun down, and the test tubes which were intended for digestion were placed in the 
Thermomixer at 370C for 5´. Digested lysates were then immediately placed on ice, 6xSDS-
sample buffer was added, and lysates were boiled for 5´ at 950C. At this temperature Proteinase K 
was completely deactivated. Protein samples were then analyzed by immunoblotting or stored at   
-200C. 
 
2.2.6. Immunoblotting 
2.2.6.1. BCA assay for protein concentration measurements 
The concentration of proteins in the sample was determined with the BCA (bicinchoninic acid) 
assay. This method is based on the ability of proteins to reduce Cu2+ to Cu+ in basic condition and 
the formation of purple chelate complexes of Cu+-ions and BCA. The amount of the colored 
product is directly proportional to the amount of Cu+ ions and to the protein concentration which 
can be then determined with colorimetric techniques. A chelate complex of Cu+ and 
bicinchoninic acid exhibits maximal light absorbance at a wavelength of 562 nm. Principles of 
the BCA reaction are described in detail in Smith et al., 1987. 
BCA reaction was performed in 96-well test plate. Reagents A and B of the BCA protein assay 
kit (Thermo Scientific) were mixed in proportion 50 to 1 according to the manufacturer’s 
instructions. This working solution was added to the wells of 96-well plate in the way that the 
total volume of reagent A+B and lysate would be 200 µl in each well. Bovine serum albumin 
(BSA) was used as a standard. In order to generate a standard curve, BSA dilution series of 0, 
0.3125, 0.625, 1.25, 2.5, 5, 10, and 20 µg/well were tested in parallel with the experimental 
samples. All samples were tested in duplicates. Test plate was sealed and incubated for 35´ at 
370C. The absorbance was measured at the wavelength 562 nm with Tecan Spark 10M plate 
reader and Spark Control Magellan 1.2 software. Calculations of protein concentrations were 
performed in Microsoft Excel. The standard curve was plotted as a function of absorbance (y) to 
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a protein concentration (x) and had to have R2> 0.998. Protein concentrations in the samples were 
calculated from the mathematic equation which was drowned from the standard curve function. 
 
2.2.6.2. SDS polyacrylamide gel electrophoresis (SDS-PAGE) 
SDS-PAGE is a technique for separation of charged proteins in the electric field according to 
their molecular masses. Anionic surfactant SDS is used here to linearize polypeptides and to 
cover them with the negative charge in order to facilitate the migration of molecules towards the 
positive pole in the electric field. Polyacrylamide gel provided a meshwork where smaller 
proteins can move faster than the big ones in the electric field. In more details the principles of 
SDS-PAGE are described in Laemmli, 1970 and Cleveland et al., 1976. 
Two-phased gels (12% or 15% resolving and 5% stacking gels) were prepared as described in the 
table below (Table 2.3). Gels were usually pre-casted 1 day in advance to gel electrophoresis and 
kept maximally 1 week at 40C covered with wet paper. 
Table 2.3 Composition of polyacrylamide gels 
 
Stacking Gel 
5% 
Resolving Gel 
12% 15% 
Acrylamide 30% 430 µl 4 ml 5 ml 
4x Tris pH 8.8 - 2.5 ml 2.5 ml 
4x Tris pH 6.8 830 µl - - 
SDS 10% 33 µl 100 µl 100 µl 
H2O 2 ml 3.34 ml 2.34 ml 
10% APS 16.5 µl 50 µl 50 µl 
TEMED 3.3 µl 10 µl 10 µl 
 
Mini-PROTEAN Tetra Cell system (Bio-Rad) and Consort electrophoresis power supply were 
employed for running the gel. The gel chamber was assembled according to the manufacturer’s 
instruction and filled with 1x electrophoresis buffer (190 mM Glycine, 0.1% SDS, 25 mM Tris-
HCl). The protein samples were loaded into the gel pockets in the amount of 20 – 30 µg of 
protein per well. The protein marker PageRuler™ Plus (Thermo Scientific) was loaded in parallel 
with the samples in order to analyze molecular weight of the detected proteins. Electrophoresis 
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was performed at RT, 20 min at 80 V to allow the proteins to enter the gel, then 1.5 h at 100 V 
for separation of the bands (until bromophenol blue reached the bottom of the resolving gel). 
 
2.2.6.3. Immunoblotting and detection 
Mini Trans-Blot Cell system (Bio-Rad) was used for transferring proteins from the gel onto the 
nitrocellulose membrane with the 0.22 µm pore size (AppliChem). The “transfer sandwich” was 
assembled in the order: cathode direction – sponge – Whatman blotting paper – gel – 
nitrocellulose membrane – sponge – anode direction. Prior to transfer, the nitrocellulose 
membrane was incubated 15´ in distilled H20 and 1 h in transfer buffer. Blotting was performed 
for 1 h at 100 V at 40C in 1x transfer buffer containing 20% Methanol. The current did not 
exceed 180 mA when 1 chamber was used and 360 mA with two chambers. After the transfer, the 
membrane was briefly washed with TBS-T and blocked with 5% non-fat dried milk in TBS-T     
(1 h, RT).  
The primary antibodies were applied o/n at 40C (most of the antibodies) or for 1 h at RT (anti-
EGFP and anti-β-tubulin antibodies). All primary antibodies and needed concentrations are listed 
in Table 2.1. After incubation with the primary antibodies, the membrane was washed 3x10´ with 
TBS-T and secondary antibodies coupled to horseradish peroxidase (HRP) were applied for 1 h at 
RT (list of the secondary antibodies and respective dilutions are given in Table 2.2). The 
membrane was washed again 3x10´ with TBS-T and chemiluminescent HRP substrate was 
applied. Lab-made ECL was used for detection of TH, EGFP, and β-tubulin. ECL1 and ECL2 
solutions were mixed in equal proportions and applied to the membrane right before the imaging. 
For synuclein protein detection and all bands which are harder to detect, we used 2 commercial 
kits: HRP Substrate Pico, Immobilon Western (Millipore) and HRP Substrate Femto, 
SuperSignal West Femto (Thermo Scientific). In each case, the reaction was based on the 
interaction of HRP with chemiluminescent substrate luminol. The HRP-enzyme oxidizes luminol 
in presence of H2O2, creating a reaction product which emits light at 425 nm. The signal was 
visualized with ChemiDocXRS+ Transilluminator (Bio-Rad) and captured by CCD camera. 
QuantityOne 4.6.9 software (Bio-Rad) was used to obtain the images and Image Lab software 
(Bio-Rad) was used for analysis of the detected bands. 
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2.2.7. Animal procedures 
Adult female Wistar rats (Janvier Labs) were used in the experiments. All animal experiments 
were conducted according to the approved experimental animal license No. 11/0409 and 
controlled by the local animal welfare committee of the University Medicine Göttingen. All 
procedures were performed in accordance with the local regulation and the Directive 2010/63/EU 
of the European Parliament and of the Council on the protection of animals used for scientific 
purposes. 
 
2.2.7.1. Animal housing, preparation for the operation and anesthesia 
Wistar rats were housed in cages in groups of 5 with 12h/12h dark/light cycle and access to food 
and water ad libitum. Animals were delivered to the laboratory at least 1 week before the 
operation. During this time they were weighted and handled every day in order to adapt to the 
experimenter before the surgery. At the time of surgery, the weight of animals was 220-250 g. 
Before, during and after the operation rats were provided with anesthetics and analgesics.  
The next drugs were used for anesthesia and analgesia: 
- Ketamine 10% (Medistar), active substance – ketamine hydrochloride, provides short-
term surgical anaesthesia combined with analgesic action.  
- Xylariem 20 mg/ml (Ecuphar), active substance – xylazin hydrochloride, is a powerful 
analgesic drug, alpha-2-agonist. In combination with ketamine, it provides deeper 
anaesthesia (as described in Van Pelt LF, 1977) 
- Rymadil (Zoetis) or Carprieve (Bayer) 50 mg/ml, active substance – carprofen, are non-
steroidal anti-inflammatory drugs (NSAID) which provide analgesia and reduce fever and 
inflammation. 
- Metapyrin 500 mg/ml (Serumwerk), active substance – Metamizole-Natrium 1 H2O, is an 
analgesic drug with a weak NSAID action. 
Rymadil and Metapyrin were given as pre-emptive analgesics 2 days before and 2 days after 
surgery. Rymadil was administered intraparietally once a day at concentration 5 mg/kg. 
Metapyrin was given in a drinking water (1.5 mg/ml) in our initial experiments, but we noticed 
that rats tend to drink less water in this case due to a bitter taste of Metapyrin. Therefore, in the 
next experiments, Metapyrin was injected subcutaneously as 100 µl of 5 mg/ml Metapyrin 
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solution. Drugs were diluted to the appropriate concentrations with sterile saline (0.9% NaCl 
solution). During the surgery, animals were deeply anesthetized with ketamine/xylazine mixture 
(150 mg/kg and 10 mg/kg body weight, respectively) which was administered via intraparietal 
injection. Before starting the surgery, it was made sure that toe pinch and eyelid reflexes are 
negative. 
Prior to the surgery, the glass capillaries (World Precision Instruments) were prepared. Glass 
capillaries were pulled with the micro pipette puller P97 (Satter Instruments Company), using the 
program with the next characteristics: Pressure setting P = 500, Heat = 5200C, Pull = 20, Velocity 
= 135. The thin tip of the pulled capillary was broken off with the forceps while examined 
through binocular. It was important that the tip was not too narrow (since then the liquid did not 
flow through the tip efficiently and it tended to break easily) and not too bright (in this case a big 
part of the injected virus would spread around needle track and would not target SN properly). 
The tip with the best size is shown in Figure 2.3 (a). The glass capillary was filled with mineral 
oil and attached to the micro injector Nanoliter 2000 and micro syringe pump controller, Micro4 
(World Precision Instruments). The surplus of mineral oil was removed, and the tip was rinsed 
and filled with sterile filtered PBS. Mineral oil and PBS were separated by the air bubble. The 
glass capillary was aligned with the stereotaxic frame. 
 
2.2.7.2. Stereotaxic injection into the rat’s substantia nigra 
Stereotaxic surgery was performed as described in Cetin et al., 2007. A deeply anesthetized rat 
was shaved and fixed in the stereotaxic frame with non-traumatic ear bars and jaw holders (David 
Kopf Instruments). Eyes were protected from drying by application of Bepanthene (Bayer) for 
the whole duration of anesthesia. The skin of the head was disinfected with iodine (Braunol, B. 
Braun) and cut longitudinally along the midline. Skin and connective tissues were removed from 
the skull so that bregma and lambda were exposed. Occasional bleeding was rapidly stopped with 
the high-temperature cautery pen (Bovie Medical Corporation).  
The coordinates of lambda and bregma were measured, a proper horizontal position of the animal 
in the stereotaxic frame was confirmed, and the coordinates of the stereotaxic injection were 
calculated. A piece of bone above the place of injection was removed by careful drilling with the 
mini drill (Praxxon) with 0.8 mm drill tip (Dremel), any bleeding at this step had to be avoided. 
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The skull was cleaned with sterile filtered PBS to remove any small pieces of bones. PBS was 
ejected from the glass capillary, and it was filled with AAV vector solution instead, the tip of the 
capillary was rinsed in sterile PBS. Prior to the surgery AAV vectors were diluted in sterile and 
filtered with 0.22 µm syringe filter PBS so that 2 µl of the solution contained the destined amount 
of viral transduction units (tu). The glass capillary was injected into the left SN according to the 
coordinates AP: −5.3 mm; ML: +2.2 mm; DV: −7.75 mm relative to bregma as shown in Figure 
2.3. (b) (Paxinos and Watson, 1986). 
 
 
Figure 2.3. Stereotaxic injection into the rat’s SN. (a) Glass capillary with the indicated dimensions 
provided the most efficient and well-targeted injection into the rat’s SN. (b) Left SN was stereotaxically 
injected according to the coordinates AP: −5.3 mm; ML: +2.2 mm; DV: −7.75 mm relative to bregma 
(Paxinos and Watson, 1986). The red circle indicates the location of the injection. 
 
The glass capillary was left to rest in the tissue for 3 min. Then, 2µl of AAV dilution containing a 
total of 1.2 x 108 tu were injected with the speed of 500 nl/min. The injection was controlled by 
micro syringe pump controller Micro4 (World Precision Instruments). After injection of the virus 
the glass capillary was left in the tissue for additional 3 min, then removed and cleaned with PBS. 
The skin above the skull was stitched.  
After the surgery, 3 ml of sterile saline were injected subcutaneously to compensate for the 
dehydration of the rat during anesthesia. Warming pads were used to keep the animal warm until 
the awakening. During the first two days of recovery after the surgery rats received softened food 
and were housed singly in the cages.  
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2.2.7.3. Transcardial perfusion and tissue processing 
Wistar rats were sacrificed by CO2 inhalation 2 and 8 weeks after virus injection. For transcardial 
perfusion an animal was fixed on the rack, the abdominal cavity was opened; diaphragm and ribs 
were carefully cut in order to expose the heart. A blunt-ended needle connected to the perfusion 
tube was inserted through the left ventricle into the aorta. The position of the needle was secured 
by clamping. The abdominal aorta and caudal vena cava were closed with the hemostat (Fine 
Science Tools) above the liver in order to provide faster perfusion of the anterior part of the body. 
Perfusion was controlled with peristaltic perfusion pump (Ismatec) and the speed of perfusion 
was set to 55 ml/min. First, the body was perfused with ice-cold sterile filtered PBS (pH 7.4) 
until the liquid, exiting the cut nose of the rat, was clear from the blood. Then, perfusion was 
continued with the fixative, ice-cold 4% PFA in PBS (pH 7.4). The PFA-perfused bodies were 
left on the rack for 15-20 min to let the tissues harden. The basics of chemical and physical 
processes behind the PFA fixation are explained in Thavarajah et al., 2012. When the rat’s body 
became rigid due to PFA infusion, the animal was decapitated, and the brain was surgically 
removed from the skull and placed for post-fixation into 4% PFA for 24 h at 4°C. Then PFA was 
substituted with 30% sucrose in PBS. Impregnation with sucrose served for dehydration and 
cryoprotection of tissue. After 3-5 days at 4°C, the brains sank to the bottom of the tube, which 
indicated complete impregnation in sucrose.  The specimens were dried (the rest of the sucrose 
solution on the brain surface was carefully removed with the Kleenex) and frozen in clean 50 ml 
tubes at -800C until further processing.   
30 µm serial coronal sections of the striatum (AP +2.2 mm to -1.4 mm relative to bregma) and 
SN (AP -4.5 mm to -6.5 mm relative to bregma) were cut on the Leica CM 3050 S cryostat 
(Leica, Germany). Every striatal or nigral section was collected into 24-well plates containing 
PBS with 0.1% NaN3 with the free-floating method. Plates were stored at 4°C. 
 
2.2.7.4. Immunohistochemistry 
2.2.7.4.1. IHC-IF on striatal and nigral sections 
Brain sections were stained with IHC-IF protocol where antibodies against dopaminergic marker 
tyrosine hydroxylase (TH) and a transgene were used in order to appreciate the location of 
injection, compare AAV transduction efficiency between and within experimental groups and 
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analyze anatomical changes in striatum due to the transgene expression (striatal fiber density and 
presence of pathological axonal structures).  
The method of IHC-IF was developed by Coons, 1958. In our experiments, every 12th section of 
SN or striatum were stained with IHC-IF. Sections were washed 3x5´ in PBS in order to remove 
NaN3. Then, sections were subjected to antigen retrieval in 1x TBS (pH 9.0) at 60
0C for 4-5 h.  
After 3x5´ wash in PBS, sections were blocked with 5% NGS and 0.1% TritonX in PBS for 2 h.  
The first antibody was applied in the following incubation solution: 0.1% TritonX + 2% NGS + 
0.02% NaN3 in PBS. The dilutions and species for each primary antibody are provided in Table 
2.1. Staining was performed with 500 µl of the primary antibody solution per well of 24-well 
plate (3-4 coronal sections) under shaking for 48 h at 40C (SN sections) or for 60 h at RT (for 
striatal sections). 
After 3x5´wash with PBS, Cy2 and Cy3-coupled secondary antibodies (Table 2.2) of appropriate 
species were applied for 2 h at RT 1:250 in the incubation solution with 0.1% TritonX and 2% 
NGS in PBS. The unbound secondary antibodies were washed with PBS (3x5´). Finally, the brain 
sections were stained with the nuclear counterstain DAPI for 15 min, washed again with PBS 
3x5´ and mounted onto SuperFrost Plus microscope slides.  Sections were dried o/n at RT, 
rehydrated in PBS and covered with pre-warmed Mowiol 4-88. 
 
2.2.7.4.2. IHC-DAB on coronal sections of SN 
Serial coronal brain sections of AP -4.5 mm to -6.5 mm relative to bregma were stained 
according to the IHC-DAB protocol, followed by Nissl staining for stereological quantification of 
dopaminergic and non-dopaminergic neuronal cell loss in SNpc. Only brains with the confirmed 
by IHC-IF staining proper injection in SNpc and comparable level of the transgene expression 
were included in IHC-DAB staining and stereological analysis.  
DAB (3,3'-Diaminobenzidine) is an organic chromogen, which produces a dark precipitation 
reaction product when oxidized by hydrogen peroxidase. DAB staining can be observed with the 
brightfield microscopy, the staining is permanent, heat and illumination stable which is an 
advantage of DAB over IF. IHC-DAB staining method was developed by Graham and 
Karnovsky, 1966, and Nakane and Pierce, 1967. 
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Every 4th section was stained. Before the staining and between each step of the protocol sections 
were washed 3x5´ with 0.1M TBS (pH 7.4). Endogenous peroxidases, an activity of which can 
lead to an unspecific staining, were deactivated by incubation for 5´ in 10% methanol and 3% 
H2O2 solution in 0.1 M TBS.  Longer than 5´incubation or higher concentrations ofH2O2 had to 
be avoided, in order to keep the physical integrity of the sections. Blocking solution contained 
5% NGS in 0.1 M TBS and was applied for 1 h at RT and shaking. After the blocking, SN 
sections were incubated 48 h at 40C in the primary antibody (anti-TH ab152, rabbit polyclonal, 
see Table 2.1) with concentration 1:3000 in 0.1 M TBS with 2% NGS. Unbound primary 
antibody was washed with 1x TBS and the secondary antibody (anti-rabbit-biotin) was applied 
for 1 h at RT at concentration 1:250 in 0.1 M TBS with 2% NGS. After washing off the unbound 
secondary antibody, sections were incubated with avidin and biotinylated enzyme for 1 h at RT. 
This incubation solution was prepared using VECTASTAIN ABC Peroxidase Standard Kit PK-
4000 (Vector Laboratories) by mixing reagents A and B in 0.1 M TBS according to the 
manufacturer’s instructions. After the following 3x5´washing in TBS, sections were stained with 
DAB Peroxidase Substrate Kit SK-4100 (Vector Laboratories). According to the instructions to 
the kit, buffer stock solution, DAB stock solution and H2O2 solution were mixed in ddH2O right 
before the application. The sections were incubated in the substrate solution for 4 min, then 
intensively washed with 0.1M TBS. Positively stained structures were visible to the naked eye. 
DAB-containing solutions had to be treated carefully due to the high toxicity of the DAB-
substrate. Brain sections were mounted onto SuperFrost Plus microscope slides and dried o/n at 
RT. 
DAB-stained sections were then further subjected to the Nissl staining protocol. Here, the 
staining agent was thionine, a basophilic amine dye, which stains nuclear acids blue. Neurons 
cytoplasm appears dark blue after the staining and neurons can be distinguished from other cells 
because neurons are rich on ribosomes and have a so-called Nissl body, a tightly packed 
endoplasmic reticulum structure. The steps of the Nissl staining protocol were as following: 
5´ddH2O => 7´ Thionine working solution => 2´ ddH2O => 2´ 70% ethanol => 2´ 90% ethanol 
=> 5´ 96% ethanol => 5´ 100% isopropanol => 2x5´ xylol. Microscope slides were dried in the 
fume hood and sections were covered with DPX.  
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2.2.8. Imaging and data analysis 
2.2.8.1. Neurotoxicity of synucleins in primary cortical neurons 
Cell culture plates were observed with the AxioObserver.Z1 microscope (Carl Zeiss 
Microscopy). Images were taken with Axiocam 503 camera using Zen 2.3 pro software. For the 
cell counting, 10x pictures were taken, 4 pictures per well, omitting the edges and the center of 
the well. Edge wells of the plates were excluded from the analysis. EGFP (100 ms), mCherry 
(500 ms) and brightfield (50 ms) signals were recorded. Acquired files (.zvi) were semi-
automatically processed in ImageJ (NIH). For the red channel (mCherry) pictures a threshold was 
adjusted so that most of the cells were visible but the background not apparent. The level of 
adjustment was the same for all pictures and groups of a given time point (dpt). Pictures were 
binarized, converted to masks and watershed. Cells were automatically counted using “Analyse 
particle” function (size of the particles 5 – 1000 microns^2, circularity 0 – 1, edges excluded). 
The measurements were saved in Excel and analyzed with GraphPad Prism statistics software. 
 
2.2.8.2. Mitochondrial morphology and motility 
The pictures and time-lapse videos of mitochondria were recorded with Axio.Examiner D1 
microscope (Zeiss) using 63x objective. The Colibri LED light source was used to visualize 
EGFP (455 nm module) and mito-TdTomato (590 nm module). In a typical experiment, live 
neurons on the glass cover slip were placed into the imaging chamber filled with warm aCSF 
medium. The chamber was constantly perfused with the speed 12 ml/h which allowed keeping 
the temperature of the liquid at ~32-340 C. From each cover slip, 10 z-stack images were taken 
for the analysis of the mitochondria morphology in the neuronal soma and neurites, and 3 time-
lapse videos of 180 sec were recorded for the studying of the mitochondrial motility in the 
neurites. The z-stack pictures were deconvoluted with the Zeiss software. The mitochondria in 
neuronal soma were classified into one of the 3 categories: elongated or tubular, partially 
condensed, and fully condensed (Figure 3.10). Somas of at least 200 neurons were characterized 
for each experimental condition. The length and width of mitochondria in the neurites were 
measured with ImageJ (NIH), and the ratio length/width was calculated in Excel for 100-150 
mitochondria per condition. MTrackJ Plugin of ImageJ was used for tracking of the mitochondria 
for the motility analysis (n = 63 per condition). All data are shown as mean + SD. 
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2.2.8.3. Stereological quantification of dopaminergic neurons in SN 
In order to analyze the extent of dopaminergic neurons loss in SNpc, stereological quantifications 
of TH-positive and Nissl-positive cells in SNpc was performed. Nissl+ neurons were counted in 
order to confirm the loss of TH+ neurons and exclude mere downregulation of TH expression in 
SNpc. Examples of TH+ and Nissl+ neurons are provided in Figure 2.4. a) and b) respectively. 
The examiner was blinded to the experimental groups, animal ages, and identification numbers. 
Every 4th section was stained with IHC-DAB protocol (see section2.2.7.4.2.), and 10 sections 
containing SNpc were analyzed using Stereo Investigator 9 software (Micro Bright Field Inc.). 
SNpr and VTA regions were excluded from the cell count. The regions of SNpc were manually 
outlined, and program parameters were set as following: low magnification lens 2.5x (for 
outlining ROIs), high magnification lens 40x (for counting cells), counting frame X and Y = 50 
µm, grid size X and Y = 100 µm, section cut thickness = 30 µm, and dissector height (real section 
thickness after the staining) = 17 µm. Counting was performed according to the Stereo 
Investigator users guide (MBF, 2009). An example of counting frame is provided in             
Figure 2.4. (c). The measurements were saved in Excel and analyzed with GraphPad Prism 
statistics software. 
 
Figure 2.4. Stereological quantification of dopaminergic neurons in SN. (a) Example of TH+ cells.  
(b) Example of Nissl+ neurons; scale bar – 50 µm. (c) Illustration of the counting frame. Neurons, which 
have a green check mark are to be counted (they cross a dashed inclusion line, or can be found entirely 
inside the counting frame). Neurons, which have a red X are not to be counted because they cross solid 
exclusion line. 
 
2.2.8.4. IHC-IF staining of SN 
SN sections, stained with IHC-IF protocol were observed with Axioplan 2 microscope (Zeiss). 
5x, 10x and mosaic overview pictures were recorded with Axiovision 4.8 software. The 
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following filter sets were selected: 20 Rhodamine filter from Zeiss (excitation: 530-570 nm; 
emission: 575-650 nm) was used for visualizing anti-TH-Cy3 signal, Endow GFP filter from 
Chroma (excitation: 450-490 nm; emission: 500-550 nm) - for EGFP or anti-synuclein-Cy2 
signal, and DAPI 01 filter from Zeiss (excitation: 350-375 nm; emission: 400-1200 nm) - for 
DAPI. The exposure times are indicated in the result section for the respective pictures. 
 
2.2.8.5. Quantification of the axonal bulbs in the striatum 
Axonal bulbs or swollen dystrophic axons were defined as the highly immunoreactive against TH 
rounded structures in the rat’s striatum with the Ferret’s diameter of above 2 µm. These swollen 
axons were counted on the 40x microphotographs, taken with the Axioplan 2 microscope (Zeiss). 
3 striatal sections were analyzed for each animal (the coordinates relative to bregma AP +0.8 
mm, AP +0.0 mm, and AP -0.4 mm), 10 pictures were taken from each striatal section (5 on the 
injected and 5 on the contralateral side). The pictures were obtained from the mediolateral and 
dorsolateral regions of the striatum where the axons were immunopositive for EGFP or 
synuclein. Six to seven animals per group and time point were analysed and the obtained data 
were represented as a number of axonal bulbs per mm2. 
 
2.2.8.6. Dopaminergic fiber density in rat’s striatum 
For the evaluation of dopaminergic fiber density, the microphotographs of IHC-IF stained striata 
were taken with a laser-scanning confocal microscope Leica TCS SP5 (Leica Microsystems, 
Wetzlar, Germany). The 63x oil immersion objective was used for magnification, and 5x zoom 
was additionally applied by the LAS AF software. EGFP and Cy2 signals were visualized with 
help of the Argon-ion gas laser with excitation at 488 nm and emission set to 495-540 nm. Cy3 
signal was visualized with 561 nm laser with emission set to 570-636 nm. For each brain, 15 
pictures from 3 striatal sections were analyzed on injected and non-injected side. The density of 
TH-immunoreactive fibers was evaluated with ImageJ software (NIH). The pictures were 
thresholded using Li function, and a percentage of area covered by fibers was calculated. The 
values for injected and non-injected sides of the brain were compared; the fiber density of 
contralateral side was taken as 100% and the data were represented as mean % relative to non-
injected side + SD. 
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2.2.9. Statistics 
 
Statistical analysis was performed with GraphPad Prism software (version 7.02). We assumed 
that the data followed the Gaussian distribution (D’Augostino-Pearson omnibus normality test). 
One-way ANOVA (analysis of variance) with Tukey’s post-hoc test was used for multiple 
comparisons between groups in in vitro and in vivo experiments. The Geisser-Greenhouse 
correction was implemented because sphericity (equal variability of differences) was not 
assumed. Student’s t-test with Welch correction was used when 2 groups were compared. Data 
are reported as mean + SD (standard deviation). The level of significance was set at p < 0.05 (*), 
p < 0.01 (**), p < 0.001 (***), p < 0.0001 (****).  
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3. Results 
 
3.1. Aggregation and toxicity of WT-βS, P123H-βS, and V70M-βS in primary 
culture of cortical neurons 
3.1.1. Experimental layout 
 
Expression of synuclein proteins in primary cortical neurons was mediated by AAV vectors of 
serotype 6. Bicistronic constructs were used, containing, first, a cDNA for human αS, WT-βS, 
P123H-βS, V70M-βS, or γS and, second, a cDNA for EGFP under control of two separate 
neuron-specific hSyn1 promoters. Expression of synuclein proteins was enhanced by the 
presence of WPRE in the 3´-end of the coding sequence in the untranslated region. WPRE is a 
posttranslational regulatory element which increases the level of transgene expression 5- to 8-fold 
(Zufferey et al., 1999). The monocistronic vector expressing EGFP was used as a control for 
possible toxicity of AAV transduction or EGFP overexpression. In addition, neurons were co-
transduced with AAV6 vector, carrying a cDNA for mCherry with a nuclear localization 
sequence, which was used as a reporter for neuronal cell numbers. Expression of nuclear 
mCherry was also driven by the neuron-specific hSyn1 promoter. The genome layout of the AAV 
vectors is described in detail in section 2.2.2., and Figure 3.1 b). Bicistronic AAV vectors with 
cDNA for WT-βS, P123H-βS, and V70M-βS were prepared in the same batch of virus production 
to assure the same transduction properties of these viruses and the same expression level of the 
proteins. Primary cortical neurons, which were seeded on PLO and laminin coated plates, were 
transduced with AAV6 vectors on the 3rd day in vitro (div 3). Bicistronic vectors coding for one 
of the synuclein proteins and EGFP (AAV6-s-Synuclein-SEIS-WB) or monocistronic vectors 
coding for EGFP alone (AAV6-s-EGFP) were applied at concentration 2 x 108 tu per well of 24-
well plate (250 000 cells/well). The AAV vector which mediated the delivery of nuclear mCherry 
(AAV6-s-nuc mCherry-WB) was applied at concentration 0.25 x 108 tu/well in all conditions. 
Primary neurons were observed for 20 days after transduction (20 dpt), and microphotographs 
were taken every 4 days in order to compare expression levels of the transgenes and to count cell 
numbers to assess the toxicity of synucleins. Afterwards, neurons were lysed and subjected to 
Proteinase K digestion and immunoblotting analysis. The experimental layout is summarized in 
Figure 3.1 a). 
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Figure 3.1. The layout of the cell culture experiments.  
(a) Primary cortical neurons were seeded on poly-L-ornithine-laminin-coated 24-well plates at 
concentration 250 000 cells/well. AAV6 vectors were applied at the day in vitro (div) 3. Synuclein 
proteins were co-expressed with EGFP (bicistronic construct) and nuclear mCherry (reporter for the 
quantity of neurons). All proteins were expressed under control of separate hSyn1 gene promoters. 
Microphotographs were taken 8, 12, 16, and 20 days post-transduction (dpt) for cell count and comparison 
of EGFP-reporter expression. The lysates of cells (dpt 20) were used for protein expression analysis with 
Western blot and proteinase K digestion assay.   
(b) Structure of the AAV vector genomes: bicistronic vector which include a cDNA for a synuclein (either 
αS, WT-βS, P123H-βS, V70M-βS or γS) and the cDNA for EGFP under control of two separate 
promoters; monocistronic vector carrying the cDNA for EGFP used as a control; and monocistronic vector 
carrying the cDNA for nuclear mCherry. Expression of the transgenes was controlled by hSyn1 - human 
synapsin 1 gene promoter (Kügler et al., 2003) and enhanced by Woodchuck hepatitis virus 
posttranscriptional regulatory element (WPRE).  
Int - intron; SV40 - SV40 polyadenylation site; bGH - bovine growth hormone gene polyadenylation site; 
TR - inverted terminal repeats. 
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3.1.2. Expression analysis 
 
Expression of synuclein proteins was compared directly - by immunoblotting and indirectly – by 
epifluorescence microscopy (EGFP reporter was co-expressed from the same AAV vector as 
synuclein). Expression of EGFP reporter was observed as early as 2 days after AAV transduction 
in all experimental conditions. Every 4 days after transduction 10x, 20x and 40x 
microphotographs were taken. The edges of the well, where the concentration of cells was 
usually the highest, and the center of the well, where cells were much less concentrated, were 
excluded from analysis. Representative 10x pictures on Figure 3.2 show the gradual increase in 
EGFP fluorescence in γS and EGFP groups from day post transduction 8 (dpt 8) to dpt 20. EGFP 
fluorescence was lower in presence of WT-βS, P123H-βS and V70M-βS, and the lowest under 
influence of αS. A decrease of EGFP fluorescence due to the presence of αS was reported before 
(Taschenberger et al., 2013) and it is probably caused by worsening of metabolic state in these 
neurons and does not indicate the decrease in synuclein expression. As concerning WT-βS, 
P123H-βS and V70M-βS, EGFP reporter showed the same intensity and pattern of 
epifluorescence increase in these 3 conditions.  The lower intensity of EGFP signal in late culture 
(20 dpt) in case of WT-βS, P123H-βS and V70M-βS as compared to γS may indicate changes in 
the metabolic state due to WT-βS and mutants’ toxicity, although the extent of this effect is lower 
than for αS. 
Immunoblotting analysis of the lysates of primary cortical neurons revealed the same expression 
level of αS, WT-βS, P123H-βS and V70M-βS with the anti-panSynuclein antibody (ab6176) as 
shown in Figure 3.3 (a). This antibody detects an epitope in the highly conserved N-terminal 
region of αS, βS and γS: amino acid residues 11th to 26th. Yet, γS has 2 different amino acids in 
this region which resulted in the lower signal of γS with anti-panSynuclein antibody. This 
observation was reported before (Taschenberger et al, 2013). During this doctoral project, I have 
not found any pan-synuclein antibody with better properties. Therefore, synuclein bands were 
also probed with the mixture of specific antibodies: anti-αS (SC-7011-R), anti-βS 
(SAB1100305), and anti-γS (ab6169) which showed similar levels of expression of all synuclein 
proteins including γS.  
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Figure 3.2. Expression analysis of synucleins in primary cortical culture.  
Representative 10x pictures of primary cortical neurons which co-express EGFP with either αS, WT-βS, 
P123H-βS, V70M-βS or γS. Expression of EGFP alone served as a control. Microphotograph from 8th, 
12th, 16th and 20th-day post-transduction (dpt) are organized in horizontal rows for each synuclein protein 
as indicated. Prominent cell loss can be observed starting from dpt 12 for αS (b-d), and from dpt 16 for 
WT-βS (g, h), P123H-βS (k, l), V70M-βS (o, p). EGFP fluorescence continues to increase in case of γS 
(q-t) and EGFP control (u-x) more rapidly than in case of αS, WT-βS, P123H-βS and V70M-βS. WT-βS 
(e-h), P123H-βS (i-l) and V70M-βS(m-p) show the same level of EGFP expression at every time point. 
Scale bar: 500 µm. Exposure time: 100 ms.  
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Figure 3.3. Immunoblotting analysis of synucleins in primary cortical culture. 
(a) Representative Western blot of the lysates of primary neurons expressing αS + EGFP, WT-βS + 
EGFP, P123H-βS + EGFP, V70M-βS + EGFP, γS + EGFP, or EGFP alone, as well as untransduced 
control (no virus). The detected bands are β-tubulin (~55 kDa), EGFP (~27 kDa and ~25 kDa), αS (~18 
kDa), βS (~20 kDa) and γS (~16 kDa). 
(b) Densitometry analysis of WT-βS, P123H-βS and V70M-βS bands on 9 independent membranes 
showed no significant differences in expression levels of WT-βS and its mutants. Data is provided as 
mean + SD. 
 
αS was detected as a band of ~18 kDa (theoretical molecular weight 14.47 kDa). WT-βS and both 
mutants, P123H-βS and V70M-βS, had the same molecular weight of ~20 kDa (theoretical 
weight - 14.28 kDa for WT-βS). The anti-γS band had a size of ~16 kDa while 13.33 kDa was 
expected. 
The higher than theoretical molecular weights of αS was frequently reported in numerous 
preceding publications (e.g., Mishizen-Eberzet al., 2003) in a range of 16-19 kDa. The difference 
between expected and detected sizes of αS bands could be explained by the high hydrophobicity 
of the synuclein molecule and its interactions with SDS micelles which slows down αS 
movement in SDS-PAGE (Surguchov, 2008), although some posttranslational modifications 
cannot be excluded. The same most probably concerns βS and γS. Human and rodent βS have 
almost identical amino acid sequence with difference in only 2 residues. Therefore, no βS 
antibodies are specific for the human protein only. Despite this, endogenous rat βS was never 
detected in the primary cultured neurons in this project. This indicate that endogenous rat βS 
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might be expressed on a very low level or not expressed at all in embryonic cortical neurons of 
the rat. 
Taken together, WT-βS, P123H-βS, and V70M-βS were expressed in primary cortical neurons on 
the same level as revealed by epifluorescent microscopy (EGFP reporter) and immunoblotting 
analysis. 
 
3.1.3. Toxicity of WT-βS, P123H-βS, and V70M-βS in primary culture of cortical neurons 
 
In order to analyze whether WT-βS, P123H-βS, and V70M-βS induce neurotoxicity to primary 
cortical cultured neurons, I counted how many cells survive during the first 20 days after 
transduction with the respective AAV6 vectors (as described in section 3.1.1.). Neurotoxicity of 
αS and WT-βS in cultured cortical neurons was reported before in Taschenberger et al., 2013. At 
the beginning of this doctoral project, I tried to repeat the experiment described in the mentioned 
above article including the groups for P123H and V70M mutants of βS. Here, EGFP-positive 
neurons were manually counted on the 10x microphotographs. Since manual counting is a tedious 
and, to some extent, subjective method, I was searching for an automated procedure for 
estimation of the cell loss. Direct automatic cell counting of EGFP-positive neurons did not give 
a reliable result since due to the cytoplasmic expression of EGFP and variable and complex 
morphology of the neurons automatic protocols could not distinguish the cells efficiently. 
Therefore, I co-expressed mCherry reporter with nuclear localization alongside with synucleins 
and EGFP. Due to the accumulation in nuclei, the mCherry signal could be seen in form of well-
separated round structures, easily distinguishable by cell counting software (Figure 3.4. (a)). The 
AAV6-s-nuc mCherry-WB vector was applied at concentration 0.25 x 108 tu/well, which 
provided efficient transduction of over 90% of the neurons. Besides, the presence of nuclear 
mCherry did not cause any apparent toxic effects in primary neurons. After the 8 dpt ~95% of all 
transduced neurons had both EGFP and mCherry signals. 
In order to count nuc-mCherry-positive cells, I used the ImageJ macro, where a picture with 
mCherry signal was thresholded, binarized, converted to mask and watersheded in the way that 
the signal from each mCherry-positive nucleus was detected as a singular cell. In order to 
validate this cell counting protocol, the results of manual and automatic cell counting were 
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compared (Figure 3.4. (b)). Here, neurons from 16 pictures of 10x magnification were counted 
for each time point: 8 dpt, 12 dpt, 16 dpt and 20 dpt. The results of manual counting of EGFP-
positive cells and automatic counting of mCherry-positive nuclei were not significantly different. 
Even though a small subset of neurons (~5%) had only mCherry or only EGFP signals, 
automated protocol could be reliably used for cell counting. 
 
 
Figure 3.4. Automatic cell counting with nuclear mCherry. 
(a) Representative microphotographs (40x, EGFP group, 20 dpt) show signals of nuclear mCherry, 
cytosolic EGFP, and their co-localization. Over 95% of neurons have both signals. Exposure time: 
mCherry 500 ms, EGFP 100 ms. Scale bar: 150 µm. 
(b) Results of automatic (mCherry) and manual (EGFP) cell counting were compared for time points 8, 
12, 16 and 20 days after transduction (div 11, div 15, div 19, and div 23, respectively). 16 pictures of 10x 
magnification were analyzed for each condition. No significant differences were revealed between 2 
counting methods. Data is shown as the number of neurons per mm2 + SD. 
3. Results 
63 
 
Neurotoxicity of human αS, WT-βS, P123H-βS, V70M-βS, γS and EGFP control was assessed 
on 8 plates per condition (6 independent cell preparations and transductions) and results are 
summarized in Figure 3.5. At 8 dpt, no significant neuronal loss was observed in any condition.  
Starting from 12 dpt αS, WT-βS, P123H-βS, and V70M-βS were significantly more toxic than 
EGFP control (p values are provided in Figure 3.5 (b)). αS appeared to be the most toxic species 
from 12th to 16th days after transduction causing the cell loss of 35.7 + 17.1% at 12 dpt, 46.3 + 
14.6% at 16 dpt, and 57.3 + 11.9% at 20 dpt when compared to cell numbers at 8 dpt. Expression 
of WT-βS resulted in neuronal loss of 24.0 + 21.1% at 12 dpt, 35.3 + 20.8% at 16 dpt, and 42.8 + 
16% at 20 dpt, respectively.  
For P123H-βS these values amounted to 27.8 + 20.7% at 12 dpt, 41.7 + 22.0% at 16 dpt, and 44.0 
+ 19.3% at 20 dpt. V70M-βS induced the cell loss of 30.2 + 17.0% at 12 dpt, 44.0 + 22.5% at 16 
dpt, and 61.4 + 15.7% at 20 dpt. Thus, there were no statistical differences between the toxicity 
of P123H-βS and WT-βS at any time point of the experiment, so P123H mutation did not 
aggravate the neurotoxicity of WT-βS in cultured primary neurons. In contrast, V70M-βS became 
more toxic than the WT-βS in the late culture at 20 dpt and reached the toxicity level of αS. 
For the control groups γS and EGFP, the loss of neurons at the final time point 20 dpt amounted 
to 7.5 + 16.0% and 15.1 + 12.7%, respectively. The neural loss in γS and EGFP groups was 
significantly lower than in αS, WT-βS, P123H-βS, and V70M-βS from 16th to 20th day after 
transduction. Cell loss in primary cortical neurons expressing γS and EGFP can be attributed to 
the aging of the culture and possibly mild toxic effects of AAV transduction and EGFP 
overexpression.  
In this experiment, I observed relatively high variability of the data despite optimization of 
culturing conditions and treating all the plates in the same way. Since primary neurons are very 
susceptible to evaporation, its effects were minimized by filling all the empty wells of a 24-well 
plate with PBS and excluding the edge wells from the analysis. Medium replenishment did not 
have any effect on the toxicity of the synuclein proteins. Exact initial amounts of cells and quality 
of the cell preparations were very important for the outcome of the experiment. The experiment 
was repeated with 6 independent cell culture preparations and transductions for each condition to 
improve the reliability of the results. 
Taken together, the effects of P123H-βS were not significantly different from WT-βS at any time 
3. Results 
64 
 
points which indicated that P123H mutation did not have an additional effect on the toxicity of 
WT-βS, while V70M-βS significantly aggravated the toxicity of the WT-βS species in the aging 
culture of primary neurons. 
 
 
Figure 3.5. Toxicity of synucleins in primary cortical culture. 
(a) Primary rat cortical neurons were transduced at div 3 (dpt 0) and imaged 8, 12, 16 and 20 days after 
transduction. Bicistronic AAV6-s-Synuclein-SEIS vectors, carrying genes for one of the synuclein species 
(αS, WT-βS, P123H-βS, V70M-βS or γS) and EGFP were applied as 2 x 108 tu/well (250 000 neurons). 
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Vector with nuclear reporter gene mCherry was applied as 0.25 x 108 tu/well. 4 picture per well of 24-well 
plate were analyzed, 6 independent transductions and cell culture preparations were performed. Cell 
numbers were acquired from the mCherry signal with automatic cell counting protocol of ImageJ software 
(NIH). Data is shown as number of neurons per mm2 + SD. 
(b) Statistical analysis of the neurotoxicity was performed with 1-way ANOVA followed by Tukey’s post-
hoc test for multiple comparisons (GraphPad Prism software). Level of significance: *p<0.05, **p<0.01, 
***p<0.001, ****p<0.0001. Statistical power (1-β err prob): 0.75 – 0.99 at 12 dpt, 0.99 – 1.0 at 16 dpt, 
and 0.89 – 1.0 at 20 dpt. 
 
3.1.4. Aggregation of WT-βS, P123H-βS, and V70M-βS in primary culture of cortical 
neurons 
 
In order to compare aggregation properties and stability of αS, WT-βS, P123H-βS, V70M-βS and 
γS expressed in the primary cultured neurons, I applied a standardized the proteinase K (PK) 
digestion protocol.  PK is a broad serine protease which is able to efficiently hydrolyze most 
proteins with the exception of β-sheet-rich aggregates of prions, synucleins and some other 
proteins. The activity of PK depends on buffer composition, temperature, PK concentration, and 
time of the reaction. Here, I tested the stability of synuclein proteins under the following 
conditions: 370 C, 5 min digestion, 2 µg/ml PK and 2 µg/µl protein in PBS/0.5% SDS lysis 
buffer. When I referred to any of the synucleins as “PK-resistant”, only a relative resistance under 
the mentioned above reaction conditions is meant.  
While γS and β-tubulin were completely digested at given conditions, 54 + 23% of αS remained 
after 5 min of PK digestion; most of it was the 18 kDa full-length form of the protein. In case of 
WT-βS, P123H-βS, and V70M-βS several fragments of 10-16 kDa were detected after PK 
digestion in addition to the minor band of ~20 kDa of the full-length protein (Figure 3.6.). 
Numerous repetitions of the PK digestion experiment showed that these partial fragments have 
the same size in WT-βS and both mutants but the total amount of resistant protein is lower in 
V70M-βS. The quantity of the PK-resistant material in V70M-βS, 28 + 12%, was significantly 
lower than in WT-βS, 51 + 18%,(unpaired t-test, p = 0.0016, power (1-β err prob) = 0.96), in 
P123H-βS, 44 + 22% (unpaired t-test, p = 0.0403, power (1-β err prob) = 0.66), and αS 54 + 23% 
(unpaired t-test, p = 0.0037, power (1-β err prob) = 0.94). The differences WT-βS vs. P123H-βS, 
WT-βS vs. αS, and P123H-βS vs. αS were not statistically significant.  
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Figure 3.6. Aggregation of synucleins in primary cortical culture. 
(a) Cell culture lysates werecollected 20 days after AAV6 virus transduction and digested with 2 µg/ml 
PK. The lanes of the immunoblot show lysates after 0 and 5 min of PK digestion. 30 µg of protein are 
loaded per well. In case of αS, the full-length form of the protein is the most prominent band which 
remains after 5 min digestion. For WT-βS and its P123H and V70M mutants, the undigested bands of 10-
16 kDa in addition to the less prominent full-length protein band are detected after PK digestion. The sizes 
of these fragments are the same in WT-βS, P123H-βS, and V70M-βS. γS and β-tubulin are completely 
digested under the same conditions. 
(b) The amount of protein remaining after 5 min of PK treatment is represented as a percentage of the 
starting material (0 min digestion). V70M-βS is digested significantly faster than αS (unpaired t-test, p = 
0.0037), WT-βS (unpaired t-test, p = 0.0016), and P123H-βS (unpaired t-test, p = 0.0403). Data are shown 
as mean + SD (n = 11 immunoblots from 6 independent experiments). The difference P123H-βS vs. WT-
βS was not significant. 
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Next, I tested PK-digested material with antibodies for epitopes in different domains of αS and 
βS in order to determine which part of the protein remains after PK digestion (Figure 3.7.). The 
partial fragments of WT-βS and mutants which are produced in the PK digestion reaction could 
be detected with the N-terminal antibody (panS, amino acid residues 11 – 26, ab6176), antibody 
against epitope in the NAC domain (amino acid residues 81 – 95, SAB1100305) but were not 
detected with the antibody to the C-terminal region (amino acid residues 108 – 125, ab6165). 
Also, synucleins with C-terminal AU1-tag were PK-digested and analyzed (Figure 3.8.). Both 
experiments revealed that C-terminal region of βS is being cleaved off in PK reaction.  
 
 
Figure 3.7. Detection of the PK-digested synucleins with various antibodies. 
Lysates of αS, WT-βS, P123H-βS, and V70M-βS were digested with PK for 0 minutes (0´-lane) or 5 
minutes (5´-lane) and detected with antibodies to different synuclein domains. 
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 (a) αS was detected antibody against N-terminal region, panSynuclein (ab6176) with epitope 
corresponding to AA 11-26 and antibody against C-terminus, sc87599 binding to AA 95-140 in αS, as 
shown in the scheme. Full-length αS is detected after PK digestion. 
(b) WT-βS, P123H-βS, and V70M-βS were detected with antibodies against N-terminus (ab6176, AA 11-
26), central domain corresponding to αS NAC-domain (SAB1100305, AA 81-95), and C-terminus 
(ab6165, AA 108-125). WT-βS, P123H-βS, and V70M-βS lost the C-terminal region in the PK reaction. 
 
 
 
Figure 3.8. PK digestion of AU1-tagged synucleins. 
The lysates of the primary cultured neurons expressing αS, WT-βS, P123H-βS, and γS with the C-terminal 
AU1-tag were digested with PK enzyme (370 C, 5 min, 4 µg PK per 1 ml lysis buffer). The panels show 
(from up to down) detection with β-tubulin, AU1 antibodies, and specific synuclein antibodies with N-
terminal epitopes. C-terminal regions of WT-βS and P123H-βS are cleaved off by the PK. 
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3.1.5. Mitochondrial morphology and motility 
 
Various impairments of mitochondrial functions were reported to be associated with the PD 
pathology (Schapira et al., 1989; Kraytsberg et al., 2006; Schapira et al., 2012). Besides, αS was 
shown to cause mitochondrial fragmentation and deformations which interfered with the 
fusion/fission homeostasis of mitochondria (Kamp et al., 2010; Nakamura et al., 2011; 
Taschenberger et al., 2013), and induce mitochondria-related pathological cascades leading to 
neuronal death (Tolö et al., 2018). Recently, WT-βS was also shown to induce mitochondrial 
pathology (Taschenberger et al., 2013).  
Here, I aimed to investigate whether the disease-associated mutations of WT-βS, V70M and 
P123H, have an effect on mitochondrial morphology and motility which, in turn, could be one of 
the mechanisms underlying the neuronal loss described in the section 3.1.3. Primary cortical 
neurons were transduced on div 3 with 0.8 x 108 tu of AAV6 vectors expressing both cytoplasmic 
EGFP and one of the synuclein proteins (αS, WT-βS, P123H-βS, V70M-βS or γS) under control 
of two separate hSyn1 promoters. The AAV6 vector expressing EGFP alone was used as a 
control. Additionally, 0.5 x 107 tu of the AAV6-s-4xmito-TdTomato-WB virus was added at div 
3 to each well of a 24-well plate for visualizing of mitochondria, mediated by the expression of 
the fluorescent protein TdTomato (Figure 3.9). 
Live cultured neurons were imaged 7 and 14 days after the virus administration. According to the 
morphology of the mitochondria in the neuronal cell bodies, neurons were divided into the three 
categories: 1st – neurons with elongated or tubular mitochondria, 2nd – neurons with partially 
condensed mitochondria (here some mitochondria gained a rounded phenotype, and were usually 
smaller in size than mitochondria of the 1st category), and 3rd – neurons with fully condensed 
mitochondria (most of the mitochondria are rounded or swollen) as illustrated on the Figure 3.10 
(a-i). Such classification of mitochondrial morphology was already reported in Taschenberger et 
al., 2013. 
Approx. 200 neurons from 4-5 cover slips were analysed for each group and time point and the 
percentage of neurons of each category was calculated for each cover slip. Only neurons with the 
high expression levels of the both fluorescent reporters, cytoplasmic EGFP, and mitochondrial 
TdTomato were selected for the analysis. 
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Figure 3.9. Scheme of the experiments on mitochondrial morphology and motility. 
(a) Primary cortical neurons were seeded at the concentration 75 000 cells/well onto PLO/laminin coated 
cover slips. At div 3, AAV vectors of serotype 6 were applied for the overexpression of cytoplasmic 
synuclein and EGFP, and mitochondrial TdTomato. At 7 and 14 days after the virus administration, 
microscopic images and time-lapse videos were recorded for the analysis of mitochondrial morphology 
and motility. 
(b) Structure of the AAV vector genomes: bicistronic vector for the expression of a synuclein (either αS, 
WT-βS, P123H-βS, V70M-βS or γS) and EGFP under control of two separate hSyn1 promoters; 
monocistronic vector expressing EGFP used as a control; and monocistronic vector carrying the cDNA for 
mitochondrial reporter TdTomato. Expression of the transgenes was controlled by the human synapsin 1 
gene promoter (hSyn1) and enhanced by Woodchuck hepatitis virus posttranscriptional regulatory element 
(WPRE). Int - intron; SV40 - SV40 polyadenylation site; bGH - bovine growth hormone gene 
polyadenylation site; TR - inverted terminal repeats, m – mitochondrial localization sequence. 
 
At 7 days post-transduction, the neurons overexpressing human αS and V70M-βS had 
significantly less frequently “healthy” elongated mitochondria in comparison with EGFP control 
(p = 0.0011, power (1-β err prob) = 0.99; and p = 0.0054, power (1-β err prob) = 0.98, 
respectively). Moreover, αS-expressing neurons significantly more often had fully condensed 
mitochondria than EGFP (p = 0.0274, power (1-β err prob) = 0.80) and γS (p = 0.046, power (1-β 
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err prob) = 0.70) groups. The differences between WT-βS vs. P123H-βS vs. V70M-βS were not 
significant at this time point (Figure 3.10). 
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Figure 3.10. Fragmentation of mitochondria in neuronal cell bodies. 
Primary cortical neurons were seeded on PLO/laminin coated cover slips with the droplet method (75 000 
cells/well). Neurons were co-transduced with the respective bicistronic AAV6 vectors (synuclein+EGFP) 
as 0.8 x 108 tu/well and an AAV6 vector with cDNA for TdTomato equipped with mitochondrial 
localization sequence (AAV6-s-4xmito-TdT-WB) at the concentration 0.5 x 107 tu/well. All transgenes 
were expressed under control of neuron-specific promoters, hSyn1. Morphology of mitochondria was 
analyzed 7 and 14 days after transduction and each cell was classified in one of 3 categories according to 
the shape of most mitochondria in the cell: 1. Elongated mitochondria (a-c); 2. Partially condensed 
mitochondria (both elongated and rounded mitochondria were present) (d-f); 3. Fully condensed 
mitochondria (most mitochondria had rounded appearance) (g-i). Approx. 200 neurons from 4 cover slips 
were classified in each condition. Percentage of the cells with elongated, partially condensed and fully 
condensed mitochondria was calculated at 7 (j) and 14 (k) days after transduction. Expression of αS, WT-
βS, and P123H, and V70M mutants of βS leads to significant increase in fragmentation of mitochondria 
from day 7 to day 14 with the most dramatic effect for αS, closely followed by V70M-βS. At 14 dpt, 
V70M-βS had significantly more neurons with fully condensed mitochondria than WT-βS (p=0.0323), 
while P123H mutant was not significantly different from WT-βS. Results of 1-way ANOVA/Tukey’s test 
are provided in Figure 3.10. (l-m). Data are shown as mean % per cover slip + SD. *p<0.05, **p<0.01, 
***p<0.001, ****p<0.0001. 
 
After 14 days of transgene expression, the percentage of neurons with mostly elongated 
mitochondria decreased in case of the overexpression of αS to 1.4 + 1.8%, WT-βS to 12 + 2%, 
P123H-βS to 11 + 4%, V70M-βS to 3.4 + 3.2%, and γS to 30 + 6% of all analyzed neurons. For 
EGFP the portion of neurons with elongated mitochondria estimated 43 + 6% which virtually did 
not change from the dpt 7. The differences between WT-βS and both mutants were not 
statistically significant in this category. P-values for the Tukey’s multiple comparison test are 
provided in Figure 3.10 (l). The fraction of the neurons with fully condensed mitochondria at 14 
dpt was significantly larger for V70M-βS (39 + 5%) than for WT-βS (24 + 7%) (Tukey’s, p = 
0.0323, power (1-β err prob) = 0.93) while the difference WT-βS vs. P123H-βS was not 
significant. For this morphological category, the V70M-βS condition was not statistically 
different from the αS with 52 + 12% of the neurons with fully condensed mitochondria. For the 
EGFP control, the percentage of fully condensed mitochondria amounted to 6 + 1% which was 
statistically lower than in αS (Tukey’s, p < 0.0001, power (1-β err prob) = 1.0), WT-βS (Tukey’s, 
p = 0.0068, power (1-β err prob) = 1.0), P123H-βS (Tukey’s, p = 0.0285, power (1-β err prob) = 
1.0) and V70M-βS (Tukey’s, p < 0.0001, power (1-β err prob) = 1.0). 
Next, the morphology of the neuritic mitochondria was analyzed by calculating length to width 
ratio of single mitochondria. The measurements were performed with ImageJ software (NIH). 
Here, at least 100 mitochondria were analyzed for each condition and time point of the 
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experiment. The investigator was blinded to the treatment groups. Although the mitochondria in 
the neurites did not have such dramatic condensed phenotype as the somatic mitochondria, we 
observed some rounding or decrease in length/width ratio of mitochondria compared to EGFP-
control in αS, WT-βS, P123H-βS and V70M-βS conditions both at 7 and 14 days post-
transduction (Figure 3.11.). Seven days after the virus administration, V70M-βS had more 
rounded mitochondria than P123H-βS (Turkey’s, p < 0.0001, power (1-β err prob) = 0.99) but at 
14 dpt the difference between these two groups was not significant anymore. WT-βS was not 
statistically different to P123H-βS and V70M-βS mutants at any time point.  
 
Figure 3.11. Morphology of mitochondria in neurites. 
(a) Primary cortical neurons were co-transduced with bicistronic AAV constructs (synuclein + EGFP) and 
mitochordrial reporter (TdTomato) as described above. Only the neurites with prominent expression of 
EGFP were included in the analysis. Scale bar: 10 µm. 
(b) Length to width ratio was calculated for 100-150 mitochondria from 4-5 cover slips per condition and 
time point. Mitochondrial morphology in neurites was evaluated 7 and 14 days after transduction. The 
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bars represent the data for αS, WT-βS, P123H-βS, V70M-βS, γS and EGFP control groups (according to 
the color code). Data are shown as mean length/width ratio + SD.   
(c) Statistical analysis with 1-way ANOVA/Tukey’s test revealed no significant differences between WT-
βS and P123H-βS or V70M-βS at 7 and 14 dpt. The mitochondria were significantly shorter in αS, WT-
βS, and V70M-βS at 7 dpt and αS, WT-βS, P123H-βS and V70M-βS at 14 dpt when compared with EGFP 
and γS. 
*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. 
 
Next, I studied the motility of the mitochondria. To that end, time lapse videos of the neurites 
were taken for 180 sec and with the 63x objective magnification. Only motile mitochondria were 
analyzed and no distinguishment between the anterograde and retrograde direction of the 
movement was made. Mitochondria were traced manually with help of the MTrackJ plugin of 
ImageJ. At least 60 mitochondria from 3 cover slips were analyzed for each condition and time 
point. The results for the mean and maximal speed of mitochondria are provided in the Figure 
3.12.  
The mean speed of mitochondria at 7 dpt was equal to 34 + 16 µm/min for αS, 44 + 15 µm/min 
for WT-βS, 43 + 15 µm/min for P123H-βS and 49 + 17 µm/min for V70M-βS, 43 + 20 µm/min 
for, and 49 + 17 µm/min for EGFP conditions. The mean speed virtually did not change from 7th 
to 14th day after virus administration. Only αS caused a significant decrease in the speed of 
mitochondria in comparison with other groups.  
The maximal speed of mitochondria at 7 dpt amounted to 74 + 39 µm/min for αS, 90 + 40 
µm/min for WT-βS, 87 + 40 µm/min for P123H-βS and 88 + 32 µm/min for V70M-βS, 85 + 43 
µm/min for γS, and 100 + 35 µm/min for EGFP conditions. The only statistically significant 
difference here was αS vs. EGFP treatments (Tukey’s, p = 0.0006, power (1-β err prob) = 0.99). 
The maximal speed slightly increased in all the transduction groups from dpt 7 to dpt 14, with 
exception of V70M-βS condition where the speed stayed the same. Only αS had a statistically 
significant effect on the maximal speed at 14 dpt: αS vs. WT-βS (Tukey’s, p = 0.0322, power (1-
β err prob) = 0.92), αS vs. γS (Tukey’s, p = 0.0351, power (1-β err prob) = 0.92), and αS vs. 
EGFP (Tukey’s, p = 0.0052, power (1-β err prob) = 0.99). WT-βS and both its mutants were not 
significantly different from each other. 
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Figure 3.12. Motility of mitochondria in neurites. 
Overexpression of αS + EGFP, WT-βS + EGFP, P123H-βS + EGFP, V70M-βS + EGFP, γS + EGFP or 
EGFP alone was mediated by AAV6 vectors (0.8 x 108 tu/well) in cultures of cortical neurons. 
Mitochondria were visualised by overexpression of TdTomato with mitochondrial localization (AAV6-s-
4xmito-TdT-WB, 0.5 x 107 tu/well). In order to analyse the motility, mitochondria moving along the 
neurites were tracked on a 3 min time-lapse videos with MTrackJ plugin of ImageJ software (n=63 
mitochondria from 3 cover slips). Maximal (a) and mean (b) speed of mitochondria are given in µm/min + 
SD.  Only αS caused significant effects on mitochondrial motility (both mean and maximal speed) after 7 
and 14 days of the transgene expression.*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. 
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Taken together, P123H-βS did not aggravate toxic effects of WT-βS on the morphology of the 
somatic mitochondria, while V70M-βS expression led to less abundant neurons with “healthy” 
tubular mitochondria and more frequent fully condensed appearance of mitochondria. The extent 
of mitochondrial pathology induced by V70M-βS was virtually as strong as in αS condition. 
Mitochondria in the neurites were also rounded under the influence of αS, WT-βS, P123H-βS, 
and V70M-βS, but no difference between WT-βS and its mutants was observed. Neither WT-βS 
nor its mutants had an effect on the motility of mitochondria. 
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3.2. Aggregation and toxicity of WT-βS, P123H-βS, and V70M-βS in 
dopaminergic neurons of the rat’s Substantia nigra in vivo 
3.2.1. Experimental design and expression analysis 
 
In order to study and compare the toxicity and aggregation properties of WT-βS and its P123H 
and V70M mutants in vivo, the synuclein proteins were overexpressed in SN of rats. 
Overexpression of human variants of αS, WT-βS, P123H-βS, and V70M-βS was mediated by 
AAV2 serotype vectors. The structures of the cDNAs are provided in the Figure 3.13 (b). 
Expression of the transgenes was controlled by the human synapsin 1 gene promoter and 
enhanced by WPRE sequence. AAV2-EGFP vector was used as a control.  
Monocistronic AAV2 vectors were injected unilaterally into the left SNpc of adult female rats 
according to the coordinates AP: -5.3 mm, ML: +2.2 mm, DV: -7.75 mm relative to bregma 
(Paxinos and Watson, 1986). 1.2 x 108 tu of the virus was injected in each case. Animals were 
sacrificed 2, 3 or 8 weeks after the AAV2 virus administration. 2- and 8-week groups were 
processed for IHC stainings, stereotaxic quantifications of dopaminergic and non-dopaminergic 
neuronal loss in SNpc, evaluation of striatal fiber density and axonal pathology. The brains of the 
3-week groups were used for the preparation of brain lysates and analysis of in vivo synuclein 
aggregation by PK digestion (Figure 3.13 (a)). 
All the brains which were collected 2 and 8 weeks after the surgery were cryosectioned (Leica 
cryostat) and analyzed with IHC methods for the expression levels of the αS, WT-βS, P123H-βS, 
V70M-βS, and EGFP. Only brains with proper targeting of SNpc, a good transduction in the 
region AP -4.5 mm to -6.3 mm relative to bregma, and similar expression levels were selected for 
the further analysis (Figure 3.14.). Double immunofluorescence staining for the dopaminergic 
marker tyrosine hydroxylase (TH) and human αS, WT-βS, P123H-βS, and V70M-βS or EGFP 
control showed major localization of the overexpressed proteins in the dopaminergic neurons of 
SNpc. Nearly 70 – 80% of SNpc neurons on the injected side of the brain were compactly 
transduced 2 weeks after the virus administration. Non-injected (contralateral) SN had no 
expression of the transgenes (Figure 3.15). Loss of dopaminergic neurons was occasionally 
observed in the 2-week groups of αS, WT-βS, P123H-βS, and V70M-βS. Eight weeks post 
transduction the loss of TH-positive neurons resulted in the extensive lesions in the left SNpc due 
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to the overexpression of αS, WT-βS, P123H-βS, and V70M-βS while contralateral SN remained 
virtually unaffected (Figure 3.15). The loss of dopaminergic neurons was quantified with 
stereological methods (see section 3.2.2.). 
 
Figure 3.13. The layout of the in vivo experiments. 
(a) Scheme of the in vivo experiments. AAV2 viruses expressing human αS, WT-βS, P123H-βS or V70M-
βS or EGFP control were unilaterally injected into the brains of adult female rats according to the 
coordinates for targeting left SNpc (anterior-posterior (AP): -5.3 mm, mediolateral (ML): +2.2 mm, 
dorsoventral (DV): -7.75 mm relative to bregma (Paxinos and Watson, 1986) with total concentration of 
1.2 x 108 tu per brain. Rats were sacrificed 2 and 8 weeks after surgery, and the brains were cryosectioned 
for IHC stainings and analysis of dopaminergic degeneration in SNpc and striatum. 3 weeks post 
transduction the brains were collected for preparation of lysates and studying the aggregation properties of 
synucleins with PK digestion and immunoblotting. 
(b) Structure of the AAV2 genomes. Monocistronic AAV2 vectors with cDNAs for human αS, WT-βS, 
P123H-βS or V70M-βS were used for targeted expression in rat’s SN and AAV2 vector with the cDNA 
for EGFP was used as a control in in vivo experiments. Expression of the transgenes was controlled by 
neuron-specific human synapsin 1 gene promoter (hSyn1) and enhanced by Woodchuck hepatitis virus 
posttranscriptional regulatory element (WPRE). bGH - bovine growth hormone gene polyadenylation site; 
TR - inverted terminal repeats. 
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Figure 3.14. Overview of the transduced SN sections on the example of an EGFP control brain (2 
weeks post-transduction).  
Monocistronic AAV2 vectors were stereotaxically injected into the left SNpc of the rat’s brain as 
described in the Figure 3.12. Representative mosaic images (a-f) illustrate the extent of the transduction 
with AAV2-EGFP vector 2 weeks after the administration of the virus. Similar transduction was also 
observed in other experimental groups: αS, WT-βS, P123H-βS, and V70M-βS. Only brains with proper 
targeting of the left SNpc and good transduction in the region AP -4.5 to -6.3 mm relative to bregma were 
selected for further analysis.  
AP stands for anterior-posterior coordinates relative to bregma and coordinates are given in mm. Cortices 
were removed prior to the IHC staining and only midbrain sections are shown. Scale bar: 1 mm. 
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Figure 3.15. Expression of the transgenes in rats’ SN, 2 weeks after AAV injection. 
Stereotaxic unilateral injections of AAV2 viruses into the left SN resulted in overexpression of EGFP, αS, 
WT-βS, P123H-βS or V70M-βS in SNpc (pictures b, h, n, t, z, respectively). Approx. 70 – 80% of the 
dopaminergic (TH-positive) neurons of the injected SNpc were transduced (c, i, o, u, aa). No transgene 
expression was noticed on the contralateral side of the brain. Representative 5x pictures (a-ad) were taken 
with Axioplan 2 microscope (Zeiss). The exposure times: anti-TH-Cy3 – 4005 ms, anti-αS-Cy2 or anti-
βS-Cy2 – 3567 ms, EGFP – 2267 ms, and DAPI – 432 ms. Scale bar: 500 µm. 
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Figure 3.16. Expression of the transgenes in rats’ SN, 8 weeks after AAV injection. 
After 8 weeks of transgene expression, a massive loss of dopaminergic neurons of SNpc was observed on 
the injected side in groups of αS, WT-βS, P123H-βS, and V70M-βS as revealed by the IHC staining 
against TH (g, m, s, y). Overexpression of αS (h), WT-βS (n) and mutants (t, z) can be seen in a few 
surviving TH-positive neurons and in non-dopaminergic cells, surrounding the SNpc. SNpc on the 
contralateral sides and EGFP-expressing SN did not have apparent loss of dopaminergic neurons (a, d, j, 
p, v, ab). The exposure times: anti-TH-Cy3 – 3005 ms, anti-αS-Cy2 or anti-βS-Cy2 – 2267 ms, EGFP – 
1267 ms, and DAPI – 432 ms. Scale bar: 500 µm. 
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3.2.2. Toxicity of WT-βS, P123H-βS, and V70M-βS in rat’s SN 
 
Progressive neurodegeneration of SNpc is one of the major hallmarks of PD and DLB. Time-
dependent loss of dopaminergic neurons in SNpc was successfully recapitulated in several rAAV 
animal models where WT or mutant αS were overexpressed (Taschenberger et al., 2012; 
Decressac et al., 2013; Davies et al., 2014). Besides, our lab has shown before that AAV-
mediated overexpression of WT-βS can also lead to the direct nigral neurodegeneration in rat’s 
brain (Taschenberger et al., 2013). Here, we aimed to compare the ability of WT-βS, P123H-βS, 
and V70M-βS to induce neurotoxicity towards SNpc. The V70M mutant was for the first time 
characterized in vivo, and the P123H mutant was for the first time characterized in the AAV 
animal model. 
In order to evaluate the loss of dopaminergic neurons, TH-positive neurons were stereotaxically 
quantified in the ipsilateral SNpc on 10 brain sections stained with the IHC-DAB protocol 
(Figure 3.17). Dopaminergic neurons of the VTA and SN pars reticulata were excluded from the 
analysis. During the stereological cell quantifications, the investigator was blinded to the 
injection groups and identification numbers of the animals. 
At 2 weeks after virus administration, the number of TH-positive neurons in the EGFP-
expressing SNpc amounted to 7653 + 1375 cells (n = 8). In the αS group the number of 
dopaminergic neurons was 4751 + 1575 (n = 8), so ~37.9% of dopaminergic neurons were lost if 
compared with EGFP control (Tukey’s, p = 0.0015, power (1-β err prob) = 0.98). V70M-βS with 
5435 + 1440 TH-positive neurons (n = 17) also caused a significant neuronal loss (Tukey’s, p = 
0.0057, power (1-β err prob) = 0.97). The numbers of dopaminergic neurons in WT-βS (6139 + 
1686, n = 11) and P123H-βS (6426 + 1067, n = 13) were not significantly reduced. The statistical 
differences WT-βS vs. P123H-βS vs. V70M-βS were not significant. 
Eight weeks post-transduction, the quantity of surviving dopaminergic neurons was similar in αS 
(3235 + 1188, n = 11), WT-βS (3481 + 1527, n = 10), P123H-βS (3123 + 1144, n = 16) and 
V70M-βS (3860 + 1304, n = 15) groups. In comparison with EGFP group (7797 + 1310, n = 10), 
the loss of dopaminergic neurons in αS, WT-βS, P123H-βS and V70M-βS estimated ~56% and 
was highly statistically significant (p < 0.0001, power (1-β err prob) = 0.99). There were no 
statistical differences between WT-βS, P123H-βS, and V70M-βS at this time point. 
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Figure 3.17. Neurotoxicity of WT-βS, P123H-βS, and V70M-βS in rat’s SN. 
(a) Representative brain section of SNpc 8 weeks after unilateral injection of AAV2 vectors carrying a 
cDNA for EGFP, αS, WT-βS, P123H-βS, or V70M-βS. Sections were stained against TH with IHC-DAB 
method followed by Nissl staining. TH-immunoreactive neurons are brown, non-dopaminergic neurons 
are blue. On the ipsilateral (injected) side of αS, WT-βS, P123H-βS, or V70M-βS brains one can see a 
lesion – loss of dopaminergic neurons of SNpc. Scale bar: 500 µm. 
(b) Stereological quantification of neurons in SNpc on injected side. Black bars represent numbers of TH-
positive neurons 2 weeks after injection of the virus. Red bars: TH+ neurons after 8 weeks of transgene 
expression. Blue bars: Nissl-positive neurons (total number of dopaminergic and non-dopaminergic 
neurons). Data are presented as the mean number of neurons per SNpc + SD (n = 8-17 animals per 
condition). 
(c) Statistical analysis with 1-way ANOVA/Tukey’s test. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. 
 
In order to test whether there is an actual loss of cells in SNpc and not mere downregulation of 
TH expression, non-dopaminergic neurons were counted on the Nissl-stained sections of SNpc. A 
basophilic amine dye – thionine – was used in the Nissl protocol to visualize the neurons. 
Thionine stains nuclear acids, including the abundant in neurons ribosomes, in a dark-blue color.  
Non-dopaminergic neurons were defined as those which had positive Nissl staining and negative 
TH-immunoreactivity. The sum of quantities of non-dopaminergic and TH-positive neurons gave 
the total number of neurons in SNpc.  
Two weeks post transduction the total numbers of neurons (dopaminergic plus non-
dopaminergic) in the ipsilateral SNpc were: αS 6119 + 1283, WT-βS 7912 + 1720, P123H-βS 
8165 + 890, V70M-βS 7092 + 1388 and EGFP 10062 + 1192. The differences EGFP vs. αS and 
EGFP vs. V70M-βS were highly statistically significant (Tukey’s, p < 0.0001, power (1-β err 
prob) < 0.99). The difference in total cell numbers WT-βS vs. P123H-βS vs. V70M-βS were not 
significant. For the non-dopaminergic neurons only, there was no significant loss in any of the 2-
week groups. 
At 8 weeks after AAV injection the total numbers of neurons in left SNpc amounted to 5245 + 
925 for αS, 5564 + 1777 for WT-βS, 5172 + 1171 for P123H-βS, 5166 + 1525 for V70M-βS and 
9816 + 1210 for EGFP group. The 1-way ANOVA and Tukey’s multiple comparison test showed 
highly significant differences in the total number of neurons in pairs EGFP vs. αS, EGFP vs. WT-
βS, EGFP vs. P123H-βS, and EGFP vs. V70M-βS (p < 0.0001, power (1-β err prob) < 0.99). The 
differences between αS, WT-βS, P123H-βS, and V70M-βS were not significant. There were no 
3. Results 
85 
 
significant differences in quantities of non-dopaminergic neurons between any groups including 
the EGFP control. 
Taken together, P123H-βS and V70M-βS did not aggravate the neurotoxicity of WT-βS in vivo in 
the rat’s SNpc although the neuronal loss in V70M-βS condition might manifest and reach 
statistical significance earlier than in WT-βS. 
 
3.2.3. Expression of WT-βS, P123H-βS, and V70M-βS in the rat’s striatum 
 
Strong impairment of the nigrostriatal projections is characteristic for PD and DLB and correlate 
with the appearance of parkinsonian symptoms (Bedard et al., 2011; Donaghy et al., 2015). Here, 
I examined whether the loss of dopaminergic neurons in SNpc due to the expression of αS, WT-
βS, P123H-βS, and V70M-βS would also cause an axonal pathology. 
First, expression of the transgenes was analyzed in coronal striatal brain sections. According to 
literature, dopaminergic neurons of rat’s SNpc innervate the striatum with a rough topographic 
localization to the lateral regions (Paxinos G, 2014). In our experiments, the overexpressed 
EGFP, human αS, WT-βS, P123H-βS, and V70M-βS were present practically along the entire 
length of the striatum in the anterior-posterior direction. EGFP had its major localization to the 
dorsolateral and mediolateral regions of the rat’s striatum, while αS, WT-βS, P123H-βS, and 
V70M-βS were present also in the medial and ventral regions on the injected side of the brain 
(Figure 3.18). After 8 weeks of the transgene expression, a few fibers on the contralateral side of 
the brain were also immunopositive for the transgenes. Striatal projections of nigral dopaminergic 
neurons on the injected side were highly immunoreactive for αS, WT-βS, P123H-βS, and V70M-
βS even 8 weeks after the administration of the virus despite the dramatic loss (~56%) of SNpc 
dopaminergic neurons, although many of the remaining neurites in the striatum revealed some 
dystrophic phenotypes which were then further analyzed. 
 
3. Results 
86 
 
 
Figure 3.18. AAV2 transduction in the rat’s striatum. 
Representative pictures of striatal coronal sections of rats injected into the left SNpc with AAV2 vectors 
expressing EGFP, αS, WT-βS, P123H-βS or V70M-βS. Dopaminergic fibers were visualized with IHC 
staining against TH (red), αS, WT-βS, P123H-βS, and V70M-βS were visualized with immunoreactivity 
against human αS and βS (green). Expression of the transgenes predominates on the injected side of the 
brain. Loss of dopaminergic fibers can be seen in the ipsilateral striatum ofthe αS, WT-βS, P123H-βS, and 
V70M-βS-expressing brains. Mosaic images were taken with CCD camera on Zeiss Axioplan 2 
microscope using 10x objective. Exposure times: DAPI - 632 ms, EGFP - 7267 ms, anti-βS-Cy2 or anti-
αS-Cy2 - 2267, anti-TH-Cy3 - 3005 ms. Scale bar: 1.5 mm.  
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3.2.4. Effects of WT-βS, P123H-βS, and V70M-βS on the striatal fiber density 
 
Dopaminergic fiber density in the rats’ striata was measured on high-magnification 
microphotographs of coronal brain sections as a percentage of area covered by TH-
immunopositive projections. The injected side of the brain was compared to the contralateral 
side. The representative pictures and the results of the measurements are depicted in Figure 3.19. 
At time point 2 weeks after virus administration no significant fiber loss was noticed in any of the 
injection groups. The percentages of dopaminergic fiber density compared to the contralateral 
side were: αS 98 + 6%, WT-βS 98 + 4%, P123H-βS 102 + 5%, V70M-βS 99 + 12% and EGFP 
104 + 3% (n = 3 rats per group). 
Eight weeks post transduction axonal pathology increased in all groups except for the EGFP 
control which had 98 + 3% dopaminergic fibers on the injected side. The loss of dopaminergic 
fibers amounted to 42 + 8% in αS, 25 + 9% in WT-βS, 20 + 6% in P123H-βS, and 38 + 6% in 
V70M-βS conditions (n = 7 rats per group). V70M-βS significantly reduced the striatal fiber 
density in comparison with WT-βS (Tukey’s, p < 0.0115, power (1-β err prob) < 0.91) and 
P123H-βS (Tukey’s, p < 0.0004, power (1-β err prob) < 0.99) and reached the level of αS 
toxicity, αS vs. V70M-βS (Tukey’s, n.s.).  
The P123H mutation did not aggravate the effects of WT-βS on the dopaminergic fiber density 
(Tukey’s, p = 0.7). αS, WT-βS, P123H-βS, and V70M-βS were significantly more toxic than 
EGFP 8 weeks after the virus administration (Tukey’s, p < 0.0001, p < 0.0001, p = 0.0002, and p 
< 0.0001, respectively, power (1-β err prob) = 1.0). 
Taken together, the striatal pathology was observed first at 8 weeks post-transduction in groups 
of αS, WT-βS, P123H-βS, and V70M-βS, although the extent of the striatal fiber loss was lower 
than the loss of dopaminergic neurons in SNpc. V70M mutation aggravated the pathology of the 
WT-βS to the level of αS, and it was significantly more toxic than WT-βS and P123H-βS. The 
difference between WT-βS and P123H-βS was not significant. 
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Figure 3.19. Dopaminergic fiber density in rat’s striatum. 
(a) Representative 63x pictures of the coronal striatal sections show the loss of dopaminergic fibers in the 
regions of αS, WT-βS, P123H-βS, and V70M-βS expression but not for EGFP control or non-injected 
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side. Dystrophic axons can be observed in αS, and V70M-βS brains, and to a lesser extent in WT-βS and 
P123H-βS conditions. 
(b) Dopaminergic fiber density was significantly reduced at 8 weeks post transduction in αS, WT-βS, 
P123H-βS, and V70M-βS – expressing brains, with αS and V70M-βS conditions showing the most 
dramatic loss of the TH-positive fibers: 42 + 8% and 36 + 6% respectively (n = 7 rats per group). At 2 
weeks after virus administration, there was no significant loss of nigrostriatal projections in any of the 
conditions (n = 3 rats per group). 
(c) Statistical analysis with 1-way ANOVA/Tukey’s test. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. 
 
3.2.5. Axonal dystrophies in rat’s striata 
 
The striatal dopaminergic fibers, immunoreactive for αS, WT-βS, P123H-βS, and V70M-βS 
displayed axonal pathology in form of axonal retraction bulb-like structures, which were 
previously described in AAV-αS rat models (Taschenberger et al., 2012; Decressac et al., 
2012b).  As “axonal bulbs” the rounded structures of at least 2 µm in diameter, highly 
immunoreactive to TH were counted (Figure 3.20).  
Two weeks post-transduction, the number of axonal bulbs per mm2 of striatum amounted to: 37 + 
22 for αS, 20 + 5 for WT-βS, 18 + 2 for P123H-βS, and 34 + 20 for V70M-βS condition, while it 
was 16 + 3 in EGFP and ~10 to 15 bulbs/mm2 on the non-injected side of the brain. The 
differences between these groups were not statistically significant (n = 6 animals per group). 
After additional 6 weeks after the virus administration, the quantity of dystrophic axons 
significantly increased in the ipsilateral striata of the brains expressing αS, WT-βS and either 
mutant of βS. αS with 365 + 93 axonal bulbs per mm2 of striatum appeared to be the most toxic 
synuclein species, causing significantly more axonal pathology than WT-βS with 132 + 46 axonal 
bulbs per mm2 (Tukey’s, p < 0.0001, power (1-β err prob) < 0.99), P123H-βS with 102 + 32 
axonal bulbs per mm2 (Tukey’s, p < 0.0001, power (1-β err prob) < 0.99), and V70M-βS with  
274 + 64 axonal bulbs per mm2 (Tukey’s, p = 0.0363, power (1-β err prob) = 0.64). The 
difference between WT-βS vs. P123H-βS was not significant, while the V70M mutant had 
significantly more dystrophic neurites than both WT-βS (Tukey’s, p = 0.0005, power (1-β err 
prob) < 0.99) and P123H-βS (Tukey’s, p < 0.0001, power (1-β err prob) < 0.99). The number of 
axonal bulbs virtually did not change from 2 to 8 weeks in EGFP-expressing brains (13 + 4 bulbs 
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per mm2), and on the contralateral sides of the brains (αS: 33 + 18, WT-βS: 10 + 7, P123H-βS: 14 
+ 14, V70M-βS: 13 + 8, EGFP: 7 + 5 bulbs per mm2).  
To sum up, the striata of the brains expressing V70M-βS were characterized by the more frequent 
formation of dystrophic neurites/axonal bulbs in comparison with WT-βS. At the same time, 
P123H mutant did not produce more axonal pathology than WT-βS. 
 
Figure 3.20. Axonal swellings in rat’s striatum. 
(a) Axonal swellings or axonal bulbs were defined as rounded structures of at least 2 µm in Feret’s 
diameter (ImageJ measurements) which are highly immunoreactive against TH. Immunostaining against 
TH (T1299) and aS (sc-7011-R) is shown. Arrows on the merged images indicate the axonal bulbs. 
(b) Axonal swellings were counted on injected and contralateral sides of the brain. 3 striatal sections and 
thirty 40x microphotographs were analyzed for each rat. Data are presented as the mean number of axonal 
swellings per mm2 + SD (for 2-week groups n = 6, for 8-week groups n = 7 animals per condition). 
(c) Statistical analysis with 1-way ANOVA/Tukey’s test. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. 
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3.2.6. Aggregation of WT-βS, P123H-βS, and V70M-βS in rat’s SN 
 
In order to study aggregation of WT-βS, P123H-βS, and V70M-βS in dopaminergic neurons in 
vivo, these proteins were overexpressed in rat’s SN using AAV2 vectors. Overexpression of 
human αS was used as the positive control for the aggregation. EGFP was used as a non-toxic 
control. Monocistronic AAV2 vectors were unilaterally injected into the left SN, and 3 weeks 
after the virus administration the samples of cortex, striatum, and SN were collected for each 
animal.  
Immunoblotting analysis revealed a 5 to 7-fold overexpression of WT-βS, P123H-βS, and V70M-
βS in the injected SN (Figure 3.21. (c)). Approx. 1/10th of the transgene proteins was present in 
the striatum on the injected side of the brain due to the anterograde transport in nigrostriatal 
projections. 
 
Figure 3.21. Immunodetection of the overexpressed proteins in cortex, striatum, and SN. 
Adult female rats were injected unilaterally into the left SN with 1.2 x 108 tu of AAV2 vectors expressing 
either αS, WT-βS, P123H-βS, V70M-βS or EGFP under control of the neuron-specific hSyn 1 promoter. 
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The samples of cortices (cx), striata (str), and Substantia nigra (SN) were collected 3 weeks after virus 
administration. Immunoblotting against β-tubulin (~55 kDa band), TH (~62 kDa band), and the transgene 
proteins were performed.   
(a) Human αS (~18 kDa band) was detected in the injected SN and, to a lower extent, in the striatal 
projections.  
(b) The same pattern was observed for EGFP (~27 kDa band) which was mostly expressed in SN, and 
nearly 1/10th of the transgene protein was present in the striatum.  
(c) The immunostaining against βS detected both human and rat βS (~20 kDa band). These two proteins 
have almost identical sequences with the difference in only 2 amino acid residues; therefore, no βS 
antibody was able to detect only the human protein. The overexpression of βS or its mutants was 5-7-fold 
in comparison to the endogenous βS. 
 
The protein lysates of SN were subjected to proteinase K (PK) digestion in order to evaluate 
possible PK resistance of WT-βS and its mutants which would be an indication of their 
aggregation state in dopaminergic neurons of SNpc. PK is a serine protease which has an ability 
to hydrolyze a wide variety of the peptide bonds, with exception of some β-sheet-rich proteins, 
such as prions or αS fibrils which show resistance to PK digestion. Here though, only relative 
“resistance” to PK is meant, which applies only to the mentioned below temperature, time, and 
PK concentration during the digestion. 
After 5 min of PK digestion (final PK dilution 2 µl/2 ml) at 370 C, I observed that some amount 
of protein remained in case of αS, WT-βS, P123H-βS, and V70M-βS. The dopaminergic marker 
TH and the neuronal marker β-tubulin were completely digested under the same digestion 
conditions. Similar to the results of the PK digestion experiments in cell culture (see section 
3.1.3.), a portion of the full-length αS (~18 kDa) was resistant to PK digestion at given 
conditions, and the undigested WT-βS, P123H-βS, and V70M-βS revealed a pattern of ~12 – 18 
kDa bands in addition to a small amount of the remaining full-length protein (~18 kDa). The 
sizes of these fragments were identical in WT-βS, P123H-βS, and V70M-βS, although the 
amount of the remaining protein was diminished in V70M-βS which might indicate lower 
aggregation propensities of this protein (Figure 3.22.).  
The amount of the PK-resistant protein in the V70M-βS-expressing dopaminergic neurons (15 + 
4%) was significantly lower than in αS (53 + 21%) (Unpaired t-test, p = 0.0103, power (1-β err 
prob) = 0.92), WT-βS (39 + 13%) (Unpaired t-test, p = 0.0108, power (1-β err prob) = 0.92), and 
P123H-βS (36 + 11%) (Unpaired t-test, p = 0.0091, power (1-β err prob) = 0.93). P123H-βS did 
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not differ in its aggregation propensities from the WT-βS. The diminished aggregation of V70M-
βS might be connected to the increased toxicity of this protein in the nigrostriatal projections. 
 
Figure 3.22. PK digestion of the injected SN. 
Lysates of the SN, where αS, WT-βS, P123H-βS or V70M-βS were overexpressed, were digested for 0 
min and 5 min with 2 µg/ml of proteinase K.  60 µg of protein is loaded per lane. 
(a) Immunoblotting was performed with anti-αS (syn211 clone, Invitrogen 32-8100), anti-βS (Sigma, 
SAB1100305, detected amino acid residues 81-95), anti-β-tubulin (Sigma, T-4026) and anti-TH (Sigma, 
T1299) antibodies. In the case of αS, a portion of the full-length form of the protein remained after the PK 
digestion. For the WT-βS and P123H and V70M mutants, the fragments of 12 – 18 kDa were detected in 
addition to the low amount of the full-length protein remaining after the digestion. TH and β-tubulin were 
completely digested under the same conditions. 
(b) Quantification of the bands intensity showed that αS had 53 + 21% of the protein resistant to PK under 
applied conditions, WT-βS and P123H-βS had 39 + 13% and 36 + 11%, respectively (sum of the 
intensities of all remaining bands). V70M-βS with 15 + 4% of the remaining material had significantly 
less remaining after digestion protein than αS (unpaired t-test, p = 0.0103), WT-βS (unpaired t-test, p = 
0.0108), and P123H-βS (unpaired t-test, p = 0.0091). Data are represented as mean + SD (n = 4 
animals/group). 
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4. Discussion 
 
The role of WT-βS in the development of synucleinopathies still remains under dispute. Both 
neuroprotective and neurotoxic properties of this protein were suggested in the literature, both 
fibrillation under certain conditions and counteraction with αS aggregation were shown in 
different models. Even less is known about the disease-associated mutants of WT-βS, P123H-βS 
and V70M-βS. Here, the abilities of WT-βS and both mutants to induce neurotoxicity and 
aggregate in primary cortical neuronal culture and dopaminergic neurons of SN were studied. 
 
4.1. Aggregation and toxicity of WT-βS, P123H-βS, and V70M-βS in primary 
cortical neurons 
4.1.1. The V70M mutation aggravates the neurotoxicity of WT-βS in cultured cortical 
neurons 
A prominent neuronal loss is observed in several regions in the brains of DLB patients such as 
Substantia nigra, basal ganglia, and cerebral cortex including hippocampus etc. (Donaghy and 
McKeith, 2014). Therefore, it is of interest to study neurotoxicity of synuclein proteins in various 
cell culture models and specific regions of animal brains. For my in vitro experiments, a 
standardized model of primary cortical cultured neurons was employed. Although studying of 
synuclein toxicity in the culture of dopaminergic neurons would be also interesting, primary 
midbrain cultures include only 5 - 10% of dopaminergic neurons, which makes them inapplicable 
for viability and biochemistry assays (Falkenburger and Schulz, 2006). A future development of 
dopaminergic iPSCs models or other alternative models would be of advantage here. 
Prior to the in vivo experiments in dopaminergic neurons of SN, I tested the neurotoxic potential 
of αS, WT-βS, P123H-βS, and V70M-βS in primary cortical cells where the transgene delivery 
was mediated by AAV6 viral vectors. All of these synuclein proteins induced significant 
neuronal loss starting from the day 12 after the virus administration in comparison with EGFP 
and γS controls. αS appeared to be the most toxic species at 12 dpt and 16 dpt. In the late culture 
at 20 dpt, I observed an increase in the V70M-βS-induced neuronal loss which reached the level 
of the αS toxicity (~60%) and was significantly higher than in WT-βS and P123H-βS-expressing 
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neurons (~40%). Surprisingly, the familial mutation of βS, P123H did not aggravate βS effects on 
the cell viability.  
Such standardized cell culture model was already employed in Taschenberger et al., 2013 for 
comparing neurotoxicity of αS, WT-βS, and γS proteins while the neurodegeneration in primary 
cortical neurons due to the disease-associated mutants P123H and V70M was described for the 
first time in this thesis. In comparison with my results, Taschenberger et al. showed somewhat 
higher neurotoxicity of both αS and WT-βS. Improved conditions for the cell culturing and 
prevention of the medium evaporation could have been the reason for a better viability of the 
current neuronal cultures. γS appeared to be non-toxic in both projects. Carefull examination of 
synuclein overexpression levels suggested that βS-induced neurodegeneration was aggravated by 
the presence of V70M mutation and not the difference in the protein expression levels.    
Some previous publications indicated a neuroprotective role of WT-βS and even suggested its 
application as an anti-aggregating agent and a therapeutic factor in synucleinopathies (Hashimoto 
et al., 2001). It was shown that WT-βS can inhibit apoptosis via downregulation of p53 and 
protection against caspase 3 activation in TSM1 neuronal cell line (da Costa et al., 2003), and via 
regulation of Akt serine-threonine kinase in B103 neuroblastoma cells (Hashimoto et al., 2004a). 
However, the toxicity of WT-βS may depend greatly on its concentration. Thus, Krassnig et al., 
2015 showed that modest WT-βS expression had some beneficial effects in the brain of tg AD 
mouse but locally highly elevated levels of WT-βS caused neurodegeneration. Taschenberger et 
al., 2013 showed that when αS and WT-βS were co-expressed in primary cortical neurons, the 
ratio of both proteins was crucial: WT-βS had some neuroprotective effects when applied in ratio 
1:30 or 1:10 to αS (although the cytotoxicity was not completely averted) but when more of WT-
βS was present in the neurons no neuroprotection was observed.   
To sum up, the V70M, but not the P123H mutation of βS aggravated neuronal loss in cultured 
cortical neurons. 
 
4.1.2. Mitochondrial pathology precedes the neuronal cell death 
Mitochondrial dysfunction has been intimately connected to interactions with αS in PD and DLB 
pathophysiology. Several familial PD and DLB mutations of SNCA gene - A53T, E46K, and 
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H50Q, as well as mutations of LRRK2, parkin, and PINK1, were associated with mitochondrial 
fragmentation and increase of ROS species production (Ryan et al., 2015). Normal neuronal 
function depends on a plentiful and efficient supply of ATP to soma, axons, and dendrites by 
healthy mitochondria, which is especially challenged in dopaminergic neurons with their long 
and extensively arborized neurites. Therefore, mitochondria regularly undergo a “quality check” 
with help of dynamic processes of fusion/fission and mitophagy, a selective process through 
which damaged mitochondria are removed (Mullin and Schapira, 2013). Mitochondrial fusion is 
the process of merging of two or several mitochondria regulated by mitofusin (Mfn) proteins of 
the outer mitochondrial membrane (OMM) which results in elongation of mitochondria. 
Mitochondrial fission is a process of mitochondrial division into smaller structures directed by 
dynamin-related GTPase (Drp1) and Fis1 protein (Pozo Devoto and Falzone, 2017). WT-αS was 
shown to bind directly via its N-terminus to OMM and cause an increase in the membrane 
curvature leading to fragmentation (Kamp et al., 2010; Dikiy and Eliezer, 2012). Mitochondrial 
fragmentation as a result of αS overexpression was described in several models before (Kamp et 
al., 2010; Nakamura et al., 2011). Both αS and WT-βS but not γS induced formation of rounded 
and swollen (condensed) mitochondria in primary cortical neurons without robust impairment of 
ATP production or changes in membrane potential (Taschenberger et al., 2013). Recently, Tolö 
et al., 2018 showed that deformation of mitochondria under the influence of αS was accompanied 
by permeabilization of OMM, thiol oxidation, and activation of apoptotic pathways, even though 
ATP production and ion handling were not disturbed in cortical neurons. 
The results of this Ph.D. project on mitochondrial fragmentation under overexpression of αS, 
WT-βS, and γS were consistent with previous publications. The mutants of βS were for the first 
time characterized with respect to their influence on mitochondrial dysfunction. P123H-βS was 
not any more toxic than WT-βS while V70M-βS caused a decrease in the number of cells with 
elongated mitochondria and increase in the number of neurons with fully condensed 
mitochondria to an extent of αS-induced effects on mitochondrial morphology. These 
characteristics were dependent on the age of the culture and more prominent at the later stage (14 
dpt). Whether V70M-βS might bind OMM with its highly conserved N-terminal region in a 
similar way to αS is not known. Increased mitochondrial condensation, which possibly led to the 
functional impairment of mitochondria, could have been one of the pathological mechanisms 
4. Discussion 
97 
 
explaining the increase in cytotoxicity of V70M-βS in comparison to WT-βS. The P123H mutant 
did not show such aggravation in abberant mitochondrial morphology when compared to WT-βS.  
Analysis of mitochondrial morphology in the neurites revealed a decrease in mitochondrial length 
to width ratio under the expression of αS, WT-βS, P123H-βS, and V70M-βS in comparison to 
EGFP- and γS-expressing control cells, with the most prominent effects observed in αS and 
V70M-βS conditions. Still, such morphological changes in neurites were very moderate in 
comparison with mitochondrial deformation in the soma. Completely rounded and swollen 
mitochondria were observed only in somas but not in the neurites of cultured cortical neurons, 
which indicates that such deformations in morphology may lead to the inability of these 
mitochondria to move along the neurites. This speculation is supported by the absence of 
dramatic effects of synuclein on motility of mitochondria in these experiments. The mean speed 
of mitochondria in the neuronal processes amounted to ~45 µm/min, the maximal speed was 
approx. 85 µm/min in all the expression groups with exception of αS-expressing neurons, where 
the motility of mitochondria was slightly decreased. These results are consistent with previously 
published data on mitochondrial motility (Toloe J, Ph.D. thesis, 2013; MacAskill et al., 2010; De 
Vos et al., 2003). 
In summary, in respect to influence on mitochondrial morphology in somas, V70M-βS but not 
P123H-βS aggravated mitochondrial condensation as compared to WT-βS, which may have been 
one of the pathophysiological mechanisms leading to the increased neurotoxicity of V70M-βS. 
 
4.1.3. V70M-βS has lower resistance to PK-digestion than WT-βS 
Aggregation properties of WT-βS are greatly dependent on the conditions of the reaction. Despite 
a suggested earlier non-amyloidogenic nature of WT-βS (Hashimoto et al., 2001; Uversky et al., 
2002), it was shown that macromolecular crowding, the presence of pesticides or heavy metals 
can force fibrillation of this synuclein species (Yamin et al., 2005). Formation of PK-resistant 
aggregates was observed under WT-βS-overexpression in rats SNpc (Taschenberger et al., 2013). 
Changing in the pH to mildly acidic values can also trigger WT-βS fibrillation (Moriarty et al., 
2017). 
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The fact that WT-βS can aggregate despite missing 11 AA in the central region of the molecule 
corresponding to the αS NAC domain, shows that the structure of other domains may be also 
important for the fibrillation process. In this Ph.D. project, I tested the aggregation propensities of 
WT-βS, P123H-βS, and V70M-βS with the PK digestion assay. In all three proteins, a C-terminal 
region was cleaved off in the digestion reaction, in the contrast to αS where the full-length form 
of the protein was resistant to PK under given conditions. These findings are consistent with the 
synuclein chimera experiments of Moriarty et al., 2017, where 8 versions of αS/WT-βS chimeric 
species with swapped domains were tested and showed higher stability and importance of the 
conserved N-terminal region for fibrillation of both proteins. At the same time, the C-terminal 
region, which has the least sequence homology between two synuclein species, had a specific 
influence on WT-βS and αS: the C-terminus of WT-βS, when introduced into αS, was able to 
prevent αS fibrillation, even at acidic pH, while WT-βS was fibrillating at pH 5.8. All three 
domains and interaction between them appeared to be important for the fibrillation properties 
specific to the synuclein species (Moriarty et al., 2017; Landau M, 2017). The P123H mutation in 
the C-terminal region of βS renders its confirmation to be more similar to αS and was shown to 
increase the fibrillation under co-incubation with αS (Janowska and Baum, 2016). The C-terminal 
region of αS was earlier shown to stabilize long-range intramolecular electrostatic interaction 
with N-terminus, important for the stability of the molecule (Bertoncini et al., 2005). 
Although the sizes of PK-stable fragments were the same in WT-βS and mutants in my 
experiments, V70M-βS had a lower amount of protein remaining after the PK reaction. This 
might indicate a lower aggregation state of V70M-βS (for example, more monomers or/and short 
oligomers). How this lower aggregation state is connected to the increased cyto- and 
mitochondrial toxicity of the V70M mutant is not yet clear. In order to reveal further differences 
in mechanisms and kinetics of fibril formation in WT-βS and mutants, they can be studied in cell-
free conditions with a variety of biophysical assays (e.g., thioflavin T assay, circular dichroism 
spectroscopy, NMR spectroscopy etc). The only previous publication addressing fibrillation of 
DLB-associated βS mutants, Wei et al., 2007, showed that the recombinant V70M and P123H-βS 
were more prone to aggregation than WT-βS in vitro, however these recombinant proteins were 
6xHis-tagged and aggregated under acidic conditions with a specific buffer which might not 
reproduce the physiological intracellular conditions. 
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Decreased PK resistance of the V70M mutant in my experiment may mean that less fibrils and 
more oligomers were present in the cultured cortical neurons, which subsequently resulted in the 
higher toxicity of V70M-βS, compared to P123H-βS and WT-βS. 
 
4.2. Aggregation and toxicity of WT-βS, P123H-βS, and V70M-βS in rat’s SN 
 
4.2.1. Loss of SN dopaminergic neurons can be induced by P123H-βS and V70M-βS 
overexpression 
In this thesis, P123H-βS and V70M-βS were for the first time studied in the AAV rat model with 
their respect to degeneration of dopaminergic neurons in SNpc and dopaminergic fiber loss in the 
striatum. Stereotaxic gene delivery with rAAV2 viruses allowed to introduce the unilateral lesion 
into SNpc and to use the contralateral side as a control for stereological cell counting. AAV 
vectors of serotype 2 produced a compact transduction in the injected SN, and hSyn1 gene 
promoter allowed for the neuron-specific expression of the transgenes. This animal model allows 
studying the effects on dopaminergic neurons of SN while their native properties and neuritic 
connections are retained. Besides, viral vector models are so far the only ones which demonstrate 
a progressive neuronal loss in SNpc, a major histopathological hallmark of PD and DLB which 
cannot be recapitulated in genetic mouse lines (Löw and Aebischer, 2012). 
The results of neuronal loss in αS, WT-βS and EGFP control groups were consistent with the 
previously published data (Taschenberger et al., 2012; Taschenberger et al., 2013). Thus, in the 
experiments of this Ph.D. project αS caused loss of ~40% of dopaminergic neurons in the 
injected SNpc at 2 weeks after virus administration and ~58% after 8 weeks. The respective 
neuronal loss in Taschenberger et al., 2012 amounted to 43% and 56% respectively, and in 
Taschenberger et al., 2013 – to ~46% and 52%. WT-βS in my experiments also caused a 
progressive loss of dopaminergic neurons: ~20% and ~55% after 2 and 8 weeks of transgene 
expression. In Taschenberger et al., 2013 dopaminergic neuronal loss due to WT-βS toxicity 
amounted to ~20 % and ~45 % at the same time points after transduction which is consistent with 
the data of this thesis. The data of other groups showed variable results in rAAV models of PD – 
from 15% (Davies et al., 2014) to 90% neuronal loss (Gombash et al., 2013) depending on the 
exact experimental layout, AAV serotype and concentration of the virus.  
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P123H-βS did not aggravate the βS neurotoxicity in vivo. V70M-βS was also not statistically 
different from WT-βS but the loss of dopaminergic neurons in V70M-βS has reached statistical 
significance earlier when compared to EGFP control (2 weeks after viral injection). At the same 
time there were no statistical differences between V70M-βS vs. WT-βS or V70M-βS vs. WT-βS 
even at the earlier time point. The level of βS overexpression (WT and mutants) estimated to 5-7-
fold in the described experiments. Application of lower viral concentration and less dramatic 
impact on neuronal death in SN might reveal the difference between WT and mutant βS. 
Loss of hippocampal neurons with regard to P123H mutation of βS was reported before in tg 
mouse line. The cross-breeding of P123H-βS and αS tg mice resulted in enhanced 
neuropathology and more pronounced loss of hippocampal neurons (Fujita et al., 2010). At the 
same time, there was no comparable WT-βS control in the study of Fujita et al., 2010. Thus, it is 
unclear if the P123H mutation or mere increase in the protein expression level was responsible 
for the cell loss.  
In the experiments described in this Ph.D. thesis, TH-positive neurons were counted. Several 
previous publications showed that αS might not only kill dopaminergic neurons but also 
downregulate TH expression by inhibition of Nurr1 transcription factor (Baptista et al., 2003; Yu 
et al., 2004; Peng et al., 2005; Chu et al., 2006). Therefore, it was important to perform a control 
staining for the loss of dopaminergic neurons. Hence, using the VMAT2 marker of dopaminergic 
neurons would have been beneficial. However, the anti-VMAT2-antibody used in our lab was 
discontinued, and testing of approx. 15 new commercial antibodies for VMAT2 revealed that 
none of them can reliably stain the dopaminergic neurons of SN. No suitable anti-VMAT2 
antibody was found at the time of my experiments. Therefore, IHC staining against TH was 
combined with the Nissl staining protocol and non-dopaminergic neurons were counted in the 
same regions as dopaminergic in order to exclude mere downregulation of TH. I revealed a true 
loss of dopaminergic neurons, numbers of non-dopaminergic neurons did not increase in any 
group or at any examined time point. Besides, a recent report of rAAV-αS models where TH- and 
VMAT2-positive cells were counted in parallel in the same animals, revealed the same cell 
numbers for both dopaminergic markers (Decressac et al., 2012b). 
In summary, V70M-βS caused significant neurodegeneration at earlier time point than WT-βS 
and P123H-βS in dopaminergic neurons of rat’s SN.  
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4.2.2. V70M-βS induces greater axonal pathology than WT-βS 
Axonal pathology in nigrostriatal projections accompanied the loss of SNpc neurons due to the 
expression of αS, WT-βS, P123H-βS, and V70M-βS. Two weeks after virus administration I have 
not observed any significant losses of dopaminergic fiber density but at 8 weeks post-
transduction, ~40% of TH-positive fibers were lost in αS and V70M-βS animal groups, and 
~23% in WT-βS and P123H-βS conditions. Although the loss of striatal projection was less 
dramatic than the loss of SNpc neurons, the remaining axons with transgene expression had 
pronounced axonal pathology at 8-weeks-time point: the neurites were swollen and axonal-bulb 
like structures highly immunopositive for synuclein and TH were detected. P123H-βS tg mice 
were characterized by pronounced axonal pathology in form of axonal swellings or retraction-like 
axonal bulbs (Sekigawa et al., 2015). Similar pathological structures in the striatum were earlier 
described in αS-overexpressing rat brains (Taschenberger et al., 2012; Decressac et al., 2012a) 
but for the first time axonal bulbs are reported in rAAV model of WT-βS, P123H-βS and V70M-
βS overexpression. Stronger striatal pathology in the αS-overexpressing brain in comparison to 
the WT-βS-overexpressing brain was reported before in Taschenberger et al., 2013. Interestingly, 
P123H-βS effects were almost identical to WT-βS, while V70M-βS induced much more 
pronounced axonal pathology in both striatal fiber loss and axonal bulb formation in the striatum 
almost reaching the level of αS toxicity. A lesser extent of striatal vs. nigral pathology indicates 
that all four proteins may trigger very rapid detrimental effects in somas of SNpc dopaminergic 
neurons and axonal pathology follows. A possible reason for that could be higher synuclein 
concentration in cell bodies in comparison to anatomically remote striatal projections.  
The pathological picture in the DLB patients’ brains, where neuronal impairments develop over 
years, might be different. Sekigawa et al., 2015 suggested that in DLB patients’ axonal pathology 
may precede and trigger the cell death. Human histopathological data confirms that WT-βS (and 
possibly its mutants) could induce axonal pathology. Thus, βS was found in axonal lesions in 
hippocampi of DLB and PD patients (Galvin et al., 1999). In brains of NBIA type 1 
synucleinopathy, βS accumulated in form of axonal spheroids (Galvin et al., 2000). Again, the 
rare V70M mutation drastically increased axonal pathology in comparison with WT-βS, which 
indicates that V70M-βS might significantly contribute to the DLB pathology but P123H does not. 
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4.2.3. Aggregation profiles of WT-βS and its mutants are similar in vitro and in vivo 
The pattern of fragments produced in the PK digestion reaction was similar between WT-βS and 
its P123H and V70M mutants, as well as between cultured cortical neurons and dopaminergic 
neurons of SNpc of the rat. The C-terminal region of the molecule was less stable than the N-
terminus and central domain. V70M-βS was less resistant to PK digestion. One could speculate 
that lower aggregation state of V70M-βS might have provided this synuclein species with more 
efficient motility and transport to the axonal terminals which might have led to the elevated 
accumulation of V70M in striatal fibers and increased axonal pathology. 
Lower stability of V70M-βS against PK digestion may indicate a decrease in amount of β-sheet 
rich fibrils and a subsequent increase of oligomeric fraction of this synuclein species. By analogy 
with αS, toxic oligomers could actually be a molecular conformation of V70M-βS, responsible 
for the neurotoxicity. In αS research, growing evidence from a variety of experimental models 
links oligomeric species with neuronal impairment and propagation of PD and DLB. At the same 
time, Lewy bodies and Lewy neurites are suggested to be a protective form for sequestration of 
toxic αS (Bengoa-Vergniory et al., 2017). Several facts support a “bystander” role of Lewy 
bodies. Firstly, nearly 10% of healthy individuals brains contain Lewy bodies without indication 
of increased neurodegeneration (Parkkinen et al., 2005). Secondly, Lewy body pathology often 
does not correlate with the severity or the modality of PD or DLB symptoms (Parkkinen et al., 
2008). Finally, a familial form of PD was described where a G2019S mutation of LRRK2 led to 
neurodegeneration without formation of Lewy bodies (Gaig et al., 2007).  
“Toxic oligomers hypothesis” in case of αS is supported by numerous studies, where oligomers 
of αS, produced in cell-free conditions, were applied to cell cultures and brains and caused 
neurodegeneration, seeding and propagation of pathology (Danzer et al., 2007; Karpinar et al., 
2009). At the same time, αS form with accelerated fibrillation and decrease in amount of 
oligomers (αS 30-110) did not cause dopaminergic neuronal loss in Substantia nigra of rats, 
unlike the oligomers-rich mutants (E57K-αS and E35K-αS) (Winner et al., 2011).  
Although oligomeric species of αS are highly heterogenous, recently some structural 
characteristics, which render αS oligomers toxicity, were described. Fusco et al. showed that an 
exposed lipophilic part of toxic oligomers caused reinforced interactions with cellular membranes 
and the rigid oligomeric core was essencial for the αS-induced membrane disruption and 
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subsequent cellular dysfunction. The N-terminus of αS, the membrane-bounding region, was 
especially important for the induction of oligomers toxicity (Fusco et al., 2017). Close proximity 
of the V70M mutation to the N-terminus of βS and high homology between the N-terminal 
regions of αS and βS (Figure 4.1) may indicate a possible mechanism of “toxic gain of function” 
in V70M-βS. Valine to methionine substitution close to the border of the N-terminus and NAC-
domain may cause conformational changes in these both regions of βS, rendering more stable 
oligomeric form and increased toxicity of V70M-βS. 
 
Figure 4.1. Amino acid sequences of αS and βS. 
Amino acid sequences of αS and βS are aligned according to their 3 domains: N-terminus, NAC-domain 
and C-terminus. Identical aa residues are highlighted in gray, non-identical aa residues are highlighted in 
yellow, and deletions are shown as dashes. Red writing shows the known mutations of αS and βS. 
 
4.3. Conclusion and perspectives 
 
Taken together, the results of this Ph.D. thesis show that the V70M mutation of βS is pathogenic 
and may contribute to the neurodegeneration in dementia with Lewy bodies. P123H-βS did not 
aggravate the effects of WT-βS in any of the neurotoxicity or aggregation experiments of this 
project which might indicate that this mutation is coincidental and might not be relevant to the 
DLB pathogenesis. V70M-βS induced more pronounced neuronal loss in cortical culture, 
dopaminergic fiber loss and axonal pathologies in rats’ striata. Some pathological mechanisms of 
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the V70M mutant may be related to its less stable aggregates (possibly toxic oligomers) in 
comparison to WT-βS and its ability to cause mitochondrial deformations – putative early events 
in cytopathology of synucleinopathies. 
It would be interesting to study further V70M-βS aggregation properties in the cell-free 
conditions which could characterize features of its aggregation and kinetics of fibril formation in 
details. One could speculate that the location of the mutation at the position 70 may be a key to 
forming less fibrils and more stable oligomeric form of V70M-βS. Most of the αS familial 
mutations are also adjacent to this region. Since valine at the position 70 is conserved between αS 
and βS, one could also generate a V70M mutation in αS and test it for the possible increase in 
amount of oligomeric species and neurotoxicity. Besides, creating a chimeric αS/V70M-βS 
species, where, for example, the NAC-domain of V70M-βS is introduced into αS, could further 
reveal the role of the V70M mutation in the aggregation process.  
Since V70M-βS caused more dramatic condensation of mitochondria than WT-βS, the mutant 
may be able to have stronger interactions with membranes. This process could be analogous to 
αS, where it was shown that αS could directly bind to OMM (Nakamura et al., 2011) and αS 
oligomers but not monomers led to OMM permeabilization (Ludtmann et al., 2018). Therefore, 
one could consider studying interactions of V70M-βS oligomeres with artificial and natural lipid 
bilayers, including OMM and IMM. Besides, further molecular mechanisms of V70M-βS 
induction of mitochondrial deformation and dysfuction could be elucidated in vitro and in vivo, 
e.g. with respect towards ROS species production and caspase activation. 
A recent publication implicates pathological reduction of autophagy in brains of DLB patients 
due to elevated level of WT-βS expression (Evans et al., 2018). Further studies of WT-βS and 
V70M-βS effects on autophagy pathways may be of the relevance for the development of 
therapeutics for DLB patients. Moreover, it is still not known how WT-βS and V70M-βS 
influence ER stress, glial and inflammatory responses, proteasomal and synaptic functions in the 
patients’ brains, and could be addressed in the upcoming experiments. 
In this Ph.D. project, a stronger difference between WT-βS and V70M-βS-induced neurotoxicity 
was observed in cortical cells in contrast to the dopaminergic neurons of Substantia nigra pars 
compacta. Although these results are compatible with DLB pathophysiology, where cognitive 
(cortical) symptoms often preceed motor (nigro-striatal) symptoms, it is not yet clear why cortical 
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neurons were more sensitive to V70M-βS then to WT-βS.  One could try to validate these results 
in other in vitro and in vivo models, e.g. in cell cultures of dopaminergic and glutamatergic 
neurons produced from the same iPSCs. Interactions of overexpressed with endogenous 
synuclein could also play a role in animal and cell culture models, since endogenous αS and βS 
are abundant in various brain regions. The experiments including αS- and/or βS-KO models 
could show whether the neurotoxicity is dependent on the endogenous proteins.  
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5. Summary 
 
Dementia with Lewy bodies is a progressive degenerative brain disorder which accounts for 7 to 
25% of all dementia cases. Two rare missense mutations of β-synuclein, P123H and V70M were 
identified in familial and sporadic cases of DLB, respectively. Some previous publications 
showed that P123H and V70M mutations may contribute to the DLB pathology by aggregation 
(Janowska et al., 2016), inducing neurodegeneration (Fujita et al., 2010) or causing lysosomal 
pathology (Wei et al., 2007). Still, their pathological roles were not clearly understood at the 
beginning of this project. Here, neurotoxicity and aggregation of WT-βS and its mutants, P123H-
βS and V70M-βS, were studied in vitro in primary cultured cortical neurons and in vivo in 
dopaminergic neurons of SNpc of rat. V70M-βS was described for the first time in an in vivo 
model. 
It was found that the V70M mutation in several conditions aggravated pathologic effects of WT-
βS, namely, V70M-βS: 
- increased cell loss in primary cortical neurons; 
- induced more condensation of mitochondria in cultured neurons; 
- caused more pronounced loss of nigrostriatal projections, and formation of axonal bulbs 
in rats striata; 
- showed less fibril formation in cultured neurons and in vivo in Substantia nigra. 
Increase in mitochondrial deformations under influence of V70M may have been an early cellular 
mechanism leading to the cell death. Moreover, increased neurotoxicity in primary cortical 
neurons correlated with lower resistance of V70M to PK digestion; this may indicate lower extent 
of V70M-βS fibril formation and increase in amount of “toxic oligomeric species”.  
Altogether, these data indicate pathologic role of V70M mutation of βS and its putative relevance 
to DLB pathogenesis.  
The P123H mutation did not contribute to the pathological features of WT-βS in any of the 
experiments of this Ph.D. project, which may indicate that it is coincidential to DLB pathology. 
However, further investigation of P123H-βS with respect to its long-term effects in different 
experimental models may be necessary to exclude its possible pathological role in DLB.
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αS – alpha synuclein 
βS – beta synuclein 
γS – gamma synuclein 
µg – microgram 
µl– microliter 
µm– micrometer or micron 
µM– micromolar 
AA – amino acid residue 
AAV – adeno-associated virus   
Aβ – amyloid beta 
aCSF – artificial cerebrospinal fluid 
AD – Alzheimer’s disease 
ALS – amyotrophic lateral sclerosis 
Amp – ampicillin  
ANOVA – analysis of variance 
AP– anterior-posterior 
APS– ammonium peroxide sulfate 
ATP– adenosine triphosphate   
BCA – bicinchoninic acid  
Bcl-xL – B-cell lymphoma-extra large 
bp– base pairs 
BPB– bromophenol blue sodium salt   
BSA– bovine serum albumin 
CA 2/3 – Cornu Ammonis area 2/3 of hippocampus 
cDNA – complementary DNA  
CJD – Creutzfeldt-Jakob disease 
CMF – Ca2+/Mg2+-free medium 
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CNS – central nervous system  
COX IV – cytochrome c oxidase subunit 4 
Cy2 – cyanine fluorophore  
Cy3 – indocarbocyanine fluorophore 
DAB– 3,3'-diaminobenzidin 
DAPI– 4',6-diamidino-2-phenylindole   
DJ1 – protein and nucleotide deglycase 
ddH2O – sterile ultra-pure water 
DLB – dementia with Lewy bodies  
DMEM – Dulbecco’s modified Eagle’s medium   
DMSO–dimethyl sulfoxide 
DNA – desoxyribonucleic acid   
dNTP – deoxynucleotide triphosphate    
DPX – distyrene, plasticizer, and xylene 
DTT– dithiothreitol   
DV– dorsoventral 
E – embryonic day 
ECL–enhanced chemoluminescence solution 
ECM – extracellular matrix 
EDTA– ethylenediaminetetraacetic acid   
EGFP– enhanced green fluorescent protein   
ER – endoplasmic reticulum  
ESI-MS – electrospray ioinization mass spectroscopy 
EtBr– ethidium bromide 
FCS – fetal calf serum   
FPLC– fast protein liquid chromatography  
FTLD – fronto-temporal lobar degeneration 
g – gravitational constant 
GWAS – genome-wide association studies 
h –hour 
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HBSS – Hank's balanced salt solution 
HCl – hydrogen chloride 
HCN – hippocampal and cortical neuron medium 
HEPES– (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid) 
HF – high fidelity 
H2O2 – hydrogen peroxide  
HRP – horse reddish peroxidase  
hSyn1 – human synapsin 1 gene promoter 
IF– immunofluorescence 
IHC– immunohisochemistry   
IMM – inner mitochondrial membrane 
IPTG – isopropyl-beta-D-thiogalactopyranoside  
kb – kilobase  
KCl – potassium chloride 
kDa– kilodalton  
KO – knock-out 
kV–kilovolt 
L-DOPA – levodopa or L-3,4-dihydroxyphenylalanine 
LB – Lewy body 
LB-medium – Luria broth  
LN – Lewy neurite 
LRRK – leucine-rich repeat kinase  
M–Mole 
MgCl2–magnesium chloride 
MgSO4 – magnesium sulphate 
min or ´– minute 
ML – mediolateral 
mm – millimeter 
MPTP – 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine  
mRNA – messenger RNA  
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MSA – multiple system atrophy  
NAC – non-Aß component of Alzheimer’s disease amyloid  
NaCl – sodium chloride 
NaHCO3 – sodium bicarbonate  
NaH2PO4 – sodium phosphate monobasic monohydrate 
NaN3 – sodium azide  
NaOH – sodium hydroxide 
NBIA – neurodegeneration with brain iron accumulation 
NDD – neurodegenerative disorder 
ng– nanogramm 
NGS – normal goat serum 
nl – nanoliter 
NLS – nuclear localization sequence 
nm – nanometer 
NSAID – non-steroidal anti-inflammatory drug 
nuc – nuclear 
OD – optical density 
OMM – outer mitochondrial membrane 
PAGE – polyacrylamide gel electrophoresis  
PBS– phosphate buffered saline   
PCR – polymerase chain reaction    
PD – Parkinson’s disease  
PDD – Parkinson’s disease dementia 
PET – positron-emission tomography 
PFA – paraformaldehyde  
PINK1 – PTEN-induced putative kinase 1  
PK – proteinase K 
PLD2 – phospholipase D2 
PLO – Poly-L-Ornithine 
PSN – penicillin, streptomycin, and neomycin antibiotic mixture 
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PTEN – phosphatidylinositol-3,4,5-trisphosphate 3-phosphatase 
qPCR – quantitative or real time PCR 
REM – rapid eye movement 
RNA – ribonucleic acid 
ROS – reactive oxygen species   
rpm – revolutions per minute  
RT – room temperature  
SD – standard deviation 
SDS – sodium dodecylsulfate  
SDS-PAGE– polyacrylamide gel electrophoresis 
SN – Substantia nigra 
SNARE – soluble N-ethylmaleimide-sensitive factor attachment protein receptor 
SNCA – ɑ-synuclein gene  
SNCB – β-synuclein gene  
SNpc – Substantia nigra pars compacta  
SNpr – Substantia nigra pars reticulata  
TBE – Tris/Borate/EDTA buffer 
TBS – Tris-buffered saline 
TBS-T – Tris-buffered saline with Tween20 
TE – Tris/EDTA buffer 
TEM – transmission electron microscopy   
TEMED– tetraeminethylendiamine    
tg – transgenic 
ThioT – thioflavin T  
TRor ITR– inverted terminal repeats 
Tris – 2-amino-2-hydroxymethyl-propane-1,3-diol 
tu – transducing units  
UTR – untranslated region 
V– Volt 
VAMP2 – vesicle-associated membrane protein 2 
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VDAC1 – voltage-dependent anion-selective channel 1 
vg – vector genome copies 
VMAT – vesicular monoamine transporter  
VTA – ventral tegmental area 
WB – Western blot  
WPRE - Woodchuck hepatitis virus posttranscriptional regulatory element   
WT – wild type 
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8.2 Publications and posters on doctoral project 
 
 
“V70M-β-synuclein induces neurotoxicity in cultured cortical neurons and dopaminergic neurons 
of Substantia nigra in a similar way with α-synuclein but P123H-β-synculein does not” 
(manuscript in preparation). 
 
CMPB Ph.D. retreat 2014, with oral presentation: "Aggregation of alpha-Synuclein: what turns a 
friend into an enemy", Leipzig, Germany, 03/12/14 - 05/12/14 
U4 Graduate School "The Aging Brain", with poster presentation: "Neurotoxic and aggregation 
properties of beta-synuclein and beta-synuclein-P123H mutant", Uppsala, Sweden, 23/08/15 - 
29/08/15 
6th biennial neuroscience conference Neurizons 2015: notes of an orchestrated brain, with poster 
presentation: "Characterization of toxicity and aggregation properties of synucleins in primary 
cortical cells", Göttingen, Germany, 26/05/15 - 29/05/15 
4th GGNB Science Day, with poster presentation: "Parkinson's disease and dementia with Lewy 
bodies: from cell culture-based model to gene therapy", Göttingen, Germany, 5/12/16 
Encephalon-2017, with poster presentation: "Neurotoxicity and aggregation of β-synuclein and 
its P123H and V70M mutants associated with dementia with Lewy bodies", Göttingen, Germany, 
1/12/17 
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